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1. Summary 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder and the most common 
form of dementia. Thereby, the abnormal deposition of the amyloid-β (Aβ) peptide into plaques 
is considered to be the primary neuropathological insult in AD. For a small proportion of all 
AD cases it is well known that rare genetic mutations are causative for very early Aβ deposition 
(familial Alzheimer’s disease). However, the vast majority of all AD cases manifest at later 
ages (late-onset Alzheimer’s disease (LOAD)) and are most likely caused by an interplay of 
multiple genetic variants and the environment.  
During the last ten years, genome-wide association studies revealed several risk loci 
that increase the susceptibility for LOAD, and interestingly, many of these genetic variants 
were found to be associated with innate immune functions of which the resident tissue 
macrophages of the brain – the microglia – are prime regulators.    
In general, the innate immune response mediated by the resident tissue macrophages is 
considered protective as it induces the production of inflammatory modulators and enables 
phagocytosis and killing of pathogens to prevent further tissue damage. However in the AD 
brain, the progressive accumulation of Aβ deposits leads to a chronic exposure of microglia to 
Aβ aggregates and induces an excessive neuro-inflammatory response that is thought to 
promote disease progression. 
Interestingly, microglia display a highly plastic phenotype and studies from peripheral 
tissue macrophages reported that a variety of environmental stimuli can determine but also 
reprogram their functional phenotype. To this end, this thesis summarizes three different 
approaches, which aimed to understand but also modulate the myeloid cell immune function 
during AD with regard to their effects on the pathology of cerebral β-amyloidosis. 
To begin with, we examined whether peripheral monocytes, which were previously 
shown to adopt a microglia-like phenotype in the healthy brain, can replace dysfunctional 
microglia in brains of two different mouse models of cerebral β-amyloidosis and may then 
restrict Aβ accumulation. For this purpose, we depleted microglia in APPPS1 and APP23 
transgenic (tg) mice that expressed the herpes simplex virus thymidine kinase (HSVTK) under 
the myeloid-cell specific CD11b promoter; the application of the thymidine kinase substrate 
ganciclovir (GCV), which is converted into a cytotoxic product, then induced microglial death. 
After a two-week ganciclovir treatment, application was discontinued from two weeks up to six 
months to allow the peripheral monocytes to repopulate the brain. Interestingly, during the first 
weeks of repopulation the number of infiltrated monocytes were twice the number of resident 
microglia in control mice, but the engrafted monocytes failed to cluster around Aβ plaques. 
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Consequently, we did not observe alterations in plaque pathology. Also, a pro-longed 
incubation for up to six months did not change Aβ load. However, long-term monocyte 
engraftment for five months induced in pre-depositing APP23 mice enabled the infiltrated 
monocytes to behave most similar to resident microglia: they began clustering around Aβ 
depositions, the cell number was virtually equal to control mice and plaque-associated 
monocytes were TREM2-positive. However, these cells also failed to alter Aβ plaque load. 
This work indicates that the tissue environment in the brain dominates over myeloid cell 
origin and thus reprograms myeloid cells to match the resident microglia population, however 
without prevention of Aβ pathology. 
Recent studies provide evidence that cells of the innate immune system can, similar to 
the adaptive immune cells, acquire immunological memory. In particular, a distinct set of 
primary immune stimuli can either enhance or suppress a subsequent immune response, which 
is referred to as “training” and “tolerance”, respectively. In a second study, we tested the 
applicability of the immune memory concept to microglia and examined if the induction of 
innate immune memory can induce long-lasting changes in the brain’s immune response and 
thereby alter pathology of neurological diseases. To this end, we injected two different doses 
of the endotoxin lipopolysaccharide (LPS) into pre-depositing APP23 mice. Whereas a single 
LPS injection was identified to induce acute training effects, consecutive injections for four 
days induced tolerance effects in microglia. Accordingly, in the brain, we acutely measured 
initially enhanced concentrations of inflammatory cytokines which decreased with further LPS 
injections.  
When we examined the long-lasting effects of the induced immune memory on Aβ 
pathology and cortical ischemia at the later time points, the initial training stimulus increased 
while the tolerance stimulus reduced pathology, which was reflected by changes in Aβ plaque 
load and neuronal damage, respectively.  
Immune memory in macrophages was previously shown to be mediated by epigenetic 
changes in enhancer regions that either stimulate or prevent gene transcription. In accordance, 
we performed chromatin immunoprecipitation sequencing for histone modifications in isolated 
microglia to determine changes in their enhancer landscape. Notably, we identified the active 
enhancer repertoire for hypoxia-inducible factor 1α (HIF-1α), a key modulator for macrophage 
inflammatory responses, to be enriched in microglia after the induction of trained immune 
memory (1xLPS). In contrast, pathways related to phagocytic functions showed an increase in 
active enhancers in the 4xLPS treatment group. Importantly, these epigenetic alterations were 
reflected by expression changes in the respective genes in the isolated microglia population. By 
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this study, we provide first evidence for long-lasting innate immune memory in the brain that 
can shape neurological disease outcome and is driven by epigenetic modifications of the 
microglial enhancer landscape. 
In a last study, we focused on the microglial phagocytic capacity as an important factor 
for the modulation of Aβ plaque pathology, as in vitro experiments have reported that microglia 
can bind to, and engulf Aβ fibrils. However, so far, in vivo studies have not convincingly 
confirmed these results. Therefore, we investigated the role of the soluble milk fat globule-
epidermal growth-factor 8 (MFG-E8) protein, that was recently hypothesized to mediate Aβ 
phagocytosis in AD pathology. To test the in vivo function of MFG-E8, we crossed mice 
expressing a functional knockout variant of Mfge8 (Mfge8-/-) with the APPPS1 and APP23 tg 
mouse models of cerebral β-amyloidosis. 
In contrast to previous reports, our results indicated that the depletion of MFG-E8 has 
no impact on Aβ uptake by microglia or subsequent Aβ degradation processes. However, 
contrary to our expectations, MFG-E8 deficiency reduced Aβ plaque load and Aβ levels in both 
mouse models without affecting amyloid precursor protein (APP) processing. 
When we immunohistochemically analyzed MFG-E8 distribution in the brain we 
observed a strong accumulation of MFG-E8 with congophilic Aβ deposits and co-staining of 
MFG-E8 with Aβ even showed a partial co-localization of both proteins at the sites of Aβ 
plaques. While the mechanism of these effects requires further studies, our results suggests that 
a direct interaction between MFG-E8 and Aβ promotes amyloid aggregation.  
Taken together, these studies examined different ways of modulating the microglial 
immune response during AD pathology. Interestingly, the replacement of dysfunctional 
microglia by peripheral monocytes in the diseased brain did not modify Aβ deposition although 
the infiltrated monocytes adopted features of plaque-associated microglia. However, when we 
applied the concept of innate immune memory to the brain through the remodeling of the innate 
immune response by epigenetic reprogramming of the microglial enhancer repertoire, we 
identified a promising approach to modify Aβ pathology. Especially the induction of a 
microglial tolerance state had beneficial long-term effects on the pathology of cerebral β-
amyloidosis while training aggravated disease outcome. These results provide, for the first time, 
evidence that long-lasting modulation of the innate immune reaction may occur due to 
immunological priming – a mechanism that introduces new targets for dampening Aβ 
pathology in Alzheimer’s disease.  
However, in contrast, a direct modification of microglial Aβ phagocytosis through the 
knockout of Mfge8 is most likely not sufficient to modulate microglia function in AD. 
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2. Preface 
In summer 2013 when I started my PhD my grandfather was sent to hospital because he was 
diagnosed with lung cancer. The clinicians could successfully remove the tumor and in theory 
he was cured. However, the surgery, and also the following weeks where he was confined to 
his bed, weakened his physiological constitution. During the next months, he got several lung 
infections and soon every physical activity became arduous. Finally, his cognitive abilities 
progressively declined. In the beginning, he failed to follow conversations, then he preferred to 
talk about his childhood and currently he sees faces in trees, against which he wants to fight. 
My grandfather became demented; but was it just co-incidence that he started to develop 
dementia or was it a side effect of his former illness? There is emerging evidence that systemic 
inflammation can aggravate the state of a neurological disease by inducing an exaggerated 
inflammatory environment in the brain and thus promote disease onset or speed up disease 
progression (Dunn et al., 2005). Therefore, the modulation of the innate immune system to 
induce an appropriate inflammatory immune response is regarded as a potential therapeutic 
target for neurological diseases. For that reason, this work will focus on the role of the innate 
immune system in Alzheimer’s disease, the most common form of dementia (Holtzman et al., 
2011). 
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3. Synopsis 
3.1 Alzheimer’s disease 
 
3.1.1 An overview on 110 years of Alzheimer’s disease research  
Alzheimer’s disease is a chronic and progressive neurodegenerative disease that, in 90-95 
percent of the cases, affects people above 65 years of age (Harman, 2006). Patients develop 
cognitive dysfunctions, behavioral disturbances and in end stages also difficulties with 
performing activities of daily living. Notably, this disease was first described in the 51-year-
old woman Auguste D. In 1901, she was presented to the physician Alois Alzheimer with 
changes in her personality such as impaired memory, disorientation or erratic behavior (Maurer 
et al., 1997). After her death in 1906, Alzheimer did a histological examination of her brain and 
found an analogous pathology as described in the context of senile dementia: a massive neuron 
loss, the presence of “small miliary foci” (later called senile plaques) of a “peculiar material in 
the cortex” (identified as amyloid-β) and clumps and condensations of intracellular fibrils he 
referred to “neurofibrillary degeneration” (Alzheimer, 1907; Maurer et al., 1997). However, 
when Alzheimer presented his findings at a congress in Tübingen, the audience paid no 
attention to this first description of a case of “pre-senile dementia”. It was four years later, when 
his mentor Emil Kraeplin introduced the eponym „Alzheimer’s disease” (AD) for the very first 
time to distinguish the atypical form of pre-senile dementia from the more common senile 
variant (Kraepelin, 1910). However, for the next decades, AD was regarded as a particularly 
serious form of senile dementia that played only a minor role as a neurological disorder 
(Hodges, 2006). But in the 1960s, when life expectancy started to rise and more elderly people 
were affected by the senile form of dementia, clinical delineation of dementia sub-forms and 
correlation between the abundance of pathology and cognitive decline unified the young onset 
Alzheimer’s disease and the common elderly dementia (Blessed et al., 1968; Roth et al., 1966). 
Finally, it was Katzmann in 1976 who commented on the concern that AD is not only a rare 
disease of younger patients, but also affects the ageing population. He suggested to consistently 
use the term Alzheimer’s disease for the pre-senile but also the common senile form of 
dementia, as both diseases share the same pathology (Katzman, 1976).  
Soon after, first attempts were made to understand the mechanisms of the disease that 
led to the discovery of the two major proteins involved in the pathological lesions, which were 
already described many years ago: the amyloid-β (Aβ) peptide forming the extracellular 
amyloid plaques (Glenner and Wong, 1984b; 1984a; Masters et al., 1985b) and microtubule-
associated protein tau (MAPT) as component of the intracellular filamentous lesions (Kosik et 
al., 1986). Furthermore, amyloid precursor protein (APP) was identified as the precursor protein 
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for Aβ (Kang et al., 1987; Masters et al., 1985a) and finally first studies could assign genetically 
heritable mutations to the pre-senile form of AD (Goate et al., 1991; Sherrington et al., 1995).  
Today, 46.8 million people worldwide are affected by AD and an estimation for 2030 
predicts 74.7 million people living with AD (Prince et al., 2015). As anticipated, AD has 
developed into a major public health challenge and is one of the most economically burdensome 
diseases in the world. According to a Forbes ranking in 2015, the global costs for dementia care 
are 818 billion US dollars annually, corresponding to the 18th largest economy in the world and 
exceeding the market values of Apple or Google (Wimo et al., 2017). The fears that arose 50 
years ago came true, however the consequent effort that was made to understand the disease 
has so far been insufficient to develop a therapy for the devastating disease. Very recently, the 
first approved AD immunotherapeutic drug, the Aβ antibody Solanezumab failed to slow down 
cognitive decline in people with mild AD (Eli Lilly Press Release, 2016). Thus, only 
therapeutics that alleviate the symptoms of AD, such as acetylcholinesterase inhibitors or 
glutamatergic receptor inhibitors – both boosting neurotransmission and thus compensating for 
neuron – loss are available (Fleischhacker et al., 1986; Jorm, 1986; McGleenon et al., 1999; 
van Marum, 2009). Therefore, even more than 110 years after the first case description of a 
patient with “pre-senile dementia” by Alois Alzheimer in Tübingen (Alzheimer, 1906; 1907), 
it is of utmost importance to study the pathogenesis of AD to identify molecular targets or 
pathways that may one day facilitate a pharmacological therapy for AD.  
 
3.1.2 Pathophysiology of Alzheimer’s disease – APP processing 
The principal proteinaceous component of amyloid plaques in AD are aggregates of the Aβ 
peptide (Gorevic et al., 1986; Masters et al., 1985b; Selkoe et al., 1986). Aβ is a small carboxy-
terminal fragment of the amyloid precursor protein (APP) with its size varying between 36 and 
43 amino acids (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 
1987). APP is a transmembrane protein with a large amino-terminal extracellular domain and 
a small carboxy-terminal cytoplasmic domain (Dyrks et al., 1988; Weidemann et al., 1989). It 
is expressed in several isoforms with APP695, APP751 and APP770 being the most abundantly 
expressed isoforms (Selkoe et al., 1988). In the brain, APP695 is amply produced in neurons 
(Kang and Müller-Hill, 1990; Rohan de Silva et al., 1997), however after a relatively brief half-
life of around 45-60 min, APP is metabolized very rapidly (Weidemann et al., 1989).
 APP is processed via at least two proteolytic cleavage pathways involving three 
different secretases. APP cleavage can occur either via the non-amyloidogenic pathway, that 
includes alpha-secretase-mediated ectodomain shedding of APP within the Aβ sequence and 
thus precluding the formation of Aβ, or via the amyloidogenic pathway resulting in the release 
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of the Aβ peptide (Zhang et al., 2011). The first critical step in liberating Aβ during 
amyloidogenic processing of APP is the amino-terminal cleavage by the beta-site APP cleaving 
enzyme (BACE1 or β-secretase) that cleaves APP into the soluble APP-β ectodomain-fragment, 
which is released into the extracellular space, and a membrane-bound 99 amino acid carboxy-
terminal fragment (CTF-β) (Seubert et al., 1993). CTF-β is further cleaved by a multi-subunit 
protease complex, the γ-secretase, that consists of the two transmembrane proteins (amongst 
other components), presenilin 1 (PS1) and presenilin 2 (PS2), that provide the catalytic core of 
the secretase (De Strooper et al., 1998; Wolfe et al., 1999). The stepwise processing of the CTF-
β fragment by γ-secretase at several cleavage sites in the carboxy-terminal end of the Aβ 
sequence results in the production of Aβ species with varying lengths ranging between 36 and 
43 amino acids, with Aβ40 and Aβ42 being the most abundant cleavage products (Selkoe, 2001; 
Takami et al., 2009). However, the longer Aβ42 is considered the more pathogenic form as it is 
more prone to aggregate (Jarrett et al., 1993). 
 
3.1.3 Genetic susceptibility to Alzheimer’s disease 
As Alzheimer indicated 110 years ago, there exist two different forms of AD that can be 
distinguished by their age of onset. The rare pre-senile form of AD (familial Alzheimer’s 
disease (FAD)) and the very common form of late-onset AD (LOAD). Genetic studies from 
families, which are affected by the pre-senile form of AD, identified dominantly inherited 
mutations in the APP,  presenilin 1 (PSEN1) and presenilin2 (PSEN2) genes, which could be 
either linked to an increase in total Aβ concentrations or to an elevation of the Aβ42/Aβ40 ratio 
(Citron et al., 1992; Shen and Kelleher, 2007; Szaruga et al., 2017).  
For AD up to date, 52 mutations in the APP gene are known (Alzforum, 2017a), from 
which most cluster around the γ-secretase cleavage site (Weggen and Beher, 2012). However, 
the well-known “Swedish double mutation”, that is commonly used to generate transgenic 
mouse models of AD, is adjacent to the β-secretase-cleavage site and promotes APP β-site 
cleavage by BACE1 (Haass et al., 1995; Mullan et al., 1992).  
For PSEN1 and 2 more than 250 mutations are described (Alzforum, 2017b) and all 
have been shown to consistently increase the relative amounts of the more aggregation prone 
Aβ42 in relation to Aβ40 (Weggen and Beher, 2012). 
A recent study identified a mechanism showing that mutations in APP and PSEN1/2 
cause a less stable enzyme-substrate interaction between γ-secretase and CTF-β resulting in the 
generation of longer more amyloidogenic Aβ species due to less sequential cleavage of Aβ 
(Szaruga et al., 2017). Consequently, in FAD, the majority of the identified mutations in APP 
or PSEN1/2 alter proteolytic processing of APP and thus suggest that the abnormal elevation 
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of Aβ42 relative to Aβ40 is critical for AD pathogenesis. On that basis, the early pathogenic 
protein accumulation of Aβ into extracellular plaques observed in FAD was postulated to be 
causative for AD and thus, the “amyloid cascade hypothesis” became the most accepted model 
for AD pathogenesis and formed the basis for many therapeutic treatment approaches 
(Beyreuther and Masters, 1991; Hardy and Higgins, 1992; Hardy and Allsop, 1991; Selkoe, 
1991).  
However, for LOAD, the disease origin is less well understood as no causative familial 
mutations have been identified. Although a variety of studies identified several different risk 
factors from observational and experimental analyses such as diabetes (Leibson et al., 1997), 
cerebrovascular diseases (Lefrère et al., 1990), hypertension (Davies), smoking or physical 
inactivity (Davies), evidence is still lacking for a definitive cause of LOAD. Thus for a long 
time, ageing was assumed to be the only causative risk factor for LOAD, which was 
corroborated by a study speculating that if life would be twice as long, everyone would develop 
AD (Research1995). In addition, a study demonstrated that ageing increases the expression of 
inflammation-related genes, a process named “inflammaging” (Cribbs et al., 2012). As brain 
inflammation is a hallmark of AD, a predisposition to inflammatory processes may contribute 
to AD with ageing. 
Interestingly in 2004, a twin study indicated that 50 percent of the risk for LOAD may 
be due to genetic factors (Pedersen et al., 2004), which were confirmed by subsequent studies 
to be crucial for LOAD (Lambert et al., 2010; 2009; 2013). Today, it is accepted that the 
interplay between the accumulation of age-related malfunctions, environmental factors and a 
pre-disposing genetic background most likely triggers pathology in LOAD and thus suggests 
to consider LOAD as a multifactorial disease (Borenstein et al., 2006). 
 
3.1.4 Genetic risk factors for LOAD 
Population-based association studies and genetic linkage analysis led to the identification of the 
first genetic risk loci for LOAD, the apolipoprotein (APOE) E4 allele which encodes the 
apolipoprotein E4 isoform (ApoE4) (Blacker et al., 1997; Saunders et al., 1993). Until today, 
APOE-E4 is the most prominent and strongest risk allele associated with LOAD (Corder et al., 
1993).The APOE gene is polymorphic with three major alleles (E2, E3, E4), of which the APOE-
E3 allele is the most common one (79%) (Ghebranious et al., 2005). Physiologically, the protein 
is involved in cholesterol transport and lipid metabolism and is produced primarily in the liver, 
but has also been found in the kidneys, spleen and brain (Mahley, 1988). Whereas the APOE-
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E2 allele is considered to be protective against LOAD (Corder et al., 1994), carriers of two 
copies of the APOE-E4 allele have an eightfold increased risk for AD (Corder et al., 1993). 
Follow up studies in humans and mice investigated the functional impact of the ApoE4 
lipoprotein on AD and found that it can bind to Aβ and influence its aggregation as well as 
impair its metabolism (Castellano et al., 2011; Kim et al., 2009). This can occur by competing 
with Aβ for the low-density lipoprotein receptor-related protein 1 (LRP1), which is known to 
initiate endocytosis of Aβ by astrocytes (Verghese et al., 2013). Additionally, ApoE4 disrupts 
LRP1-mediated efflux of soluble Aβ across the BBB through the redirection of ApoE4-bound 
Aβ to a very-low-density-lipoprotein receptor (VLDLR) that is slower at internalizing Aβ at 
the BBB (Deane et al., 2008).  
During the last decade, novel techniques such as genome wide association studies 
(GWAS), whole genome sequencing and gene-expression network analysis emerged that 
enabled the screening for many more gene networks and genetic variants, which are associated 
with LOAD. These data support LOAD as a disease with polygenic contributions in which the 
identified common disease susceptibility loci have small effects on AD risk (Escott-Price et al., 
2015). A set of these identified genes such as clusterin (CLU), ATP-binding cassette transporter 
7 (ABCA7) or sortilin related receptor 1 (SORL1) are involved in lipid metabolism as shown for 
APOE, and thus support the importance of this pathway in conferring AD risk (Harold et al., 
2009; Hollingworth et al., 2011; Lambert et al., 2009; 2013).  
Another important role was attributed to functions of the innate immune system, which 
represents the first line of immune defense in the brain. Thereby the immune response is 
conducted by microglia, which are immune cells of the myeloid lineage and the brain resident 
tissue-macrophages (Prinz and Priller, 2014). Once activated, microglia can produce a set of 
neurotoxic molecules to trigger an inflammatory response, but also possess the capability to 
engulf pathogens through phagocytosis (a more detailed overview on the microglial immune 
response can be found in section 3.1.5). Numerous of the identified genetic variants associated 
to the innate immune system are either directly expressed by glial cells or are part of the innate 
immune response, for example: triggering receptor expressed on myeloid cells 2 (TREM2), 
complement receptor 1 (CR1), myocyte enhancer factor 2c (MEF2C), and inositol 
polyphosphate-5-phosphatase D (INPP5D) (Fig. 1) (Gjoneska et al., 2015; Guerreiro et al., 
2013; Hollingworth et al., 2011; Jonsson et al., 2013; Lambert et al., 2013; Naj et al., 2011). 
However, the investigation on the functional impact of the identified risk genes on LOAD has 
only recently started and thus our understanding remains limited.  
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Figure 1: Genetic risk factors for Alzheimer’s disease. Apart from rare mutations in the APP, PSEN1 and 
PSEN2 genes, which cause familial Alzheimer’s disease, genetic analysis methods have identified a set of common 
genomic variants that show smaller effects on AD risk. Although, a variety of the genes encode proteins that can 
be related to functions of the innate immune system (highlighted in blue) and are expressed in microglia (encircled 
in red), the ascription of alterations in the biological functions to all detected variants is still on-going.  
The most controversially discussed risk factor is TREM2. Rare coding variants 
identified in the gene locus such as the arginine to histidine amino acid substitution (R47H) 
significantly increase the risk for LOAD by two- to threefold (Guerreiro et al., 2013; Jonsson 
et al., 2013). TREM2 is a V-type immunoglobulin domain that is highly expressed by microglia 
and is suggested to play a role in phagocytosis (Hickman and Khoury, 2014). TREM2 
expression is not restricted to the brain and can also be found on peripheral tissue macrophages 
like osteoclasts (Cella et al., 2003; Humphrey et al., 2006; Paloneva et al., 2003) or alveolar 
macrophages (Ulrich et al., 2017; Wu et al., 2015). The exact ligands that activate TREM2 
signaling are not known but are assumed to include phospholipids, bacterial products or cell 
debris (De Strooper and Karran, 2016). After activation, TREM2 associates with its signaling 
partners, DAP12 (DNAX-activation protein 12/TYROBP) and DAP10 (Peng et al., 2010), 
leading to the initiation of signaling cascades, which promote the anti-inflammatory functions 
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of the immune system such as phagocytosis (Takahashi et al., 2005), the suppression of pro-
inflammatory cytokines and chemokines (Bouchon et al., 2001; Mazaheri et al., 2017), but also 
cell survival (Wang et al., 2015) and proliferation (Otero et al., 2012). Moreover, TREM2 
activation can interfere with toll-like receptors (TLRs)-induced cytokine production by 
macrophages to restrain macrophage activation and thus negatively regulate the inflammatory 
response (Hamerman et al., 2006; Turnbull et al., 2006).  
The linkage between TREM2 and AD is not entirely clear. It remains to be elucidated 
whether genetic variants of TREM2 that are associated with LOAD increase or impair TREM2 
function. Remarkably, loss of function mutations in TREM2, which cause the severe 
neurological disorder Nasu Hakola disease, were also found to increase the risk for AD 
(Guerreiro et al., 2013; Song et al., 2017). This supports a similar impairment of TREM2 
function in AD. Conversely, other mutations (D87N and T96K), which are potentially 
associated with LOAD, increase TREM2 activity (Guerreiro et al., 2013; Song et al., 2017). 
Thus, it seems that an overall disruption of TREM2 homeostasis by several different genetic 
variants may be responsible for the increased risk of LOAD. 
For this reason, the modulation of AD pathology by TREM2 has now started to be 
extensively studied in mouse models in which TREM2 levels were found to be increased in 
plaque-associated myeloid cells (Frank et al., 2008; Melchior et al., 2010) and seem to be 
important for plaque-associated myeloid-cell accumulation (also known as microgliosis) as 
TREM2 deficiency decreased the number of cells that surround Aβ plaques (Jay et al., 2015; 
Wang et al., 2015; 2016). A reduction of microgliosis has also been observed in human post-
mortem brain sections from R47H variant carriers (Yuan et al., 2016). Additionally, gene 
expression analysis revealed that knocking out Trem2 in mouse models for AD results in a 
decrease in inflammation-related genes associated with microglial activation in response to Aβ 
(Ulrich et al., 2014; Wang et al., 2015). Furthermore, TREM2 deficiency was reported to 
suppress the induction of microglial phagocytic pathways and to impair Aβ phagocytosis by 
myeloid cells (Jay et al., 2017; Keren-Shaul et al., 2017). However, the effect of TREM2 
deficiency on Aβ burden is very conflicting and different studies either reported decreased Aβ 
deposition at early diseases stages but conversely exacerbated plaque pathology at later stages 
(Jay et al., 2017) or aggravated pathology restricted to certain brain regions (Wang et al., 2015). 
Ultimately, these results suggest opposing roles for TREM2 at different stages of the disease 
and consequently further studies are required to decipher its definite role in the regulation of 
the inflammatory immune response during AD.  
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Other genetic variants associated with the immune system were identified in the locus 
encoding complement receptor 1 protein (CR1) (Lambert et al., 2009). CR1 is a glycoprotein 
and a component of the complement response that can adhere to particles that are opsonized 
with complement factors C1q or iC3b to initiate phagocytosis. CR1 is predominantly expressed 
in the periphery, but was also identified in cultured human microglia (Walker et al., 1995). CR1 
is also an important regulator of the converting process of the central complement component 
C3 to the active C3b and iC3b complement factors (Krych-Goldberg and Atkinson, 2001; van 
Beek et al., 2003). It was shown that CR1 expression on erythrocytes is involved in the 
peripheral clearance of iC3b-opsonized Aβ from human blood, suggesting that alterations in 
CR1 structure or expression due to genetic polymorphisms could influence Aβ clearance 
(Rogers et al., 2006). Studies also reported a positive correlation between mRNA expression of 
the rs6656401 CR1 variant and Aβ plaque burden (Chibnik et al., 2011; Zhang et al., 2010). 
However, no further study could confirm a correlation of the identified genetic variants in the 
CR1 locus and AD pathology so far (Fonseca et al., 2016). 
Even though the functional association of these genes is still under investigation, the 
understanding for the innate immune response as an important factor driving AD pathology 
impressively increased during the last 20 years and was further reinforced by the identification 
of several genetic variants expressed in genes of the innate immune system reported in 
landmark studies by Lambert et al. in 2009 and 2010 (Fig. 2) (Lambert et al., 2009; 2010). 
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Figure 2: Evolution of the importance for inflammation in Alzheimer’s disease. During the last 20 years, 
research on the contribution of inflammatory processes to the etiology of Alzheimer’s disease grew exponentially 
and was further reinforced by the identification of several genetic variants in immune-related genes by Lambert et 
al. in 2009 and 2010 (Lambert et al., 2009; 2010). The numbers of published papers per year for the term 
“Inflammation” and “Alzheimer’s” were assessed on PubMed Central (26.01.2018). 
 
3.1.5 Microglia – mediators of the innate immune response in AD 
The identification of several risk genes that contribute to innate immune responses in the central 
nervous system (CNS) or are directly encoded by microglia, support the long-standing 
hypothesis that alterations in the innate immune system contribute to the pathology of AD 
(Heneka et al., 2015b; Meyer-Luehmann and Prinz, 2015; Ransohoff and Khoury, 2015). As 
the resident immune cells in the CNS, microglia play an essential role in brain immune 
responses.  
Microglia, as a new cell entity, were first described in 1919 by the Spanish 
neuroscientist Pío del Río Hortega. Through the invention of a new staining method based on 
silver carbonate he was able to visualize the finest morphological details of different brain cells 
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and classified the formerly named “third element” cells into two new cell types: microglia and 
oligodendrocytes (Rezaie and Hanisch, 2014). However, the functional designation of these 
cells was inconclusive for a long period. Today, it is well known that microglia are the tissue 
resident immune cells and the fundamental effectors and regulators of the innate immune 
response in the brain. They account for 5-12 percent of the cells in the CNS (Lawson et al., 
1990). Fate mapping analysis in mice revealed that these cells arise from primitive myeloid 
progenitors of the yolk sac during embryonic development (Ginhoux et al., 2010). In particular, 
before embryonic day 10.5 (E10.5), primitive macrophages exit the yolk sac and invade the 
neuroepithelium where they start to differentiate, expand and colonize the whole CNS. Through 
the closure of the blood brain barrier (BBB) around day E13.5 (Ben-Zvi et al., 2014), the CNS 
is uncoupled from the periphery resulting in a restricted environment that excludes the invasion 
of any peripheral blood-derived monocytes into the healthy brain (Ajami et al., 2011; Ginhoux 
and Jung, 2014; Hagan and Ben-Zvi, 2015). Based on the segregation of the CNS from the 
peripheral macrophage cell pool, it is suggested that microglia maintenance is mediated by self-
renewal via local proliferation that resembles peripheral tissue-resident macrophages in the 
steady-state (Ajami et al., 2007; Hashimoto et al., 2013). However, in contrast to other short-
lived peripheral tissue macrophages, microglia were initially assumed to be extremely long-
lived cells with a turnover rate of 0.05 percent (Lawson et al., 1992), implicating that microglia 
are almost never renewed. However, a recent study revisited the longevity of microglia and 
found a ten times higher turnover rate in mice that estimates the self-renewal of the brain’s 
microglial population every 95 days and questions the view of microglia as a long-lived 
population (Askew et al., 2017; Tay et al., 2017). A similar study with human microglia 
reported an average lifespan for these cells of around four years with an annual turnover rate of 
28 percent implicating multiple cycles of microglial renewal throughout life (Réu et al., 2017). 
Conversely, a recently published study, in which single microglia where imaged in vivo for up 
to 15 months, calculated an average lifetime of adult mouse microglia of 22 months proving 
the longevity of these cells (Füger et al., 2017). 
This relative longevity of microglia makes these cells vulnerable to environmental 
insults or monogenic disorders. Noteworthy, mutations in the gene for colony stimulating factor 
1 receptor (CSF1R), a key regulator of myeloid lineage cells, which controls proliferation, 
differentiation and survival of macrophages (Patel and Player, 2009), causes hereditary diffuse 
leukoencephalopathy with spheroids (HDLS) (Rademakers et al., 2011), a disease of the CNS 
with a variety of neurological symptoms such as dementia, depression or seizures (Axelsson et 
al., 1984; Wider et al., 2009).  
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Under steady-state conditions, microglia execute several functions. They actively scan 
their microenvironment for any tissue disturbances and support neuronal function and survival 
by synapse maintenance and elimination via phagocytosis (Kettenmann et al., 2013; Paolicelli 
et al., 2011; Tremblay et al., 2010). They are further involved in the remodeling of neuronal 
circuits and the release of different trophic factors (Parkhurst et al., 2013; Schafer et al., 2012). 
However, a major part of the microglial role in the brain is the initiation of an immune response. 
Upon sensing of pathogen invasion, tissue damage, toxic proteins or apoptotic cells by pattern 
recognition receptors (PRRs), microglia become activated to undergo morphological 
remodeling. They begin extending their processes towards the lesion and subsequently migrate 
to the site of the injury where they finally mediate the immune response. This includes the 
production of pro- or anti-inflammatory cytokines, chemokines and other neurotoxic factors, 
but also the induction of phagocytic pathways to engulf the invaded pathogens or other toxic 
material (Ransohoff and Perry, 2009). During acute inflammatory events, the microglial 
immune response supports the resolution of the pathological alterations with immediate benefit 
to the environment. However, long-lasting pathological events, can induce a microglia-
mediated non-resolving inflammatory milieu that in turn drives microglia into a persistent 
dysfunctionality with a detrimental outcome for pathology (Heneka et al., 2015a).  
In particular, during AD the recognition of Aβ by microglia is mediated by a repertoire 
of cell-surface innate immune receptors and receptor complexes consisting of scavenger- or 
toll-like receptors (TLRs) (Liu et al., 2005; Paresce et al., 1996; Stewart et al., 2010). Receptor 
ligation triggers the initiation of the microglial innate immune response with the production and 
secretion of pro-inflammatory modulators such as the cytokines IL-1β, IL-6 or tumor necrosis 
factor alpha (TNF-α), reactive oxygen species or nitrogen monoxide (Mogi et al., 1994; 
Morimoto et al., 2011). However, the enduring production and deposition of Aβ during AD 
leads to a sustained exposure of microglia to Aβ and thus to a chronic activation of the cells 
with a permanent production of inflammatory cytokines which can in turn for example 
upregulate BACE1 enzymatic activity for enhanced Aβ production and, subsequently, stimulate 
a positive feedback loop that may induce microglial dysfunction (Sastre et al., 2003). 
Furthermore, it has been reported that the persistent exposure to Aβ or other pro-inflammatory 
molecules impairs Aβ internalization by microglia (Heneka et al., 2013; Krabbe et al., 2013). 
Thus, AD reflects a chronic pathological event that modulates the microglial immune response 
in a detrimental fashion, contributing to disease progression rather than supporting the 
resolution of inflammation. 
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However, several studies on macrophages suggest different experimental approaches to 
alter the macrophage phenotype. In this context, it was reported that the phenotype of already 
differentiated macrophages can be re-programmed by alterations in the local tissue environment 
(Lavin et al., 2014). Moreover, it was also shown that an appropriate immune stimulus to 
macrophages can induce epigenetic changes in these cells that shape the immune response upon 
future immune challenges (Saeed et al., 2014). Finally, the genetic depletion of proteins 
involved in the mediation of the myeloid immune response was utilized to modify the 
phenotype of microglia and concomitantly alleviate cerebral β-amyloidosis and cognitive 
dysfunction in AD mouse models (Berg et al., 2012; Heneka et al., 2013; Yamamoto et al., 
2007). Altogether, these concepts present promising methods to modify the microglial immune 
response in AD and will be comprehensively addressed in relation to the findings of my doctoral 
project in the following sections. 
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3.2 Environmental factors as regulator for myeloid cell function  
In reference to: 
 
Replacement of brain-resident myeloid cells does not alter cerebral amyloid-β deposition in 
mouse models of Alzheimer’s disease 
  
Nicholas H. Varvel*, Stefan A. Grathwohl*, Karoline Degenhardt, Claudia Resch, Andrea 
Bosch, Mathias Jucker and Jonas J. Neher 
 
The Journal of Experimental Medicine 2015 Vol. 212, No. 11, 1803-1809, 
doi:10.1084/jem.20150478 
 
3.2.1 Microglia targeting approaches  
The best methods to study microglial function are genetic modification strategies, which enable 
labeling, alteration of gene expression and depletion of microglia. However, although microglia 
are a myeloid cell population that is developmentally and functionally distinguishable from 
other tissue macrophages such as peripheral monocytes, the specific targeting of microglia to 
study their biological function in vivo is difficult (Hoeffel and Ginhoux, 2015; Lavin et al., 
2014). While some putative microglia-specific genes such as P2ry12 or Hexb, Sall1 have been 
identified (Butovsky et al., 2014; Hickman et al., 2013; Koso et al., 2016), both microglia and 
monocytes share a wide range of receptors.  
The in vivo visualization of cells by fluorescent protein expression in mice is a 
commonly used method to analyze cell development, morphology or transcription of specific 
genes (Chudakov et al., 2010). In the brain, the replacement of one allele of the Cx3cr1 gene, 
encoding the fractalkine receptor (CX3CR1), with complementary DNA encoding fluorescent 
proteins (for example: green fluorescence protein (GFP)) (Cx3cr1+/GFP), is the most widely used 
technique to investigate the function of microglia (Jung et al., 2000). However, Cx3cr1 is also 
expressed by other peripheral mononuclear phagocytes and circulating monocytes (Geissmann 
et al., 2003; Jung et al., 2000). Therefore, Cx3cr1+/GFP mouse models would only allow for 
selected targeting and visualization of the CX3CR1-positive immune cells and not specifically 
microglia. This makes it challenging to specifically mark one of these populations, especially 
for the controversial debate under which conditions peripheral monocytes can invade into the 
CNS. 
 However, the insertion of a sequence encoding a Cre recombinase fused to a mutant 
estrogen-binding domain (Cre/ER system) into a microglia-specific gene allows an inducible 
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activation of the Cre recombinase to induce site-specific recombination of loxP-sites flanked 
(floxed) genes upon administration of tamoxifen (Feil et al., 2009; Hayashi and McMahon, 
2002; Yona et al., 2013). In terms of microglia visualization, mice carrying the Cre/ER system 
under the macrophage-specific promoters Cx3cr1 (Goldmann et al., 2013), CD11c (Town et 
al., 2008) or LysM (Dighe et al., 1995), can be crossed to reporter mouse lines such as Rosa26 
(R26-yfp) in which yellow fluorescent protein (YFP) reporter gene activity is induced after 
tamoxifen induced recombinase activation to excise a floxed STOP element preceding the 
reporter gene (Goldmann et al., 2013; Wieghofer et al., 2015). Consequently, this technique 
allows for the specific visualization of the long-lived microglia in Cx3cr1CreER:R26-yfp animals, 
because after tamoxifen-induced recombination the short-lived peripheral monocytes are 
replaced by bone-marrow-derived progenitor cells, which experienced no tamoxifen-induced 
recombinase activity. Thus, a complete microglia-specific labeling was reported to be achieved 
around four weeks after tamoxifen administration (Goldmann et al., 2013; Parkhurst et al., 
2013). 
Additionally, these mouse lines can be used to conditionally delete floxed genes to study 
their impact on microglia function. In order to assess the effect of the microglial mediated 
inflammatory immune response on CNS homeostasis for example, the inducible site-specific 
recombinase technique was used for the dissection of microglia-specific pathways or single 
genes such as the “transforming growth factor (TGF)-β-activated kinase 1” (Tak1), which is a 
kinase known to be involved in the upstream signaling of NF-κB-mediated microglial immune 
response (Sato et al., 2005). The genetic deletion of Tak1 showed that this kinase acts as a key 
regulator of microglia-mediated CNS inflammation, as the inflammatory response was 
mitigated in autoimmune demyelination as well as after acute LPS stimulation in conditional 
Tak1 knockout mice (Goldmann et al., 2013; Wendeln et al., 2018) These results underline the 
unfavorable role of microglia when executing their inflammatory response, both in models of 
multiple sclerosis and AD.   
Another approach to study the role of microglia in brain pathology is to delete the total 
microglia pool. This can be achieved through the insertion of the herpes simplex virus 
thymidine kinase (HSVTK) gene under the CD11b promoter. HSVTK is a “suicide kinase” that 
phosphorylates the antiviral nucleotide analog ganciclovir (GCV), a synthetic analog of 2´-
deoxy-guanosine. Instead of 2´-deoxy-guanosine trisphosphate, phosphorylated GCV is 
incorporated into the DNA leading to strand breaks, which induce apoptosis in CD11b-positive 
cells (Wieghofer et al., 2015). To restrict HSVTK (TK+) expression to the brain, TK+ mice can 
either be lethally irradiated and reconstituted with wildtype bone marrow or GCV can be 
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applied exclusively to the brain by a surgically implanted osmotic pump (Grathwohl et al., 
2009; Heppner et al., 2005; Varvel et al., 2012). In the latter case, intracerebroventricular (i.c.v.) 
administration of GCV ablates up to 90 percent of the microglia within two weeks. The few 
remaining microglia show a hyper-ramified phenotype (Varvel et al., 2012). This approach was 
used to investigate whether microglia are necessary for the formation and maintenance of Aβ 
plaques. However, after two and also four weeks of nearly complete absence of microglia no 
effect on Aβ formation, number and morphology of neurons or dystrophic neurites were 
observed (Grathwohl et al., 2009). In principle, this argues against a significant contribution of 
microglia to AD pathology; however, the period of microglial absence may have been too short 
to reveal any significant effects. 
Interestingly, studies suggest that infiltrating monocytes are the principle cells that 
mediate Aβ plaque-associated gliosis and that its elimination cause a reduction in pathology as 
well as decreased neuroinflammation (Jay et al., 2015). These results posit that, not microglia 
but infiltrating monocytes are involved in the inflammatory milieu that emerges in the brain 
regions where Aβ deposition occurs. 
 
3.2.2 Monocytes – co-workers of microglia? 
In the healthy brain the blood brain barrier (BBB) shields the brain from the invasion and 
differentiation of circulating monocytes into brain macrophages (Geissmann et al., 2010; 
Obermeier et al., 2013). However, engraftment of monocytes into the microglia-populated brain 
during inflammation is controversially discussed and could be promoted by damage of the BBB 
due to age-induced cerebrovascular dysfunctions or during cerebrovascular changes in AD 
pathology (Bell and Zlokovic, 2009; Minogue et al., 2014; Pimentel-Coelho and Rivest, 2012).  
Peripheral circulating blood monocytes express several receptors, which are used for 
classification into different subsets. In mice, there exists the pro-inflammatory (classical) cell 
population (CX3CR1low, CCR2pos, Ly6Chigh) that is recruited to inflamed tissue where it 
differentiates into a monocyte-derived macrophage population to mediate an inflammatory 
response, and an anti-inflammatory (non-classical) cell population (CX3CR1high, CCR2neg, 
Ly6Clow) representing the patrolling monocytes of the blood (Auffray et al., 2009). The 
patrolling monocytes are the longer-lived cells with a half-life of around two days, whereas the 
immune response-mediating CX3CR1low, CCR2pos, Ly6Chigh cells are short-lived, having a 
half-life of about 20 hours (Yona et al., 2013). In humans, the presence of CD14+, CD16- cell 
surface receptors corresponds to the pro-inflammatory (classical) monocyte subpopulation, 
which has a relatively short circulation life span in the blood of one day, but can be recruited to 
sites of infection. In contrast, cells expressing higher levels of CD16 (CD14low, CD16+) have a 
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longer circulation life span of about seven days and represent the patrolling (non-classical) 
monocytes of the vasculature (Passlick et al., 1989; Patel et al., 2017).  
Peripheral monocytes can be targeted by antibodies, liposomes or cell transfer and thus 
display an attractive option for therapeutic manipulation (Biber et al., 2016). For example, the 
induction of experimental autoimmune encephalomyelitis (EAE), a murine model for the 
inflammatory aspects of multiple sclerosis, initiates the production of the monocyte 
chemoattractant protein 1 (MCP-1 or CCL2) in the CNS which is the ligand for C-C chemokine 
receptor type 2 (CCR2) expressed on the surface of monocytes (Dogan et al., 2008). Increased 
levels of CCL2 were shown to affect BBB integrity and to attract the reactive CX3CR1low, 
CCR2pos, Ly6Chigh monocyte population to transmigrate into the brain where they contribute to 
the severity of autoimmunity (Izikson et al., 2000; Mildner et al., 2009; Saederup et al., 2010; 
Stamatovic et al., 2005). In line with this, depletion of CX3CR1low, CCR2pos, Ly6Chigh 
monocytes by application of liposomes containing dichloromethylene diphosphonate induced 
a significant alleviation of the symptoms of experimental autoimmune encephalomyelitis 
(EAE) (Brosnan et al., 1981; Huitinga et al., 1990).  
In AD, however, it remains to be clarified whether a CCL-CCR2-dependent infiltration 
of monocytes occurs and whether this would affect disease outcome. Studies have shown that 
CCL2 concentrations are increased in AD and may be released by microglia and astrocytes in 
response to Aβ deposition (Khoury et al., 2003; Naert and Rivest, 2013; Smits et al., 2002; 
Vukic et al., 2009). This in turn, would induce monocyte extravasation from the blood into the 
brain (Fiala et al., 1998). Interestingly, the genetic deletion of Ccr2 reduced plaque-associated 
cells and increased Aβ deposition as well as intracellular forms of Aβ (Khoury et al., 2007; 
Naert and Rivest, 2011). These studies hypothesize that recruitment of peripheral monocytes 
upon CCL attraction into the brain play a critical role for the etiology of AD. However, none 
of these studies could clearly prove that the aggravation of Aβ pathology was due to a failure 
of the CCL-CCR2-mediated infiltration of peripheral monocytes or caused by secondary effects 
of Ccr2 deletion, because of the lack of a specific marker that enables discrimination between 
invaded monocytes and the resident microglia.  
For that reason, studies made usage of bone marrow irradiation to first eliminate bone 
marrow (BM)-derived monocytes, which were then replaced by GFP-labelled bone marrow 
cells in mouse models of AD. These studies showed a massive infiltration of GFP-positive cells 
into the brain where they associated to Aβ depositions and modulated plaque pathology 
(Mildner et al., 2007; Simard et al., 2006; Stalder et al., 2005). However, total-body irradiation 
was shown to cause artificial damage of the BBB that promotes and thereby obscures the 
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relative contribution of the infiltration of peripheral monocytes (Mildner et al., 2007). This can 
be circumvented by shielding the head of animals during irradiation, which remarkably resulted 
in a lack of GFP-positive monocytes in the brain (Mildner et al., 2011). Similar results were 
seen in a parabiosis study in which the blood circulation of CD45.2+ 5xFAD mice was joined 
with congenic CD45.1+ mice. Analogous to head-shielded mice, the brain of 5xFAD was free 
of BM-derived CD45.1+ monocytes (Wang et al., 2016).  
Another approach to study a possible monocyte infiltration after a potential microglia 
loss or dysfunctionality in disease, is the HSVTK-dependent ablation of microglia in the adult 
brain. Therefore, mice that expressed the CD11b-HSVTK (TK+) construct were crossed to mice 
which carried the gene for red fluorescent protein (RFP) under the Ccr2 promoter (Ccr2+/Rfp). 
Microglia ablation was induced by two weeks of GCV treatment that was shown to deplete >90 
percent of all brain myeloid cells (Grathwohl et al., 2009; Varvel et al., 2012). To examine cell 
repopulation of the brain, the mice were housed for another two weeks until an infiltration of 
cells positive for the cell surface marker CD45 and RFP-labeled CCR2 was observed. These 
cells entered the brain from small blood vessels confirming their peripheral and hematopoietic 
origin. Of note, the CCR2-RFP-positive cells were distributed across the brain as observed for 
the resident microglia in control mice, however their number was highly enriched and 
morphological differences like enlarged cell soma and shorter, asymmetrically orientated 
processes were detected (Varvel et al., 2012). Remarkably, the number of the invaded CCR2-
RFP-positive cells remained stable over a 27-week observation period with a similar rate of 
proliferation as observed in microglia. Furthermore, the engrafted myeloid cells took over 
essential surveillance functions such as covering of the neuropil by their processes or the 
migration towards experimentally induced neuronal damage indicating that under certain 
conditions monocytes can replace dysfunctional microglia and adopt their phenotype. These 
results were further supported by a study in which infiltration of peripheral myeloid cells after 
GCV application was tracked by performing isochronic parabiosis with mice expressing 
enhanced green fluorescent protein (GFP) under the ubiquitously expressed actin promoter 
(Act.GFP). In the TK+ mice, where microglia were depleted, a substantial number of GFP-
positive cells were found in the brain two weeks after GCV discontinuation (Prokop et al., 
2015).  
Contrary to the HSVTK model, another study found that after microglial depletion using 
pharmacological inhibition of colony stimulating factor 1 receptor (CSF1R) signaling that is 
mandatory for microglial survival, the repopulating cells that rapidly infiltrated the brain 
resembled microglia in morphology and cell number (Elmore et al., 2014). However, these cells 
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were assumed to originate from a resident microglia progenitor pool through self-renewal rather 
than being replaced by infiltrating monocytes, as no CCR2-RFP-positive cells could be detected 
(Elmore et al., 2014). The reported controversies for the origin of the repopulating cells could 
be due to the different approaches that were used to deplete the initial microglia pool. It is 
possible that pharmacological CSF1R inhibition leads to a small subset of surviving cells, 
which could be responsible for the rapid self-renewing of phenotypically similar microglia.  
In summary, under special conditions such as a compromised BBB or pharmacological 
microglia ablation the brain becomes repopulated by cells that have the ability to adopt a 
microglial phenotype.  
 
3.2.3 Environment determines macrophage function in the brain 
Based on the findings from Varvel et al. that, upon microglia depletion, invading myeloid cells 
were capable of maintaining tissue homeostasis in a similar way as microglia do (Varvel et al., 
2012), we wanted to examine whether the replacement of dysfunctional microglia by myeloid 
cells in mouse models of cerebral β-amyloidosis alters amyloid deposition and could thus be of 
therapeutic value as already implicated in a mouse model of Rett syndrome (Derecki et al., 
2012). To this end, CD11b-HSVTK (TK+) mice were crossed to two mouse models of AD, 
namely APPPS1 mice which contain human transgenes for mutated APP and PSEN1 with early 
Aβ deposition and APP23 mice which overexpress mutated human APP with late Aβ deposition 
(Radde et al., 2006; Sturchler-Pierrat et al., 1997). Remarkably, in TK+-APPPS1 mice, which 
were analyzed two weeks after discontinuation of GCV treatment to deplete the endogenous 
microglia pool, the infiltrated cells did not cluster around congophilic plaques as observed in 
TK- control mice. In fact, all cells displayed a homogenous phenotype with shorter processes 
and enlarged cell bodies in accordance with what was described by Varvel et al. in wildtype 
animals (Varvel et al., 2012). Interestingly, the lack of clustering around Aβ deposits induced 
no changes in Aβ load. Also, extended ageing time points (up to six months) after GCV 
treatment in the APP23 mouse line did not change plaque pathology. However, after this long-
term brain engraftment, some of the myeloid cells in the TK+ mice were found to cluster around 
Aβ plaques. Furthermore, the initial myeloid cell number in TK+ mice that was determined two 
weeks after discontinuation of GCV application was approximately doubled in comparison to 
TK- mice, but was virtually equal to cell number of age matched TK- controls after long-term 
cell engraftment (Varvel et al., 2015).  
Finally, we tested whether the replacement of microglia before amyloid deposition in 
APP23 mice might be more beneficial in terms of the pathology of cerebral β-amyloidosis. 
Therefore, GCV treatment was started before Aβ plaque deposition allowing the myeloid cells 
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to repopulate the brain before onset of Aβ deposition. Surprisingly, five months after treatment, 
when Aβ plaque pathology was present, myeloid cells of TK+ mice behaved similar to microglia 
of TK- mice. Cells clustered tightly around plaques and those in plaque-free areas reflected a 
more microglia-like morphology, with smaller cell bodies and a ramified appearance. Of note, 
no changes in plaque pathology became apparent. Furthermore, similar to microglia, the 
engrafted plaque-associated cells in the long-term repopulated brain were positive for TREM2, 
whereas myeloid cells that were analyzed shortly after repopulation were TREM2-negative 
(Varvel et al., 2015). Thus, it can be concluded, that Trem2 expression seems to be influenced 
by the local environment and is not strictly cell-specific regulated.  
In line with our findings that monocytes that engraft in the brain become microglia-like 
and adopt essential microglial functions, a study from Lavin et al. could show that bone 
marrow-derived macrophages that arise from transplanted bone marrow after lethal irradiation 
replace the ablated tissue resident macrophages and establish a new but tissue-specific identity 
(Lavin et al., 2014). Additionally, differentiated peritoneal macrophages, which were isolated 
and transferred into the alveolar cavity, showed downregulation of peritoneal-specific markers 
and a parallel upregulation of lung-macrophage specific genes. Overall, in the engrafted 
peritoneal derived macrophages, 70 percent of genes that were differentially expressed in 
peritoneal macrophages compared lung macrophages were switched to resemble lung 
macrophages indicating that the new environment can reprogram the genetic identity of 
macrophages (Lavin et al., 2014). Another study showed that isolated microglia, which were 
only cultured with IL-34, an essential factor for microglia development (Greter et al., 2012; 
Wang et al., 2012), expressed a completely different gene set than observed in vivo (Gosselin 
et al., 2014).  
According to our findings that the AD brain micro-environment shapes monocyte and 
microglial function independent of cell origin, these studies additionally suggest that the 
environmental-induced identities and functions of tissue resident macrophages are regulated 
through the induction of tissue-specific regulatory elements of the transcriptional process that 
modify the enhancer landscapes of the macrophages genes (Lavin et al., 2014).  
However, apart from signals of the micro-environment, systemic alterations during 
lifetime might also be able to influence the genomic profile of tissue resident macrophages and 
could therefore be a potential tool to manipulate these cells.   
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3.3. Modification of CNS pathology by molecular reprogramming of the innate 
immune response  
In reference to:  
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3.3.1 Systemic inflammation as trigger for neurological disease 
The CNS is considered an immune-privileged region as the BBB shields the brain from the 
periphery. However, communication between the periphery and the CNS clearly exists, since 
several peripheral diseases, for example viral infections or sepsis, induce the development of a 
sickness behavior. Sickness behavior describes behavioral changes of the affected individuals 
such as the loss of appetite, lethargy or hyperalgesia, which are accompanied by metabolic 
changes going along with an altered body temperature, increased somnolence and loss of body 
weight, to facilitate the organisms combating of a disease (Hart, 1988). Also, an experimentally-
induced acute systemic infection by infusion of recombinant cytokines or injections of bacterial 
cell wall components such as the endotoxin lipopolysaccharide (LPS) was reported to induce 
sickness behavior (Brydon et al., 2008; Dantzer, 2001; Harrison et al., 2009).  
During systemic infection, inflammatory modulators which are produced by the resident 
immune cells as a local inflammatory response to the infection are transmitted to the brain along 
different humoral and nerve routes without compromising of the BBB (Kent et al., 1992; 
Konsman et al., 2002). In turn, microglia, as the resident immune effector cells in the brain, 
become rapidly activated and induce a robust non-specific but systemic response to the 
infection including the above-mentioned behavioral and metabolic alterations (Dantzer, 2001). 
The duration of sickness behavior upon an acute systemic infection is tightly regulated by the 
production of anti-inflammatory modulators like IL-10, TGF-β or glucocorticoids in the brain 
to dampen the immune response in the periphery but also in the CNS to avoid detrimental 
effects for the brain (Bogdan et al., 1992; Rivest, 2009).  
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Apart, from acute systemic infections that induce a strong release of inflammatory 
mediators, the presence of subclinical but sustained endotoxemia experimentally induced by 
LPS administration was reported to positively correlate with peripheral pathologies such as 
insulin resistance, atherosclerosis or chronic kidney disease mediated by an upregulation of the 
inflammatory immune response (Mehta et al., 2010; Terawaki et al., 2010; Wiesner et al., 
2010).  
Interestingly, an enhanced expression of inflammatory cytokines was also seen in brains 
of animal models of neurodegenerative diseases, a state that is suggested to prime or pre-
activate microglia to become more susceptible to phenotype switching following further 
immune challenges (Betmouni et al., 1996; Cunningham et al., 2002; Depino et al., 2003; Perry 
et al., 2002; 2007; Sly et al., 2001; Walsh et al., 2001). Moreover, increased levels of the pro-
inflammatory IL-6 cytokine, but decreased levels for the anti-inflammatory IL-10 cytokine 
were reported in the brain of aged mice, implying that ageing causes an inflammatory 
environment as already described by the term “inflammaging” (Cribbs et al., 2012; Ye and 
Johnson, 1999; 2001). Remarkably, studies showed that a systemic immune stimulus, when 
administered to aged mice or during chronic neuroinflammation, induced an exaggerated 
inflammatory response with enhanced production of pro-inflammatory cytokines, but also 
increased acute neurodegeneration (Cunningham et al., 2005; Godbout et al., 2005).  
With respect to AD as a chronic neurodegenerative disease, an acute systemic immune 
challenge temporarily increased the production of cytokines such as IL-1β, TNF-α and IL-6, 
Aβ40 levels and tau hyperphosphorylation in transgenic mouse models of AD (Lee et al., 2002; 
Sly et al., 2001). Intriguingly, the exposure to a chronic but localized inflammation exacerbated 
and accelerated neuroinflammation as well as Aβ pathology in APP/PS1 mice (Kyrkanides et 
al., 2011).  
Additionally, several human studies reported similar trends. Thus, people that were 
affected by chronic periodontitis or type 2 diabetes were reported to have a higher risk to be 
affected of AD (Kamer et al., 2008; Rojas-Gutierrez et al., 2017; Sparks Stein et al., 2012). 
Accordingly, patients with mild to severe AD, which suffered from severe infections, show an 
accelerated cognitive decline (Holmes et al., 2011; 2009). Furthermore, a recent study 
examined the relationship between systemic inflammation in midlife and neurodegeneration. 
Interestingly, this longitudinal study could associate heightened inflammatory markers in the 
blood during midlife with lower brain volumes and reduced episodic memory 24 years later 
(Walker et al., 2017). Additional evidence for the influence of systemic inflammation on 
neurological disease outcome comes from a retrospective study that examined patients with 
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incident dementia, in which it was observed that preceding infections episodes increased the 
likelihood for a later dementia diagnosis (Dunn et al., 2005). Consequently, these observations 
suggest that systemic infections may not only exacerbate ongoing neurological diseases, but 
also promote their onset.  
However independently of the exacerbation or promotion of a neurological disease, the 
occurrence of systemic inflammatory events of different severity and duration during or before 
chronic neurodegenerative diseases cause an exaggerated immune response of the CNS. As 
microglia are exclusively sensitive to disturbances in the brain, it is assumed that “microglial 
priming” through the mentioned preceding inflammatory events is the principle process 
inducing an exaggerated secondary immune response towards emerging neurological diseases 
(Perry et al., 2007). Accordingly, microglial priming implicates that the innate immune system 
possesses the capability – following the adaptive immune system – to elicit an exaggerated 
immune reaction in response to subsequent inflammatory insults.  
 
3.3.2 The concept of innate immune memory 
Systemic infections within a host initiate an immune response that is mediated by the innate 
immune system – an evolutionarily old defense strategy and the first line of protection against 
invading pathogens. This form of immunity is found in all classes of plant and animal life as 
well as in fungi and other multicellular eukaryotes (Janeway et al., 2001) and is triggered by 
the sensing of pathogen-derived molecules (pathogen-associated molecular patterns (PAMPs)) 
or endogenous danger signals (damage-associated molecular patterns (DAMPs)) by pattern 
recognition receptors (PRRs), which initiate the synthesis of inflammatory cytokines and 
chemokines by macrophages and other immune cells (C A Janeway, 1989). Upon the generation 
of an inflammatory milieu to restrict spreading of the infection, tissue- resident macrophages 
engulf the pathogenic substance through phagocytosis and recruit monocytes and other 
leucocytes as well as lymphocytes from the blood to rapidly resolve the inflammation. 
Collectively, the innate immune response presents a first, relatively unspecific, line of host 
defense that is, in the later stages of an infection, supported by the adaptive immune system, 
which triggers a very specific but delayed immune reaction (Alberts et al., 2002). 
It was long believed that only the adaptive immune system is able to create an 
immunological memory after exposure to a pathogenic stimulus, which leads to an enhanced 
response in case of a second encounter with the same pathogen(Janeway et al., 2001). First 
evidence for immunological memory of the innate immune system was provided by studies in 
plants and invertebrates, which lack the adaptive immune system. In plants, the phenomenon 
of “systemic acquired resistance” (SAR) describes the heightened immune response towards 
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reinfection by a primary pathogen (Durrant and Dong, 2004; Kachroo and Robin, 2013). 
Invertebrate animals also exhibit a similar form of immune memory; for example, after the first 
exposure to the tapeworm Schistocephalus solidus, the copepod crustacean is protected against 
a reinfection with the same pathogen through a more efficient and specific immune response 
(Kurtz and Franz, 2003). These results point towards a special form of immunity that is gained 
after the first contact with pathogens and intensifies the second immune response; an effect that 
was recently denoted as “trained immunity” (Netea et al., 2011).  
Furthermore, studies in mice, which showed that the animals were protected against a 
lethal infection after the initial exposure and priming with microbial ligands of PRRs such as 
β-glucan, the peptidoglycan component muramyl dipeptide or flagellin, introduced the principle 
of trained immunity to vertebrates (Di Luzio and Williams, 1978; Krahenbuhl et al., 1981; 
Muñoz et al., 2010; Zhang et al., 2014). Moreover, compelling evidence for trained immunity 
was provided by studies conducted in mice that lacked the thymus, the essential organ for T-
cell maturation. In these mice, vaccination with tuberculosis bacillus Calmette Guérin (BCG) 
protected, in a T-cell-independent fashion, against reinfection with Candida albicans or 
Schistosoma manosi (Tribouley et al., 1978; van 't Wout et al., 1992). Importantly, there is also 
evidence for innate immune memory from vaccination studies in humans, in which 
immunization with live but attenuated vaccines such as the BCG or the measles virus turned 
out to be protective against non-targeted diseases (Benn et al., 2013).  
Interestingly, studies in which macrophages were challenged with LPS to examine their 
potential for acquiring memory, it could be shown that macrophages became more or less 
responsive as a result of the initial differential stimulation paradigms with LPS (Foster et al., 
2007). These findings expand the capability of innate immune memory from a priming or 
training effect to a “tolerizing” effect mediated by chronic exposure to LPS. LPS-induced 
tolerance is considered an immune paralysis state characterized by a hypoinflammatory profile 
that can be induced by severe sepsis or experimentally mimicked by continuous or high-dose 
endotoxin challenges possibly as result of receptor desensitization or an imbalance in the 
production of inflammatory mediators (Medvedev et al., 2000; van der Poll and Opal, 2008). 
Accordingly, cultured monocytes, which were exposed for 24 hours to LPS to induce immune-
tolerance, showed a decreased production of pro-inflammatory cytokines such as TNF-α or IL-
6 upon a secondary immune stimulation (Saeed et al., 2014).  
However, it is of importance to distinguish between immune memory and acute 
immunological processes as both include immune cell activation. Whereas immune cell 
activation or differentiation in the context of immunological processes occurs as a direct and 
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acute function of pathogen sensing or changes in the environment, mechanistic studies suggest 
that alterations in macrophage function due to training or tolerizing immune challenges through 
primary pathogen contact are mediated by epigenetic reprogramming that results in persistent 
changes in chromatin marks, which modify the cell-mediated immune response upon further 
stimuli subsequent to the initial insult (Netea et al., 2016).  
So far, persistence of microbial ligand-induced immune memory in vitro, in short-lived 
monocytes or macrophages, was studied only for a limited time period from one to five days 
(Ifrim et al., 2014; Ostuni et al., 2013; Saeed et al., 2014). However recently, long-lived 
epithelial stem cells were also attributed to innate immune memory, as a preceding immune 
stimulus resulted in a more rapid wound healing 180 days after the primary immune stimulus 
(Naik et al., 2017). In line, vaccination studies with BCG in healthy volunteers showed an 
enhanced release of cytokines from blood monocytes for up to three months (Kleinnijenhuis et 
al., 2012), indicating the possibility of a longer-lasting acquirement of trained immunity that 
must take place at the level of progenitor cells, as circulating monocytes have a suggested half-
life in circulation of about one day (Yona et al., 2013).  
 
3.3.3 Epigenetic reprogramming induces immune memory in macrophages 
The DNA of a cell is arranged around histone cores and further structured in nucleosomes, 
which are the primary components of chromatin. Besides other functions, the chromatin 
complex is required to tightly pack DNA but also to control gene expression. Epigenetic 
modification of specific regions in histones, for example by methylation or acetylation of 
certain amino acid residues, can induce changes in the local chromatin structure allowing 
enhanced or repressed transcription of genes. In particular, post-translational methylation of the 
lysine (K) residue 4 and acetylation of K27 at histone 3 (H3) were shown to define active 
enhancer sites, which are positively associated with gene transcription of nearby genes (Fig. 
3C). In contrary, histones that bear H3K9 and H3K27 trimethylation (me3) mark a closed 
chromatin conformation that does not allow gene transcription (Ivashkiv, 2013). Additionally, 
trimethylation of H3K4 (H3K4me3) and acetylation of H3K27 (H3K27ac) are reliable marks 
for active promoter regions where the RNA polymerase II protein complex can easily bind to 
the DNA to catalyze transcription (Fig. 3D). 
Enhancer regions belong to cis-regulatory elements that contain DNA-binding sites for 
transcription factors that, upon binding, can increase the likelihood for transcription of a 
particular gene. Structurally, active enhancer regions are devoid of nucleosomes and the DNA 
is easily accessible for transcription factors. Thereby, the DNA-binding sites are flanked by 
histones characterized through the above mentioned H3K4me1 or H3K27ac modifications. 
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Figure 3: Epigenetic changes in the chromatin landscape of macrophages can occur in response to 
endogenous but also exogenous signals. (A) During macrophage development, lineage determining transcription 
factors bind to enhancer regions of genes that are essential for cell maturation and (B) induce the acquisition of 
histone 3 (H3) lysine residue 4 (K4) monomethylation (me1) (H3K4me1), the main epigenetic signature for 
potentially active enhancers (pre-determined enhancer state). Upon further endogenous or exogenous signals 
H3K4me1 labeled enhancer become activated (C) through the recruitment of stimulus-dependent transcription 
factors that initiate H3K27 acetylation (ac). (D) Active enhancers support the transcription of the required genes 
by promoting gene transcription via RNA polymerase II at interacting promotor sites. (E) Rather than activating 
enhancers, recruitment of stimulus-dependent transcription factors can also induce a suppressed enhancer 
configuration by trimethylation of the H3K9 and H3K27 residues. (F) Developmentally unmarked “latent” 
enhancer regions can become marked via stimulus-dependent transcription factors to induce gene transcription. 
During the process of cell maturation, the binding of lineage determining transcription 
factors (LDTFs) to nucleosomes enables the recruitment of enzymes for H3K4 methylation, 
shifting the marked enhancer regions into a pre-determined poised, active (which is further 
characterized by additional H3K27ac marks (Creyghton et al., 2010; Rada-Iglesias et al., 2011)) 
or repressive state, (Fig. 3A,B (shown is an exemplary representation of a poised enhancer)) 
(Heinz et al., 2010; Ostuni et al., 2013). Studies in primary macrophages have shown that PU.1 
acts as a master LDTF that determines cell specificity of the macrophage lineage (Barozzi et 
al., 2014; Ghisletti et al., 2010; Heinz et al., 2010). 
Upon further macrophage stimulation, due to environmental changes for example, 
stimulus-responsive transcription factors, such as NF-κB, AP-1 or STAT family members, are 
recruited to pre-marked enhancer and promoter regions within the genome. These proteins act, 
similar to LDTFs, as co-activators for enzymes such as the histone acetyltransferase to enable 
histone acetylation (H3K27ac) in enhancer regions of genes whose enhanced transcription is 
required (Fig. 3C, D) (Barozzi et al., 2014; Ghisletti et al., 2010; Heinz et al., 2010; Ramirez-
Carrozzi et al., 2009; 2006; Smale and Natoli, 2014; Smale et al., 2014). On a molecular basis, 
it was shown that histone acetylation leads to the addition of negative charges to the positive 
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lysine residue, which in turn further reduces the interaction between DNA and histones leading 
to improved accessibility of the DNA for other co-regulatory proteins required for the 
transcriptional process (Creyghton et al., 2010; Smale et al., 2014).  
In addition to LDTFs pre-marked enhancer regions, in vitro experiments defined 
“latent” enhancer regions in macrophages, which are epigenetically unmarked and inactivated 
regulatory elements, but can be directly activated in response to distinct environmental stimuli 
and gain H3K4 monomethylation as well as H3K27 acetylation (Fig. 3F) (Kaikkonen et al., 
2013; Ostuni et al., 2013). Notably, histone modifications in such “latent” enhancer regions, 
which were acquired upon LPS or cytokine stimulation, were shown to have different stability 
(Fig. 4A/B). Whereas H3K27ac was lost quickly after the cessation of the stimulation, 
H3K4me1 was maintained leading to a poised enhancer state with an enhanced epigenetic status 
(Fig. 4C). However, upon subsequent re-stimulation histone acetylation was re-established, 
enhanced and in turn induced a faster and stronger induction of genes adjacent to these enhancer 
regions (Fig. 4D) indicating the presence of a short-term transcriptional memory (Ostuni et al., 
2013). 
Interestingly, the identified “latent” enhancer in that study accounted for 15% of all 
LPS-induced activated enhancer and were assigned closer than LDTF-pre-determined enhancer 
to nearby induced genes, suggesting an important role for “latent” enhancer during the LPS-
mediated cellular response (Ostuni et al., 2013). Consequently, it can be assumed that the 
unveiling of “latent” enhancers resembles the in vivo situation, in which the response of 
differentiated tissue macrophages towards microenvironment-specific signals may be mediated 
by the activation of “latent” enhancers as regulators for the induction of an individual 
environment-specific enhancer repertoire (Gosselin et al., 2014; Lavin et al., 2014).  
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Figure 4: A model for the temporary acquisition of histone modifications for latent enhancer. (A, B) During 
macrophage stimulation the binding of stimulus-dependent transcriptions factors, to “latent” enhancer regions 
enables the deposition of H3K4me1 and H3K27ac marks to shift these enhancers into an active state. (C) After 
cessation of the of the primary stimulus, bound transcription factors and H3K27ac marks are lost, whereas 
H3K4me1 modifications are retained (so-called poised enhancers). (D) Upon a secondary immune stimulation, 
“re-activated” enhancer regions can more quickly re-acquire H3K27ac marks, leading to stronger and faster 
activation of the corresponding gene transcription. 
 
3.3.4 The molecular basis of immune memory in macrophages  
Emerging data support that apart from a direct influence on innate immune signaling 
pathways upon acute macrophage activation, changes in metabolic pathways play critical roles 
in the induction of the immune response as well (Ganeshan and Chawla, 2014). Macrophages 
acutely activated by LPS were reported to shift their energy metabolism from oxidative 
phosphorylation to the faster adenosine trisphosphate (ATP) supply via the glycolytic pathway 
in the cytosol. The sudden metabolic switch from oxidative phosphorylation to glycolysis 
increases the mitochondrial membrane potential due to the electron transport chain across the 
mitochondrial membrane being disrupted (Tannahill et al., 2013). Additionally, acute activation 
of macrophages was shown to interfere with the citric acid cycle to enable a sufficient supply 
of the intermediate product succinate. Oxidized succinate (fumarate), in combination with an 
increased mitochondrial membrane potential, is required for the enhanced production of 
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reactive oxygen species (ROS) by reverse electron transport (RET), which in turn alters activity 
of the transcription factor (TF), hypoxia-inducible factor-1α (HIF-1α) (Mills et al., 2016).  
HIF-1α is known to drive gene expression of the pro-inflammatory cytokine IL-1β (Jha 
et al., 2015; Mills et al., 2016; Tannahill et al., 2013). Concurrently, accumulation of fumarate 
decreases the expression of the anti-inflammatory cytokine IL-10 (Mills et al., 2016).  
To pursue the role of cellular metabolism during epigenetic macrophage 
reprogramming, further in vitro studies were performed, in which isolated human or murine 
monocytes were stimulated with a training or tolerizing immune stimulus and incubated for up 
to seven days until a secondary immune stimulus was administered to induce immune memory 
(Cheng et al., 2014; Saeed et al., 2014). Remarkably, the applied inflammatory stimuli largely 
altered cellular metabolism pathways acutely, but also after the prolonged incubation period. 
Specifically, β-glucan stimulation of monocytes, which induced trained immunity, increased 
glucose consumption, lactate production and the ratio of nicotinamide adenine dinucleotide 
(NAD(+)) to its reduced from (NADH) representing a shift to aerobic glycolysis energy 
metabolism upon restimulation of the cells. These alterations indicate that changes in the 
cellular metabolism are crucial for the induction of trained immune memory (Cheng et al., 
2014). Moreover, the glycolysis favored-ATP production induced by training was reported to 
be dependent on the activation of the dectin-1/Akt/mammalian target of rapamycin 
(mTOR)/hypoxia-inducible factor-1α (HIF-1α) (Akt/mTOR/HIF-1α)-pathway (Cheng et al., 
2014).  
So far, it is not completely clear why metabolic circuits are drastically affected during 
the epigenetic formation of immune memory. It is suggested, that metabolic intermediates of 
the respective up- or down-regulated metabolic pathways are co-factors for the regulation of 
histone modifications which, in turn, suppress or activate phenotype-associated genes (Bénit et 
al., 2014; Donohoe and Bultman, 2012; Gut and Verdin, 2013; Saeed et al., 2014). 
Apart from alterations in the cellular metabolism during the induction of training or 
immune tolerance, further signaling pathways were shown to be differentially modified. The 
cyclic adenosine monophosphate (cAMP)-dependent signaling pathway, which is important for 
the cell communication, was also identified as a crucial regulator of trained immunity in 
macrophages (Saeed et al., 2014). Additionally, it was found that immune training of monocytes 
induced phosphorylation of the activating transcription factor 7 (ATF7) which, in turn, reduces 
the repressive histone mark H3K9me2 in regions where genes of the immunological network 
are located (Yoshida et al., 2015). In contrast, LPS-induced tolerance increases levels of 
repressive histone modifications in promoter regions of the inflammatory cytokines IL-1β and 
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TNF-α, which inhibits the transcription of these genes upon subsequent pathogen stimulation 
(Gazzar et al., 2009).  
While there is convincing evidence for innate immune memory in macrophages from in 
vitro studies, none of the studies has examined the consequences of epigenetic remodeling of 
the innate immune response in macrophages on a subsequent pathology in vivo and only a few 
experiments investigated the microglial potential of immune memory (Holtman et al., 2015). 
For that reason, we applied the model of trained- and tolerance-induced immune memory to a 
mouse model of cerebral β-amyloidosis to investigate the effects of immune memory on the 
reflected neurological disease hallmarks of AD pathology. 
 
3.3.5 Innate immune memory in the brain shapes neurological disease hallmarks 
Most of the studies on training and tolerance-induced epigenetic remodeling of the chromatin 
landscape during the establishment of innate immune memory have been done in peripheral 
macrophages or blood-derived monocytes (Cheng et al., 2014; Saeed et al., 2014). For 
microglia, the resident tissue macrophages of the brain, it is generally accepted that these cells 
can adopt altered phenotypes upon different pathogenic stimuli (Norden and Godbout, 2013; 
Perry and Holmes, 2014; Raj et al., 2014). However, the often-described microglial priming is 
only a functional definition as few studies have investigated the transcriptional profile that is 
induced by different priming stimuli. Moreover, priming is normally observed during acute 
inflammatory processes and could therefore not reveal microglial immune memory (Combrinck 
et al., 2002; Cunningham et al., 2005). Therefore, we were interested if LPS-induced 
inflammation in the periphery – a well-established method to prompt a microglial response in 
the brain – can evoke a training or tolerance immune memory effect in microglia, similar to 
what was reported for monocyte-derived macrophages (Saeed et al., 2014). 
In our study, we could show that low dose LPS (500 µg/kg bodyweight) injected 
intraperitoneally (i.p.) on four consecutive days in young adult mice induced acute alterations 
in brain cytokines, reminiscent of immune training and tolerance (Fig. 5A). Thus, after a small 
cytokine response following the first LPS injection, the second LPS injection induced a drastic 
increase in brain cytokine levels (such as IL-1β, IL-6 or TNF-α) indicating a training effect 
induced by the first LPS injection. However, the third and fourth LPS injections abolished 
cytokine production and thus implied a tolerant immune state in the brain. 
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Figure 5: Experimental design to induce immune memory in microglia. (A) To study the acute effects of 
different doses of peripherally applied LPS in the brain and to identify microglia as mediators of the immune 
response, wildtype, APP23 and CX3CR-CreER x Hdac1/2fl/fl as well as CX3CR-CreER x Tak1fl/fl mice, which 
received prior tamoxifen treatment to induce Hdac1/2 and Tak1 depletion, were treated at three months of age 
with different immune challenges (1xLPS, 2xLPS, 3xLPS, 4xLPS), and analyzed 3h after the injections. Thereby, 
a single LPS injection was identified to induce training effects whereas four consecutive LPS injections induced 
immune tolerance. (B) In a second experiment, the long-term effects of LPS treatment on immune memory and 
the consequences for the pathology of cerebral β-amyloidosis in the APP23 mouse model were investigated. After 
six months of incubation, the mice were anesthetized and analyzed for their immune profile and Aβ pathology as 
well as for potential changes in the microglial epigenetic signature of histones and in expression levels of 
corresponding genes.  
To examine whether the observed memory effects were microglia-specific, we used the 
CX3CR1-CreER (Cre) mouse line that was crossed to mice carrying either the loxP flanked 
genes: “transforming growth factor (TGF)-β-activated kinase 1” (Tak1) or “histone 
deacetylases-1 and -2” (Hdac1/2). TAK1 and Hdac1/2 are major regulators of transcriptional 
processes, macrophage inflammatory responses and the epigenetic chromatin architecture 
(Goldmann et al., 2013; Kannan et al., 2013; Sato et al., 2005; Shakespear et al., 2011). In these 
mice, tamoxifen induced Cre recombinase expression results in efficient target gene 
inactivation. After an incubation period of four weeks following tamoxifen application, the loxP 
flanked (floxed; fl) genes: Tak1 and Hdac1/2 are efficiently ablated in the stable microglia 
population but present in the short-lived and continuously replenished peripheral monocytes 
(Fig. 5A) (Goldmann et al., 2013). Consequently, LPS injections into the CX3CR1-CreER x 
Tak1fl/fl and CX3CR1-CreER x Hdac1/2fl/fl mice did not alter the peripheral immune response 
but restricted the amplification of brain cytokines. Thus, we could confirm that the alterations 
in brain cytokine levels after the LPS-induced inflammatory state were mediated predominantly 
by microglia. Based on these observations, a single peripheral LPS stimulus (1xLPS) was 
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identified to elicit a training effect whereas prolonged (four days, 4xLPS) peripheral LPS 
administration induced immune tolerance in microglia.  
After identification of these two different stimulation paradigms, we tested whether the 
induced immune training and tolerance state in microglia can lead to long-term alterations in 
the brain and thereupon modulate the pathology of neurological diseases. Therefore, we 
peripherally injected three-month-old APP23 mice, which develop cerebral β-amyloidosis and 
microgliosis from six months of age (Sturchler-Pierrat et al., 1997), as well as wildtype 
littermate controls and analyzed pathology at an age of nine months (Fig. 5B). Notably, our two 
different microglial stimulation paradigms (1xLPS vs. 4xLPS) significantly influenced Aβ 
pathology in APP23 mice. Thus, a training stimulus resulted in an increased cortical Aβ plaque 
load compared to PBS-treated control APP23 mice. In contrary, the induction of tolerance by 
consecutive injections of LPS for four days, decreased Aβ plaque load significantly. In line 
with these observations, the cytokine production in the brain, but not in the periphery, was 
influenced at that stage of the disease. Immune tolerance suppressed IL-1β production whereas 
training blocked IL-10 production. 
When we tested the immune memory function of microglia in a second mouse model 
of neuropathology, in particular, after the induction of a focal cortical ischemia one month after 
peripheral LPS treatment, we observed also differences in the acute microglial immune 
response. Remarkably, the release of inflammatory cytokines with suppression of IL-10 by 
1xLPS and IL-1β by 4xLPS, but enhancement of IL-1β by 1xLPS was similar to what we 
observed in the APP23 mice with Aβ pathology. Moreover seven days after the ischemic insult, 
4xLPS treatment reduced the volume of neuronal damage and microglia activation indicating 
that the induced immune tolerance can modify stroke pathology through long-term modulation 
of the brain’s immune response. 
In a third approach, we tested whether immune stimuli other than LPS elicit a similar 
immune memory effect in the brain. Therefore, we peripherally injected individual cytokines 
at different concentrations and analyzed mice four weeks later after the administration of an 
acute secondary immune stimulus. In line with the previous results, the measured brain 
cytokines reflected comparable training and tolerance effects that were undetectable in the 
periphery.  
In vitro studies established that immune memory in monocytes can be induced by 
epigenetic reprogramming of the enhancer landscape, which leads to changes in the 
transcription of assigned genes involved in the innate immune response (Ivashkiv, 2013; Saeed 
et al., 2014). To test whether our peripheral immune challenges could induce alterations in the 
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microglial enhancer repertoire in vivo, we analyzed the epigenetic landscape of the microglia 
isolated from the differentially treated APP23 or wildtype mice by the examination of 
H3K4me1 and H3K27ac histone marks, which define active enhancers states (Kaikkonen et al., 
2013; Ostuni et al., 2013). 
To begin with, we analyzed the profile of H3K4me1 histone modifications, which 
should be persistently established in response to the initial stimulus, that is i.p. LPS stimulation 
(compare Fig. 3/4). As expected, H3K4me1 histone marks were established both in wildtype 
and APP23 mice after primary immune stimulation. However, H3K4me1 levels were 
differentially regulated among wildtype and APP23 mice that received either the training or 
tolerant immune stimulus and showed diverse pathway enrichment patterns. In particular, 
H3K4me1 levels that were increased by a single LPS treatment compared to the 4xLPS 
treatment in wildtype mice were almost exclusively enriched for the “thyroid hormone 
signaling pathway”. Strikingly, that pathway includes an enhancer for HIF-1α, which is known 
to be a key modulator of pro-inflammatory gene expression (Cheng et al., 2012; Tannahill et 
al., 2013). Likewise, detected upregulations in H3K4me1 histone modifications in microglia 
from APP23 mice with 1xLPS compared to 4xLPS treatment were found to be enriched for the 
“HIF-1 signaling pathway”. 
Interestingly, the tolerant immune challenge (4xLPS) in APP23 but also wildtype mice 
induced the largest number of differentially expressed H3K4me1 levels and showed enrichment 
in pathways related to phagocytosis (for example: “Ras-related protein 1 (Rap1) signaling 
pathway” or “Endocytosis” pathway). Importantly, neither wildtype nor APP23 microglia from 
mice that received no priming stimulus displayed any pathway enrichment in relation to the 
differentially regulated H3K4me1 state underlining the induction of distinct molecular 
signaling pathways upon varying primary immune stimuli.  
As a second marker for enhancer activation, we analyzed the differential regulation of 
the H3K27ac histone modification among our wildtype and APP23 treatment groups. Here, we 
could detect a high number of differentially activated enhancers among the APP23 groups that 
was rather low in the wildtype groups pointing towards the requirement of an (secondary) acute 
stimulus to induce changes in the H3K27 acetylation pattern (Ostuni et al., 2013). 
 In line with the reported HIF-1α-dependent induced trained immunity in monocytes 
(Cheng et al., 2014) and the observed increase in H3K4me1 levels enriched for the “HIF-1 
signaling pathway”, increased H3K27ac levels in APP23 mice that received a single LPS 
injection showed highest enrichment for the same pathway in microglia compared to APP23 
control mice.  
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Again, in line with the H3K4me1 signature, the identified active H3K27ac enhancers in 
the group of APP23 mice that received the immune tolerance stimulus (4xLPS) were enriched 
for the “Rap1 signaling pathway” in comparison to APP23 control animals without LPS 
stimulation. Interestingly, the “Rap1 signaling pathway” induces the activation of the αMβ2 
integrin receptor on macrophages (complement receptor 3) and thereby enhances phagocytosis 
of C3bi-opsonized targets (Caron et al., 2000).  
Moreover, when we compared the 1xLPS treatment to the 4xLPS treatment in APP23 
mice, it became apparent, that a set of inflammation-related pathways such as the “Toll-like 
receptor signaling pathway” or the “Chemokine signaling pathway” were enriched by the 
highly increased H3K27ac levels observed in the 1xLPS group supporting the induction two 
epigenetically differentially regulated signatures by 1xLPS or 4xLPS.  
Interestingly, acute brain pathology alone was also sufficient to induce a small number 
of differentially regulated H3K27ac levels in untreated APP23 mice compared to the wildtype 
group, which could be related to the “thyroid hormone signaling pathway” as well as the 
“mTOR signaling pathway”. 
Remarkably, microglial mRNA sequencing and subsequent gene expression analysis by 
weighted gene correlation network analysis (WGCNA) to cluster genes into certain modules 
revealed significant correlations between the epigenetically induced alterations in H3K27ac 
levels of enhancer regions and the direction of change in the expression of their nearest genes. 
For example, increased gene expression in the red module that included the “HIF-1 signaling 
pathway” correlated positively with the 1xLPS-treated APP23 animals, in which we detected 
an enrichment in microglial H3K27ac levels for the “HIF-1 signaling pathway”. Furthermore, 
single genes within that module such as Hif1α or Inpp5d were significantly upregulated in the 
1xLPS-treated APP23 group, but downregulated with 4xLPS.  
HIF-1α has been shown to play an essential role in the regulation of pro-inflammatory 
signal molecules, but also in the expression of glycolytic enzymes in inflammatory-stimulated 
macrophages (Cheng et al., 2014; Cramer et al., 2003). In that context, it was interesting to 
note, that the green module, which was enriched for pathways involved in glycolysis, showed 
a positive correlation with the 1xLPS APP23 group. Simultaneously, there was also an 
upregulation of genes included in that module in APP23 versus wildtype control animals, which 
was further increased by 1xLPS and decreased by 4xLPS treatment in APP23 animals.  
Energy generation via glycolysis results in faster energy supply, but also in 
mitochondrial hyperpolarization and lactate production, which has been reported to be 
dependent on HIF-1α signaling (Cheng et al., 2014; Mills et al., 2016). Accordingly, the 
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measured mitochondrial membrane potential in our 1xLPS-treated APP23 animals was strongly 
increased and correlated well with lactate production compared to the untreated and 4xLPS 
APP23 group. Furthermore when we immuno-stained brain sections for HIF-1α, we could 
detect increased HIF-1α protein levels in plaque-associated microglia (which are the cells 
mostly affected by Aβ-pathology), which were even more upregulated in the 1xLPS-treated 
APP23 mice. This finding of differentially regulated HIF-1α signaling and the subsequent 
metabolic switch to glycolysis in response to Aβ-pathology suggests an important function of 
HIF-1α signaling in AD, which can be further enhanced by immune training or alleviated by 
immune tolerance induced in microglia. Interestingly, the Apoe gene, whose E4 allele is 
described as major risk factor for LOAD (Corder et al., 1993), can be found in the same module 
(red) as Hif1a and thus strengthens the assumption of HIF-1α being a modulator of AD 
pathology. 
In contrast to the previous modules, the grey module, which was enriched in pathways 
related to phagocytosis such as the “Rap1 signaling pathway”, showed a positive correlation 
with wildtype control animals but not with APP23 control animals. In line, there was a 
downregulation of genes assigned to that module in the control and 1xLPS APP23 groups. 
However, the 4xLPS-treated APP23 group showed similar levels of gene expression as 
wildtype controls. Accordingly, when we measured microglial phagocytosis by the 
determination of Aβ levels in isolated microglia in APP23 animals we saw an increase in the 
Aβ content after 4xLPS administration compared to the APP23 control and 1xLPS-treated 
groups, which may be responsible for the decrease in cortical Aβ deposition observed in the 
4xLPS APP23 treatment group and provides further functional evidence for the detected 
changes in the microglial gene expression analysis. 
Interestingly, the brown module comprised genes that were recently described to 
distinguish different microglial phenotypes due to their activation state (Keren-Shaul et al., 
2017). These genes characterizing homeostatic but also “disease-associated microglia” were 
significantly upregulated after a single but also repeated LPS stimulation in wildtype as well as 
APP23 microglia implicating once more a change in the microglial phenotype due to 
inflammatory stimuli. 
Taken together, our in vivo study provides first evidence for a long-lasting innate 
immune memory function in a tissue-resident macrophage population, which is sufficient to 
alter the pathology of neurological diseases in response to the induction of a trained or tolerant 
microglial phenotype. Importantly, we show that the training or tolerance induced remodeling 
of the microglial immune response occurs due to epigenetic changes in their enhancer 
Synopsis 
 
 45 
landscape. Although we observed a significant impact of primary immune stimulation on 
secondary pathology, the epigenetic changes were rather small in magnitude. However, data 
obtained by immunohistochemical staining for HIF-1α, a transcription factor that was 
differentially regulated by our training or tolerance immune stimulus, suggest that the observed 
alterations in epigenetic reprogramming and gene expression are mainly mediated by plaque-
associated microglia, which represent the minority of microglia at the examined stage of 
pathology. Thus, for further studies, it would be of great interest to discriminate the microglia 
population into different subgroups based on their localization in the brain in order to examine 
the epigenetic profile of plaque-associated and non-plaque associated microglia individually. 
Furthermore, our two different LPS stimulation paradigms identified a differential 
regulation of the “mTOR signaling pathway” and the transcription factor HIF-1α, which was 
strongest APP23 mice. Interestingly, the “mTOR signaling pathway” as well as HIF-1α are 
known to play a role in AD and interact via the Akt/mTOR/HIF-1α pathway (Cheng et al., 
2014; Ulland et al., 2017; Wang et al., 2014). Since 4xLPS treatment suppressed, but 1xLPS 
treatment enhanced HIF-1α signaling, which occurred in parallel with alleviated or aggravated 
Aβ deposition, we suggest that epigenetic activation of mTOR and the subsequent regulation 
of HIF-1α might induce alterations in AD pathology.  
Even if we provide evidence for an immune memory effect in microglia after the 
induction of systemic inflammation that had detrimental or beneficial consequences for brain 
pathology, it would be misleading to predict preceding peripheral infections as trigger for 
changes in the microglial immune function. Thus, future studies are required to investigate the 
effect of further peripheral pathological conditions on neurological diseases, but also on other 
developmentally distinct macrophage populations as well as to determine the exact duration of 
innate immune memory. 
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3.4 Genetic modification of the microglial phagocytic capacity during AD  
In reference to:  
 
Lack of MFG-E8 reduces pathology in mouse models of cerebral β-amyloidosis 
 
Karoline Degenhardt*, Jessica Wagner*, Konstantina Kapolou, Domenico Del Turco, Thomas 
Deller, Mathias Jucker, Jonas J. Neher 
Manuscript in preparation 
 
3.4.1 Aβ clearance mechanisms in the CNS 
Based on the “amyloid cascade hypothesis”, research suggests that impaired clearance 
mechanisms for soluble or fibrillar Aβ structures contribute to the induction of LOAD 
(Mawuenyega et al., 2010). Under physiological conditions there exist several pathways for Aβ 
clearance and degradation, which maintain a balanced Aβ metabolism. Importantly, Aβ 
transport across the BBB – a process named transcytosis – represents a major systemic 
clearance route from the brain to the plasm (Bell et al., 2006; Deane et al., 2009; 2004; Shibata 
et al., 2000; Storck et al., 2016). Thereby Aβ40 is rapidly cleared by direct binding to the soluble 
lipoprotein receptor-related protein 1 (sLRP1), which is localized in capillaries at the abluminal 
side of the cerebral endothelium (Bell et al., 2006; Deane et al., 2004; Shibata et al., 2000). In 
addition, studies have shown that extracellular chaperons such as ApoE, or ApoJ (clusterin) can 
also stimulate Aβ clearance from the CNS most likely through binding to LRP receptors 
(DeMattos et al., 2004). Especially, Aβ42 binding to ApoJ enhances efflux across the BBB, 
whereas Aβ40/ApoE3 complex formation delays efflux rate (Bell et al., 2006). 
Furthermore, Aβ from the interstitial fluid (ISF) in the brain can be cleared via bulk 
flow into the cerebrospinal fluid (CSF) sink, which comprises the ventricles and subarachnoid 
space (Abbott, 2004). In turn, Aβ in the circulation of CSF can either be absorbed through 
arachnoid villi to cross the blood-cerebrospinal fluid barrier (BCSFB) into the blood (Silverberg 
et al., 2003), or cleared along the perivascular lymphatic drainage pathway, which has recently 
been identified as predominant outflow pathway (Carare et al., 2008; Iliff et al., 2012; Ma et 
al., 2017; Tarasoff-Conway et al., 2015; Weller et al., 2008). However, Aβ that is transported 
along the perivascular drainage route is hypothesized to become entrapped in the perivascular 
basement membranes and impair perivascular clearance as seen in cerebral amyloid angiopathy 
(CAA) (Hawkes et al., 2011; 2014).  
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Consistently, the Aβ clearance rate measured in CSF of human AD patients (>60 years) 
was reduced by ~30 percent compared to healthy individuals and reflects a clear defect in Aβ 
clearance that occurs during AD (Mawuenyega et al., 2010).  
Besides the absorption of Aβ into the peripheral circulation, Aβ uptake by the resident 
glial cells is another important mechanism for Aβ clearance. Aβ degrading enzymes such as 
insulin degrading enzyme (IDE), neprilysin or different matrix-metalloproteinases (MMPs), 
represent a group of proteases, which cleave Aβ into smaller fragments in the brain(Miners et 
al., 2008). These proteases are mainly produced by glial cells and get released into the 
extracellular space via exosomes where they degrade monomeric but also fibrillar Aβ species 
(Saido and Leissring, 2012). Moreover, neprilysin can also degrade intracellular Aβ (Tarasoff-
Conway et al., 2015). 
Furthermore, microglia may also directly internalize and degrade Aβ. In vitro, soluble 
Aβ, for example, is engulfed via fluid phase pinocytosis, while uptake of Aβ fibrils is mediated 
by receptor-mediated endocytosis (Chung, 1999; Mandrekar et al., 2009). Thereby, microglia 
use pattern recognition receptors (PRRs) to sense exogenous pathogen-associated molecular 
patterns (PAMPs) including misfolded and aggregated Aβ (Lucin and Wyss-Coray, 2009). In 
particular, scavenger receptors of class A, a subgroup of PRRs, were shown to be involved in 
the uptake of Aβ by primary murine microglia (Chung et al., 2001; Paresce et al., 1996). 
Conversely, scavenger receptors of class B such as CD36 only produce chemokines for further 
microglia recruitment upon Aβ binding (Coraci et al., 2002). Another group of PRRs are toll-
like-receptors (TLRs), which are also able to bind to Aβ and induce engulfment. In particular, 
TLR2 and 4 in conjunction with the co-receptor CD14 were shown to induce phagocytosis of 
monomeric as well as fibrillar Aβ (Liu et al., 2005; Reed-Geaghan et al., 2009; Tahara et al., 
2006). Accordingly, knockout of Tlr2 in APP/PS1 mice increased levels of Aβ42 (Richard et al., 
2008). 
Furthermore, the complement system, another pathogen defending mechanism of the 
innate immune system, is involved in the uptake of Aβ by microglia. Thus, the deficiency of 
complement 3 (C3) factor, but also the absence of the respective microglial membrane attack 
complex receptor (Mac-1/C3-receptor/CD11b) reduced Aβ uptake in vivo (Fu et al., 2012). 
However, these experiments were done in wildtype mice that received injections of 
fluorescently labeled fibrillar Aβ preparations into the brain and, also, many of the 
aforementioned studies, which presented microglial uptake of Aβ, were conducted under in 
vitro conditions and could not always be confirmed in vivo. Alarmingly, recent studies showed 
that microglia that were cultured in vitro have reduced expression of microglia-specific genes 
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(Gosselin et al., 2017) and, even more important, the addition of serum to microglia cultures 
increases their intrinsic phagocytic capacity (Bohlen et al., 2017). Thus, it is conceivable that 
the capability of microglia to phagocytose Aβ in vivo is very limited. Studies from Grathwohl 
et al., Spangenberg et al. and Dagher et al., which showed that depletion of microglia does not 
impair plaque deposition and Aβ levels, underline the possibility that microglia are unable to 
efficiently phagocytose Aβ (Dagher et al., 2015; Grathwohl et al., 2009; Spangenberg et al., 
2016). However, in vivo studies, in which single Aβ plaques were continuously tracked by two-
photon imaging, reported decreasing plaque sizes when amyloid plaques were surrounded by a 
growing number of microglia (Bolmont et al., 2008). Furthermore, enlarged plaques after 
diphtheria toxin-induced microglia depletion indicate that microglia can regulate plaque size 
(Zhao et al., 2017). 
These results would suggest that microglia are indeed able to phagocytose Aβ. 
However, as already discussed in the previous sections, several environmental factors such as 
the modification of the innate immune system or a developing pathology can influence the 
microglial gene expression profile and thereby determine cell functionality. Accordingly, the 
exposure of microglia to Aβ, was reported to induce a downregulation of microglial Aβ 
phagocytosis receptors and consequently impair microglial Aβ phagocytosis (Hickman et al., 
2008; Krabbe et al., 2013). Following these findings and to gain further insight into the in vivo 
phagocytic capacity of microglia during AD pathology, I will focus on “milk fat globule-
epidermal growth-factor 8” (MFG-E8), a protein that was recently identified to be involved in 
the phagocytosis of Aβ (Boddaert et al., 2010). 
 
3.4.2 MFG-E8-mediated phagocytosis  
Milk fat globule-epidermal growth-factor 8 (MFG-E8) is a bivalent-binding, secretory 
glycoprotein, which was initially identified as a mammary epithelial cell surface protein (Stubbs 
et al., 1990). In mice, the protein consists of an amino-terminal signal peptide, which is required 
for its secretion into the extracellular space, two epidermal growth-factor homologous regions 
(E1, E2) and two carboxy-terminal discoidin regions homologous to coagulation factor-V/VIII 
(C1, C2) (Fig. 6) (Wang, 2014). MFG-E8 is present in two isoforms, with the shorter isoform 
being more abundant but lacking a proline/threonine-rich domain between E2 and C1. MFG-
E8 has been implicated in wound healing, autoimmune disease and cancer. However, the major 
function of the protein is the recognition of apoptotic cells or molecular debris in order to initiate 
its uptake by phagocytes in many different tissues (Hanayama et al., 2002; 2004). Thus, MFG-
E8 acts as an opsonin to mark dead or dying cells for phagocytosis. Thereby, the carboxy-
terminal end of C2 of MFG-E8 has a high binding activity to phosphatidylserine (PS) (Oshima 
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et al., 2002). PS is exposed by apoptotic cells and acts as an “eat me” signal that can be bound 
by MFG-E8 but also other opsonins (Hanayama et al., 2002; Li et al., 2012). Upon binding of 
MFG-E8 to apoptotic cells, an arginyl-glycyl-aspartic acid (RGD)-motif in the E2 domain 
facilitates phagocytic engulfment via the ligation to the vitronectin receptor (αvβ3, αvβ5 integrin 
dimer) expressed on the cell surface of the tissue macrophages. Upon MFG-E8 recognition, the 
αvβ3, αvβ5 integrin induces the CrkII-DOCK180-dependent Rac1 signaling pathway to 
transform the macrophage into a phagocyte (Akakura et al., 2004; Albert et al., 2000). 
 
 
Figure 6: Murine MFG-E8 protein structure. MFG-E8 consists of two amino-terminal EGF-like domains 
(EGF) and two carboxy-terminal discoidin-like domains (C1, C2). In addition, the amino-terminal part harbors a 
signal peptide, which is required for secretion of the protein. In mice, the more abundant, shorter isoform of MFG-
E8 lacks a proline/threonine-enriched domain, which is located between the EGF and C1 domain in the long 
isoform. The cell adhesion RGD-motif, which enables the recognition by macrophages via the αvβ3/5 integrin 
dimer, is positioned in the second EGF domain. N: amino-terminal, C: carboxy-terminal, EGF: epidermal growth-
factor homologous regions, C1/C2: discoidin regions, P/T: proline/threonine-enriched domain, RGD: arginyl-
glycyl-aspartic acid. 
In the brain, the majority of MFG-E8 was shown to be expressed and secreted by 
astrocytes and microglia in order to induce the phagocytosis of apoptotic cells or PS-exposing 
stressed neurons (Boddaert et al., 2010; Fricker et al., 2012; Fuller and Van Eldik, 2008; 
Kawabe et al., 2018; Spittau et al., 2014). Strikingly, one in vitro study showed that addition of 
synthetic Aβ to a mixed neuronal/glial culture induced release of MFG-E8, which in turn, 
mediated engulfment of Aβ by microglia. Interestingly, this study reported a strong 
accumulation of MFG-E8 around synthetic Aβ preparations before internalization (Kawabe et 
al., 2018). This interaction of MFG-E8 and Aβ was further confirmed by the surface plasmon 
resonance technique, which identified a dose-dependent increase in the interaction of the 
recombinant proteins Aβ and MFG-E8 (Boddaert et al., 2010). In accordance, the 
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pharmacological neutralization or genetic deletion of MFG-E8 suppressed phagocytosis of 
synthetic Aβ in murine and human peripheral macrophages indicating an essential contribution 
of MFG-E8 on macrophage-mediated phagocytosis of Aβ (Boddaert et al., 2010). Furthermore, 
it was reported that mRNA as well as protein levels of MFG-E8 in brains of human AD patients 
and Tg2576 mice were altered in comparison to healthy individuals and wildtype mice 
(Boddaert et al., 2010; Fuller and Van Eldik, 2008). Remarkably, MFG-E8 levels were 
dramatically decreased with AD. Nevertheless, MFG-E8 was detectable in brains of AD 
patients where it was mainly found in plaque-free regions indicating that in regions with high 
Aβ levels the protein may be depleted due to its requirement for Aβ phagocytosis (Boddaert et 
al., 2010). However, whether MFG-E8 is indispensable for the microglial-mediated removal of 
Aβ during AD pathology in vivo is unknown, but was addressed in a study presented in the 
following. 
 
3.4.3 Lack of MFG-E8 does not affect microglia-mediated Aβ phagocytosis 
To examine how deficiency of MFG-E8 affects microglial phagocytosis and the pathology of 
cerebral β-amyloidosis, we crossed Mfge8-/- mice to the APPPS1 tg mouse line (Radde et al., 
2006; Silvestre et al., 2005). We used the resulting APPPS1 x Mfge8-/- mouse line, which shows 
rapid amyloid deposition starting at six weeks of age, to investigate possible alterations in 
microglial function as well as Aβ pathology (Radde et al., 2006). 
To begin with, we quantified the number of cortical and plaque-associated microglia in 
APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice at two and four months of age. The number 
of microglia was indistinguishable between the two different genotypes, but showed the 
pathology-induced increase in microgliosis between the two and four-month-old examined age 
groups. 
When we next analyzed the in vivo phagocytic capacity of microglia for Aβ in these 
mice, we observed that deficiency of MFG-E8, in contrast to what was reported for peripheral 
macrophages (Boddaert et al., 2010), had no influence on microglial phagocytosis of Aβ as 
assessed by Methoxy-X04 labeled detection of Aβ in primary isolated microglia by 
fluorescence activated cell sorting and direct Aβ measurements in isolated microglia. Using 
these methods, we neither observed differences in Aβ phagocytosis at early disease stages (two 
months of age) nor during more advanced Aβ pathology (four months of age). Accordingly, 
activation of the phagolysosomal compartments, quantified by immunohistochemical staining 
for CD68, within microglia was unchanged between APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-
/- mice.  
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However interestingly, the microglial production of different inflammatory cytokines 
such as TNF-α or IL-10 was attenuated in four-month-old APPPS1 x Mfge8-/- mice, nonetheless 
indicating that the lack of MFG-E8 influences the inflammatory profile emerging during AD 
pathology, but possibly by a mechanism different from Aβ phagocytosis. We therefore 
quantified Aβ plaque pathology in cortical regions of two- and four-month-old APPPS1 x 
Mfge8+/+ and APPPS1 x Mfge8-/- mice. Unexpectedly, we observed a significant reduction in 
Aβ deposits in APPPS1 x Mfge8-/- mice at two months of age. Correspondingly, total Aβ levels 
assessed by ELISA and Western blot were significantly decreased whereas as the Aβ42/40 ratio 
was only slightly affected. However, at four months of age the reduction in Aβ pathology in 
APPPS1 x Mfge8-/- mice was lost. Thus, the decline we observed in the cytokine levels in four-
month-old APPPS1 x Mfge8-/- primary microglia may be a consequence of the reduced plaque 
load at earlier time points, as Aβ deposition is thought to be causative for the inflammatory 
response. 
To confirm the reduction in Aβ pathology in the absence of MFG-E8, we generated 
APP23 x Mfge8-/- mice, which were analyzed at nine and twelve months of age. In line with the 
APPPS1 x Mfge8-/- mice, we detected a decrease in Aβ levels as well as in the cortical Aβ 
plaque load in the younger APP23 x Mfge8-/- mice, whereas in twelve-month-old mice, which 
show robust Aβ pathology, Aβ plaque load was indistinguishable from the APP23 x Mfge8+/+ 
group. 
When we investigated the brain levels of MFG-E8 in relation to ageing in wildtype but 
also in mouse models of AD pathology (APPPS1 and APP23) we observed an age-dependent 
increase in MFG-E8 levels that was also reported earlier (Fuller and Van Eldik, 2008). 
However, Aβ pathology also altered MFG-E8 levels, which started to dramatically rise with the 
onset of Aβ plaque deposition. Remarkably, immunohistochemical staining of brain sections 
identified MFG-E8 accumulating in close vicinity to Aβ deposits and electron microscopy 
revealed that MFG-E8 was associated to Aβ fibrils. These results support on one hand a recently 
published study showing a strong accumulation of MFG-E8 around freshly prepared Aβ in 
vitro, but are in contrast with the described functional consequences of the Aβ-MFG-E8 co-
localization, as accumulation of MFG-E8 around Aβ in vitro was suggested to regulate Aβ 
uptake, which we were unable to confirm (Kawabe et al., 2018).   
Intriguingly, studies in humans identified a 50-amino acid long amyloidogenic fragment 
named medin in the C2 domain of human MFG-E8 (Häggqvist et al., 1999). Medin forms 
vascular amyloid deposits in the medial layer of arteries in 97 percent of the human population 
>50 years(Häggqvist et al., 1999). However, so far there exists no evidence for a pathological 
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outcome of these deposits. As human and mouse MFG-E8 share 64 percent of their amino acid 
sequence, it is conceivable that medin exists also in mice.  
Of note, in the Mfge8-/- mouse model used in our study, the C2 domain that contains the 
medin sequence, is truncated and thus Mfge8-/- mice potentially lack medin. Furthermore, medin 
was shown to promote the aggregation of Serum amyloid A (AA) into fibrils – another amyloid 
depositing in the vasculature – by a potential cross-seeding mechanism (Larsson et al., 2011). 
Accordingly, we hypothesize that the decrease in Aβ pathology we observed in the APP tg mice 
deficient for MFG-E8 may be due to an effect of MFG-E8 on the Aβ fibril formation process 
that promotes initial Aβ aggregation, but is delayed in the absence of MFG-E8. This hypothesis 
is reinforced by the observation of a reduced number of small-sized, but not medium or large-
sized Aβ plaques in brains of APPPS1 x Mfge8-/- mice. 
Ultimately, this study showed that, in vivo, MFG-E8 is not required for microglial 
phagocytosis of Aβ in mouse models of cerebral β-amyloidosis. However, we identified MFG-
E8 to be strongly associated with aggregated Aβ and hypothesize that MFG-E8 promotes the 
initial process of Aβ fibrillization as absence of MFG-E8 decreased Aβ pathology in APP tg 
mice. 
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3.5 Conclusions 
In this work, we investigated three different strategies to modulate the pathology of cerebral β-
amyloidosis through manipulating the innate immune system in the CNS, which is represented 
by microglia. 
Our initial approach to deplete dysfunctional microglia and to replace them with 
infiltrating monocytes failed to improve Aβ pathology, but confirmed that a new 
microenvironment can induce fundamental changes in the function of engrafted or infiltrated 
macrophage populations. This knowledge will help to further understand the high plasticity of 
myeloid cells during the pathogenesis of AD, which is accompanied by many different disease 
states and molecular changes in the brain.  
Remarkably, in a second study, which examined the modulation of the microglial innate 
immune response, we provide first evidence for experimentally induced immune training and 
tolerance in microglia and confirm the presence of innate immune memory in tissue-resident 
macrophages in vivo. Moreover, we identified epigenetic reprogramming to cause changes in 
the microglial immune response by affecting the expression profile of different immune-related  
genes, which subsequently resulted in alterations of the pathology of cerebral β-amyloidosis. 
Strikingly, we identified the transcription factor HIF-1α to be simultaneously to the observed 
changes in Aβ deposition upregulated by immune training and suppressed by tolerance. Thus, 
we suggest HIF-1α activation as an important modulator of AD, whose inhibition might have 
beneficial effects for pathology.  
Since genetic data have placed inflammatory processes at the center of the etiology of 
LOAD, it would be of great interest to investigate further downstream events of the Aβ cascade 
such as neuronal loss, synaptic dysfunction and finally also cognitive behavior after induction 
of innate immune memory in microglia. Furthermore, having shown that epigenetic and 
functional changes of microglial can last for at least six months, pro-longed experiments could 
help to examine whether epigenetic remodeling of the microglial immune response could last 
for the whole life of microglia or might even be inherited after cell division.  
Recent studies have revealed the transcriptome of certain microglial subsets by single 
cell sequencing approaches and identified differential phenotypes in response to their 
parenchymal environment (Keren-Shaul et al., 2017). The discrimination into these microglial 
subpopulations after the induction of immune memory in microglia would provide further 
information about the effects of epigenetic reprogramming in distinct categories of microglia. 
This would finally allow for the application of customized stimuli in order to effectively shape 
the immune memory function of different microglia populations.  
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Finally, when we investigated whether microglial phagocytosis of Aβ – an important 
function of the microglial immune response – is dependent on MFG-E8, we unexpectedly 
revealed a prominent co-localization between MFG-E8 and aggregated Aβ as well as a 
reduction of cerebral β-amyloidosis upon MFG-E8 deletion, but no obvious alterations in the 
microglial phenotype. These results suggest that MFG-E8 is dispensable for microglial 
phagocytosis. However, the presence of medin amyloid, as a fragment of MFG-E8 has lead us 
to the hypothesis that MFG-E8 may be involved in the formation of Aβ fibrils and thus 
contribute to the progression of AD.  
The here presented results highlight microglia and their innate immune response as an 
essential factor in the pathogenesis of AD. However, importantly, we could show that a set of 
distinct inflammatory events can induce long-term modifications of the microglial innate 
immune response through the induction of epigenetic changes in the enhancer landscape, which 
in turn shaped pathology of cerebral β-amyloidosis. With the identification of innate immune 
memory in microglia induced by preceding peripheral immune stimulation, we suggest a new 
strategy to alter the microglial immune response, which should be considered in future studies 
examining the contribution of the innate immune system on neurological diseases. 
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Abstract 28 
‘Innate immune memory’ is a vital mechanism of myeloid cell plasticity that occurs in response to 29 
environmental stimuli and alters subsequent immune responses. Two types of immunological 30 
imprinting can be distinguished, training and tolerance, which are epigenetically mediated and 31 
enhance or suppress subsequent inflammation, respectively. Whether immune memory occurs in 32 
tissue-resident macrophages in vivo and how it may affect pathology remains largely unknown. Here 33 
we demonstrate that peripherally applied inflammatory stimuli induce acute immune training and 34 
tolerance in the brain and lead to differential epigenetic reprogramming of brain-resident 35 
macrophages, microglia, that persists for at least six months. Strikingly, in a mouse model of 36 
Alzheimer’s pathology, immune training exacerbates cerebral β-amyloidosis while tolerance alleviates 37 
it; similarly, peripheral immune stimulation modifies pathological features after stroke. Our results 38 
identify immune memory in the brain as an important modifier of neuropathology.   39 
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Main text 40 
Contrary to the long-held assumption that immunological memory exists only in cells of the adaptive 41 
immune system, recent evidence indicates that myeloid cells also display memory effects1,2. For 42 
example, certain immune stimuli ‘train’ blood monocytes to generate enhanced immune responses to 43 
subsequent immune insults3,4. In contrast, other stimuli induce immune tolerance, i.e. suppression of 44 
inflammatory responses to subsequent stimuli3,5. Innate immune memory lasts for several days in vitro 45 
and for up to three months in circulating monocytes in vivo and is mediated by epigenetic 46 
reprogramming in cultured cells, with chromatin changes also apparent in vivo3,6,7. However, whether 47 
immune memory occurs in long-lived tissue-resident macrophages and whether it alters tissue-specific 48 
pathology remains unknown.  49 
Microglia, the brain-resident macrophages, were recently shown to be very long-lived cells8,9. This 50 
makes them particularly interesting for studying immune memory, as virtually permanent modification 51 
of their molecular profile appears possible. As microglia are also known to significantly affect many 52 
neurological diseases10-12, we investigated whether immune memory occurs in microglia in vivo and 53 
how it affects neuropathology.  54 
 55 
Acute immune memory in the brain 56 
It is well-established that inflammation in the periphery can prompt immune responses in the brain13. 57 
To evaluate whether immune memory is inducible in the brain by peripheral stimulation, mice received 58 
daily intraperitoneal injections of low-dose lipopolysaccharides (LPS) on four consecutive days, 59 
leading to mild sickness behaviour and temporary weight loss (Fig.1a and Extended Data Fig.1a). 60 
Three hours after application, the first LPS injection (1xLPS) led to a pronounced increase of blood 61 
cytokine levels, but only modest increases in brain cytokines. Upon the second injection (2xLPS), the 62 
blood levels of the pro-inflammatory cytokines IL-1β, TNF-α, IL-6, IL-12 and IFN-γ were diminished 63 
compared to 1xLPS while IL-10 release occurred at similar levels, indicating peripheral immune 64 
tolerance. In sharp contrast, brain cytokines were dramatically increased with 2xLPS injections, 65 
indicating a brain-specific training effect induced by the first LPS stimulus (Figs.1b/c and Extended 66 
Data Fig.2). Accordingly, a conspicuous morphological change in microglia occurred after 2xLPS, 67 
while activated (GFAP+) astrocytes only increased after 3xLPS (Extended Data Figs.1b-d). 68 
Importantly, 4xLPS virtually abolished TNF-α, IL-1β and IL-6 release in the brain while IL-10 remained 69 
elevated, indicating immune tolerance.  70 
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Next, we examined the contribution of microglia to immune memory in the brain using inducible 71 
CX3CR1-CreER (Cre) mice crossed with mouse lines carrying loxP-flanked genes, where tamoxifen-72 
induced Cre expression results in persistent recombination in long-lived microglia but not in short-lived 73 
myeloid cells, including blood monocytes14. We induced microglial knockout of either ‘transforming 74 
growth factor-β-activated kinase 1’ (Tak1), which results in inhibition of NF-κB, JNK and ERK1/2 75 
pathways14, or histone deacetylases-1 and -2 (Hdac1/2), two major regulators of epigenetic 76 
reprogramming and macrophage inflammatory responses15,16. As expected, tamoxifen-induced 77 
knockout of either Tak1 or Hdac1/2 did not alter the peripheral inflammatory response. Furthermore, 78 
brain cytokine levels were indistinguishable after 1xLPS, but the training effect following 2xLPS 79 
injections was virtually abolished in Cre+ animals. Notably, the cytokines showing the most 80 
pronounced training and tolerance effects (IL-1β, TNF-α, IL-6) were also most affected by microglial 81 
gene knockout (Figs.1b/c and Extended Data Fig.2), indicating that immune memory in the brain is 82 
predominantly microglia-mediated. Moreover, after 1xLPS, Cre+ and Cre– mice showed 83 
indistinguishable weight loss (Extended Data Fig.1a) and sickness behaviour (not shown); however, in 84 
animals with microglial Tak1 knockout, sickness behaviour after 2xLPS was noticeably alleviated 85 
(Supplementary Movie 1).  86 
After intraperitoneal injections, LPS was found in the blood but not in the brain, indicating that neither 87 
significant entry of LPS into the brain nor opening of the blood-brain barrier occurred, corresponding 88 
with previous reports17. The latter was confirmed by the absence of blood iron in the brain 89 
parenchyma. Also, using 'type 2 CC chemokine receptor’ (CCR2) reporter mice18, no extravasation of 90 
circulating monocytes was found (Extended Data Figs.1e-g), confirming that immune memory was 91 
mediated by brain-resident macrophages alone. 92 
 93 
Immune memory shapes neuropathology 94 
Next, we analysed whether the training- and tolerance-inducing stimuli 1xLPS and 4xLPS, 95 
respectively, could lead to long-term alterations of brain immune responses and thereby modify 96 
disease pathogenesis. APP23 mice are a model of Alzheimer’s disease (AD) pathology, where 97 
plaques of insoluble amyloid-β develop from 6 months of age. Amyloid plaques lead to activation of 98 
microglia19, thereby providing a stimulus that should reveal microglial immune memory. We injected 3-99 
month-old APP23 mice with 1x/4xLPS, then analysed pathology 6 months later (Fig.2a). Strikingly, 100 
1xLPS significantly increased while 4xLPS significantly decreased both plaque load and total amyloid-101 
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β levels compared to control animals (Fig.2b), with plaque-associated neuritic damage correlating 102 
directly with plaque size in all treatment groups (Extended Data Figs.3a-c). Also, the protein levels of 103 
amyloid-β precursor protein (APP) and its cleavage products were indistinguishable amongst groups, 104 
indicating equivalent amyloid-β generation (Extended Data Fig.3d). Furthermore, neither the total 105 
number of microglia nor the number of microglia clustering around plaques was altered by LPS 106 
treatments (Fig.2c), while the number of activated (GFAP+) astrocytes decreased slightly both with 1x 107 
and 4xLPS treatment (Extended Data Fig.3e). However, the brain levels of IL-1β, IL-6 and IL-12 were 108 
reduced in 4xLPS-treated APP animals, while in 1xLPS-treated APP mice IL-10 was reduced. In 109 
contrast, brain cytokine levels were not altered in wildtype littermate controls and baseline blood 110 
cytokine levels were unchanged in wildtype and APP animals. Furthermore, an additional LPS 111 
injection at 9 months of age caused indistinguishable peripheral cytokine responses (Fig.2d and 112 
Extended Data Figs.4a-c). Thus, peripheral immune stimuli cause long-term alterations in the brain 113 
immune response and differentially affect AD pathology. 114 
To test for immune memory effects in a second disease model, we injected wildtype animals with 115 
1x/4xLPS and induced focal brain ischemia one month later. One day post-ischemia, neuronal 116 
damage and microglial numbers were indistinguishable amongst treatment groups (Fig.3a), indicating 117 
that the initial ischemic insult was unaffected by 1x/4xLPS. However, the acute inflammatory 118 
response, which is driven by brain-resident cells early after ischemia12, differed, showing increased 119 
levels of IL-1β in 1xLPS- and decreased levels in 4xLPS-treated animals. In contrast, the release of 120 
IL-10 was significantly suppressed by 1xLPS only (Fig.3b), reminiscent of results in APP animals 121 
(Fig.2d). Other brain cytokines and blood cytokine levels were indistinguishable amongst groups 122 
(Extended Data Fig.5). Importantly, seven days after brain ischemia, the volume of neuronal damage 123 
and microglial activation was strongly reduced by 4xLPS but unaffected by 1xLPS (Figs.3c/d). These 124 
results confirm long-term modulation of brain immune responses and suggest persistent modification 125 
of stroke pathology following a tolerizing but not a training stimulus, possibly due to the severity of the 126 
insult preventing its further exacerbation through amplification of the immune response.  127 
 128 
Microglial molecular profiles 129 
In vitro, immune memory in macrophages results from epigenetically-mediated alterations in the 130 
enhancer repertoire, leading to transcriptional changes3,20,21. Since our data indicated that acute 131 
immune memory in the brain is mediated predominantly by microglia, we isolated microglia by cell 132 
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sorting (Extended Data Fig.6) from 9-month-old animals stimulated with 1x/4xLPS at 3 months of age 133 
and performed chromatin immunoprecipitation for mono-methylation at lysine 4 of histone 3 134 
(H3K4me1) and acetylation at lysine 27 of histone 3 (H3K27ac), which define active enhancers20,21. 135 
Thus, we identified 20,241 putative active enhancers across all conditions.  136 
First, we focussed on H3K4me1 marks, which should mark all enhancers activated in response to the 137 
first and/or second immune stimulus (as enhancers may lose H3K27ac after cessation of inflammation 138 
but retain H3K4me1 marks)20,21. Strikingly, H3K4me1 levels differed significantly between control and 139 
LPS treatment groups both in wildtype and APP animals but also between 1x- and 4xLPS-treated 140 
mice (Extended Data Fig.7b; Supplementary Table1). For example, enhancers with increased 141 
H3K4me1 levels in microglia from 1xLPS versus 4xLPS wildtype animals showed enrichment for the 142 
‘thyroid hormone signalling pathway’, including a putative enhancer for hypoxia inducible factor-1α 143 
(HIF-1α). Similarly, enhancers with higher H3K4me1 levels in 1xLPS versus 4xLPS-treated APP mice 144 
were enriched for the ‘HIF-1 signalling pathway’. On the other hand, 4xLPS-treated APP animals 145 
showed increased H3K4me1 levels in putative enhancers related to phagocytic function (Fig.4a). 146 
Importantly, no pathway enrichment was found when comparing H3K4me1 levels in microglia from 147 
APP and wildtype controls (Fig.4a), indicating that H3K4me1 levels were altered predominantly in 148 
response to LPS stimulation.  149 
Next, we analysed enhancer activation by determining differential regulation of H3K27ac levels. In line 150 
with the requirement of an acute stimulus for H3K27ac deposition20, differential enhancer activation 151 
was more pronounced in APP animals (where amyloid plaques activate microglia) than in wildtype 152 
groups (190±18 in APP, 69±5 in wildtype groups; Extended Data Fig.7e; Supplementary Table2). For 153 
example, differentially regulated H3K27ac levels in microglia from 1xLPS-treated versus control APP 154 
animals were enriched for the ‘HIF-1 signalling pathway’, with enhancer regions also being enriched 155 
for HIF-1α binding motifs (Fig.4b and Extended Data Fig.8), in line with changes in H3K4me1 levels 156 
(Fig.4a) and the reported key role of HIF-1α in trained immunity and macrophage inflammatory 157 
responses4,22.  158 
Active enhancers in microglia from 4xLPS-treated versus control APP animals only showed 159 
enrichment for the ‘Rap1 signalling pathway’, a pathway implicated in phagocytosis of opsonized 160 
targets23,24, again matching changes in H3K4me1 levels (Figs.4a/b). Strikingly, the comparison of 161 
microglia from APP animals that received the training- (1xLPS) and tolerance-inducing (4xLPS) 162 
stimuli, showed no pathway enrichment for active enhancers in 4xLPS-treated animals while 163 
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enhancers in 1xLPS-treated animals were enriched for a large number of inflammation-related 164 
pathways, highlighting the differential effects of the two immune memory states. Finally, the 165 
comparison of microglia from vehicle-treated wildtype and APP animals demonstrated a small number 166 
of differentially activated enhancers with enrichment for the ‘thyroid hormone signalling pathway’ 167 
(including a putative active enhancer for Hif1a) as well as the ‘mTOR signalling pathway’ (Fig.4b), 168 
indicating that microglia are also epigenetically reprogrammed in response to brain pathology alone.  169 
We next examined microglial mRNA levels under the same conditions to determine whether 170 
epigenetic alterations were reflected in gene expression levels (Supplementary Table3). First, we 171 
determined the concordance between 772 enhancers with significantly increased/decreased H3K27ac 172 
levels (Supplementary Table2) and the direction of change in the expression of their nearest gene. 173 
Indeed, there was a significant (albeit modest) concordance between alterations in H3K27ac levels 174 
and gene expression (median concordance of pairwise comparisons =58%, P=0.03). This suggested 175 
that gene expression is directly affected by the microglial active enhancer repertoire. Accordingly, 176 
weighted gene correlation network analysis (WGCNA25) revealed striking parallels to epigenetic 177 
changes (Figs.5a-c and Supplementary Table4). For example, the red module (MEred) contained the 178 
Hif1a gene, showed enrichment for the ‘HIF-1 signalling pathway’ and correlated strongly with the 179 
1xLPS-treated APP group. Furthermore, gene expression in MEred was significantly upregulated in 180 
APP versus wildtype control animals and further increased by 1xLPS but downregulated by 4xLPS 181 
treatment.  182 
HIF-1α activation in inflammatory-stimulated macrophages can occur downstream of mitochondrial 183 
hyperpolarization; enhanced HIF-1α signalling in turn promotes glycolysis, measurable as lactate 184 
release26. Accordingly, the green module (MEgreen), which correlated positively with control and 185 
1xLPS-treated APP groups but negatively with control and 4xLPS-treated wildtype groups, was found 186 
to be enriched in genes of the ‘glycolysis’ pathway. Microglial gene expression in MEgreen was 187 
upregulated in APP versus wildtype control animals and again further increased in APP animals by 188 
1xLPS but decreased by 4xLPS treatment. Therefore, we analysed mitochondrial membrane potential 189 
and lactate release in microglia. Strikingly, microglia from 1xLPS-treated APP animals showed 190 
strongly increased mitochondrial membrane potential, which correlated positively with the release of 191 
lactate (Fig.5d), functionally corroborating the epigenetic and transcriptional alterations in trained 192 
microglia. Additionally, immunostaining confirmed higher protein levels of HIF-1α in plaque-associated 193 
microglia, which were further increased in 1xLPS-treated APP animals (Figs.5e/f). Thus, HIF-1α 194 
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signalling and a metabolic switch to glycolysis are activated in response to cerebral β-amyloid 195 
deposition, and are enhanced by immune training but reduced by immune tolerance in microglia. 196 
In contrast to MEred/green, MEgrey correlated positively with the control wildtype but negatively with 197 
control and 1xLPS-treated APP groups. Compared to wildtype controls, microglial gene expression in 198 
MEgrey was downregulated in APP control animals and further decreased by 1xLPS stimulation, but 199 
showed unchanged levels in 4xLPS-treated APP animals (Figs.5a-c). Importantly, MEgrey was 200 
enriched for phagocytosis-related pathways, including the ‘Rap1 signalling pathway’ (Figs.5a-c), again 201 
reflecting epigenetic changes (Fig.4). We therefore tested whether phagocytosis of Aβ was enhanced 202 
in 4xLPS-treated APP animals. Indeed, microglial Aβ content was increased ~1.75-fold in 4xLPS-203 
treated compared to APP control animals (Fig.5g), providing further functional validation of the 204 
microglial enhancer repertoire and gene expression profiles.  205 
Recent data indicate that context-specific microglial phenotypes exist, e.g. ‘disease-associated 206 
microglia’ (DAM27) and the ‘microglial neurodegenerative phenotype’ (MGnD28). Interestingly, the 207 
brown module (MEbrown), which was significantly upregulated by both LPS treatments in wildtype as 208 
well as in all APP groups, contained a number of homeostatic microglial genes (e.g. Hexb, Cx3cr1, 209 
Csf1r) but also all of the ‘stage 1 DAM’ core-genes except Apoe, as well as 4 of 12 ‘stage 2’ core-210 
genes27 (Fig.5c). Of note, the gene encoding ApoE, which may be crucial for promoting a detrimental 211 
microglial phenotype28,29 was found in the same module as Hif1a (MEred). MEred also contained other 212 
genes genetically linked to AD risk, namely Cd33 and Inpp5d30, suggesting that HIF-1α may also be a 213 
detrimental modulator of AD pathology.  214 
 215 
The epigenetic landscape of microglia has only been described under homeostatic conditions31-33. Our 216 
data now demonstrate epigenetic modifications in microglia in response to peripheral immune 217 
stimulation but also as a result of cerebral β-amyloidosis, including activation of the HIF-1α and mTOR 218 
pathways, and leading to transcriptional and functional alterations. While the global epigenetic and 219 
transcriptional changes were relatively modest, they were likely driven by a small number of microglia 220 
that received the required secondary immune stimulation, as evidenced for example by increased 221 
levels of HIF-1α in plaque-associated microglia (Fig.5). mTOR activation is a well-known event in early 222 
AD34 and was recently shown in microglia, where it activated HIF-1α and glycolysis to sustain 223 
microglial energy demand in AD models35. Our data now indicate that mTOR activation may be 224 
mediated by epigenetic microglial reprogramming in response to cerebral β-amyloidosis and that HIF-225 
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1α signalling downstream of mTOR could be a detrimental event, because augmentation or 226 
suppression of HIF-1α signalling occurred concomitantly with aggravated or alleviated Aβ deposition, 227 
respectively.  228 
We here provide evidence of both immune training and tolerance in microglia and demonstrate their 229 
impact on neuropathology for the first time. While we cannot completely exclude that other cell-types 230 
contribute to immune memory and modulation of pathology in the brain, microglial-specific gene 231 
knockout of Tak1 or Hdac1/2 virtually abolished immune training (Fig.1), indicating that microglia are 232 
likely the major effectors of immune memory. Importantly, in our experiments, immune memory effects 233 
mostly became apparent following a secondary inflammatory stimulus, corroborating the concept of 234 
innate immune memory1,3. However, while in the periphery training may be beneficial due to enhanced 235 
pathogen elimination7,36,37, and tolerance may be detrimental due to higher rates of infection resulting 236 
from immune suppression5, we found that training promotes while tolerance alleviates neuropathology. 237 
This is consistent with the beneficial effects of preventing microglial pro-inflammatory responses in 238 
models of AD pathology and stroke12,38 and the worsening of cerebral β-amyloidosis in response to 239 
pro-inflammatory peripheral stimuli in animal models39. Similarly, immune training has recently been 240 
described in epithelial stem cells, where it promotes wound healing but may also underlie autoimmune 241 
disorders40. Thus, immune memory in the brain could conceivably affect the severity of any 242 
neurological disease that presents with an inflammatory component, but this will need to be studied for 243 
each individual condition.  244 
Our data provide proof-of-principle for innate immune memory in microglia, and while our different LPS 245 
injection paradigms may not necessarily model physiological stimuli, we found that individual cytokines 246 
applied peripherally may also elicit immune memory effects in the brain (Extended Data Fig.9). These 247 
results suggest that a wide variety of immune challenges may induce microglial immune memory and 248 
provide a possible mechanism for LPS-induced immune memory in the brain. It will be crucial to 249 
determine which other stimuli may lead to long-term modulation of microglial responses and thereby 250 
contribute to the severity of many neurological diseases. 251 
 252 
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Materials and Methods 433 
 434 
Animals 435 
For all experiments, 3 month-old hemizygous APP23 transgenic (C57BL/6J-Tg(Thy1-436 
APPK670N;M671L)23), APP23 transgene-negative littermates or C57BL/6J (wildtype) mice (Jackson 437 
Laboratory) were used.  438 
For experiments analysing immune responses after acute LPS and cytokine stimulation (see below), 439 
both male and female mice were used. For microglia-specific gene knockouts, CX3CR1-CreER 440 
animals were crossed with Tak1 fl/fl animals and Cre recombinase expression was induced by 441 
subcutaneous tamoxifen injections as previously described14. Similarly, microglial-specific knockout of 442 
Hdac1/2 was achieved after crossing CX3CR1-CreER animals with a Hdac1/2 fl/fl line15. Both Tak1 fl/fl 443 
and Hdac1/2 fl/fl were injected at 2-3 months of age and were incubated for four weeks without further 444 
treatment. Tamoxifen-injected CX3CR1-Cre negative littermates were used as controls (because 445 
responses in CX3CR1-Cre negative animals were indistinguishable in Hdac1/2 fl/fl and Tak1 fl/fl lines, 446 
pooled data are shown in Fig. 1).  447 
As there is a significant gender effect on the pathology of both brain ischemia and cerebral β-448 
amyloidosis,41,42 only female mice were used for the analyses of brain pathology. APP23 mice express 449 
a transgene consisting of human amyloid-β precursor protein (APP) with the KM670/671NL mutation 450 
under the Thy-1 promoter, and have been backcrossed with C57BL/6J mice for >20 generations. 451 
Female mice develop cerebral β-amyloid lesions in the neocortex around 6 months of age19.  452 
Animals were maintained under specific pathogen-free conditions. All experiments were performed in 453 
accordance with the veterinary office regulations of Baden-Württemberg (Germany) and were 454 
approved by the Ethical Commission for animal experimentation of Tübingen and Freiburg, Germany. 455 
 456 
Peripheral immune stimulation 457 
3-month-old mice were randomly assigned to treatment groups and were injected intraperitoneally 458 
(i.p.) with bacterial lipopolysaccharides (LPS from Salmonella enterica serotype typhimurium, Sigma) 459 
at a daily dose of 500 µg/kg bodyweight. Animals received either four LPS injections on four 460 
consecutive days (4xLPS), a single LPS injection followed by three vehicle injections on the following 461 
three days (1xLPS) or four vehicle injections (PBS). Acute stimulation showed indistinguishable 462 
cytokine responses in wildtype and APP23 transgenic animals; Figure 1 shows the pooled data from 463 
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both genotypes (see Extended Data Fig. 2 for data separated by genotype). Furthermore, as cytokine 464 
responses were indistinguishable in animals treated with 1/2/3/4xPBS, pooled data from all time points 465 
are shown. 466 
For peripheral cytokine treatments, recombinant murine cytokines (TNF-α, IL-10; PeproTech) were 467 
aliquoted as by the manufacturer’s instructions and stored at -80°C until use. To determine whether a 468 
long-term change in the brain’s immune response (training or tolerance) occurred after peripheral 469 
cytokine injection, mice were treated on four consecutive days with 0.1 μg/g bodyweight IL-10 or once 470 
with 0.1/0.2 μg/g bodyweight TNF- α. Control mice received four vehicle injections (PBS). Four weeks 471 
later, cytokine- and control-treated mice received LPS (1 μg/g bodyweight) or PBS, and were prepared 472 
3 hours after the injection. 473 
At the specified time-points, animals were deeply anaesthetised using sedaxylan/ketamine (64 474 
mg/kg//472 mg/kg), blood was collected from the right ventricle of the heart and animals were 475 
transcardially perfused with ice-cold PBS through the left ventricle. The brain was removed and 476 
sagitally separated into the two hemispheres, which were either fixed in 4% paraformaldehyde (PFA) 477 
or fresh-frozen on dry ice. Fresh-frozen hemispheres where homogenised using a Precellys® lysing kit 478 
and machine at 10 or 20% (w/v) in homogenisation buffer (50 mM Tris pH 8, 150 mM NaCl, 5 mM 479 
EDTA) containing phosphatase and protease inhibitors (Pierce). Fixed hemispheres were kept in 4% 480 
PFA for 24h, followed by cryoprotection in 30% sucrose in PBS, subsequently frozen in 2-481 
methylbutane and coronally sectioned at 25 μm using a freezing-sliding microtome (Leica).  482 
 483 
Focal brain ischemia 484 
For the induction of a focal cortical stroke, we modified existing models of endothelin-1 (ET-1)-induced 485 
brain ischemia43 to avoid traumatic injury to the brain. Under anaesthesia and analgesia (Fentanyl, 486 
Midazolam, Medetomidin: 0.05//5//0.5 mg/kg bodyweight), 3-month-old animals were fixed in a 487 
stereotactic frame and a circular piece of skull was removed (5 mm diameter, centred on Bregma; as 488 
described in44). The dura mater was carefully removed with the help of a microhook (Fine Science 489 
Tools) and 5 µl of ET-1 (Bachem; 64 µM) in Hanks Buffered Salt Solution (Invitrogen) or vehicle 490 
solution was topically applied to the cortex and incubated for 10 min. The craniotomy was then 491 
covered with a 5 mm glass coverslip, which was fixed in place with dental cement (Hybond), the skin 492 
was sutured, then the mice received antidote (Flumazenil, Atipamezol: 0.5//2.5mg/kg bodyweight) and 493 
were health-monitored. Control mice underwent the same surgical procedure with application of 494 
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vehicle solution to the cortex. After 4 weeks, animals were deeply anesthetized and prepared as 495 
described above. 496 
 497 
Western Blotting analysis 498 
For Western Blotting, total brain homogenates were sonicated 3x5 seconds (LabSonic, B. Braun 499 
Biotech), protein levels of the brain homogenates were quantified with a microplate bicinchoninic acid 500 
(BCA) assay (Pierce) and adjusted accordingly. Samples were then analysed on NuPage Bis-Tris gels 501 
(Invitrogen) using standard procedures. Proteins were transferred to nitrocellulose membranes, 502 
blocking was performed with 5% milk in PBS containing 0.05% Tween (PBST) for 1h and blots were 503 
incubated with mouse anti-Aβ (6E10; 1:1000, Covance) in PBST overnight at 4°C. Membranes were 504 
then probed with the secondary HRP-labelled antibodies (1:20,000, Jackson ImmunoLaboratories). 505 
Protein bands were detected using chemiluminescent peroxidase substrate (ECL prime, GE 506 
Healthcare). Densitometric values of the protein band intensities were analysed with the software 507 
package Aida v.4.27 and normalised to GAPDH intensities. 508 
 509 
Immunostaining 510 
Immunohistochemical staining was performed on free-floating sections using either Vectastain Elite 511 
ABC kits (Vector laboratories) or fluorescent secondary antibodies (Jackson Immunolaboratories). 512 
Unless otherwise noted, brain sections were blocked for 1h with 5% normal serum of the secondary 513 
antibody species, followed by primary antibody incubation overnight at 4°C. Primary antibodies used 514 
were: rabbit anti-Pu.1 (1:1000, Cell Signalling), rabbit anti-Iba1 (1:1,000; Wako; catalogue no. 019-515 
19741), rabbit anti-GFAP (1:500, Biozol; catalogue no. Z0334), rabbit anti-Aβ (CN3; 1:2,00045), mouse 516 
anti-HIF-1α (1:500; Novus Biologicals, catalogue no. NB100-105, clone H1alpha67), rat anti-CD11b 517 
(1:2000; Millipore, catalogue no. MAB1387Z), rabbit anti-APP (antibody 5313 to the ectodomain of 518 
APP, 1:750; kind gift of Prof. Christian Haas, Munich). Sections were then washed and incubated with 519 
secondary antibodies. Cresylviolet and Congo Red staining was conducted according to standard 520 
procedures. Fluorescent plaque staining was achieved using Methoxy-X04 (4% vol of 10 mg/ml 521 
methoxy-X04 in DMSO, and 7.7% vol CremophorEL in 88.3% vol PBS) for 20 min, RT.  522 
Images were acquired on an Axioplan 2 microscope with Axioplan MRm and AxioVision 4.7 software 523 
(Carl Zeiss). Fluorescent images were acquired using a LSM 510 META (Axiovert 200M) confocal 524 
microscope with an oil immersion 63X/1.4NA objective and LSM software 4.2 (Carl Zeiss), using 525 
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sequential excitation of fluorophores. Maximum-intensity projections were generated using IMARIS 526 
8.3.1 software (Bitmap).  527 
For quantitative comparisons, sections from all groups were stained in parallel and analysed with the 528 
same microscope settings by an observer blinded to the treatment groups. To quantify the intensity of 529 
total microglial HIF-1α staining, high-resolution bright field images were acquired using fixed camera 530 
exposure time and lamp intensity and subsequently analysed with Fiji software. Colour channels were 531 
split and a fixed intensity threshold was applied to the red channel. On each image, the thresholded 532 
area over the total image area was calculated. Area fractions were measured on images of at least 9 533 
plaques and 15 plaque-free regions per animal. To exclude an influence of plaque-size on microglial 534 
HIF-1α levels, plaques of similar size were selected for analysis of HIF-1α levels in the different 535 
treatment groups (average plaque size: PBS i.p.: 1.73±0.15, 1xLPS i.p.: 1.84±0.19, 4xLPS i.p. 536 
2.27±0.39% Congo red area fraction).  537 
For nuclear HIF-1α staining, a modified staining protocol was used. Briefly, sections were blocked with 538 
mouse Ig blocking reagent (Vector laboratories) for 1h, RT, followed by blocking with normal donkey 539 
serum for 1h, RT. Sections were then incubated overnight with mouse anti-HIF1α (clone mgc3, 1:50; 540 
Thermo Fisher Scientific, catalogue no. MA1-516) and rabbit anti-Pu.1 (1:250; New England Biolabs, 541 
catalogue no. 2258S. Clone 9G7), 4°C. To quantify the intensity of nuclear HIF-1α staining, z-stacks 542 
from 3 plaques and plaque-free regions per animal were acquired with the same microscope settings 543 
and subsequently analysed with IMARIS 8.3.1 software. Using the surfaces tool, a mask based on 544 
microglial nuclei was created using staining for Pu.1. A filter for area was applied to exclude 545 
background staining. The created surface was used to mask the HIF-1α channel. The mean masked 546 
HIF-1α intensity was then determined. 547 
To quantify neuronal dystrophy, fluorescent images from 5-10 plaques per animal were acquired with 548 
the same microscope settings and subsequently analysed with Fiji software. Maximum intensity 549 
projections were generated to choose the region of interest consisting of APP-staining and the plaque. 550 
Fluorescence channels were split and intensity thresholds were applied to each channel. For every 551 
plaque, the thresholded area within the region of interest was calculated as a measure of plaque size 552 
and dystrophic area. 553 
 554 
Stereological and morphological quantification 555 
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Stereological quantification was performed by a blinded observer on random sets of every 12th 556 
systematically sampled 25 μm thick sections throughout the neocortex. Analysis was conducted using 557 
the Stereologer software (Stereo Investigator 6; MBF Bioscience) and a motorized x-y-z stage coupled 558 
to a video microscopy system (Optronics). For quantification of total Pu.1- and GFAP-positive cells, 559 
the optical fractionator technique was used with three-dimensional dissectors as previously 560 
described46. For the quantification of plaque-associated cells, plaques were identified based on Congo 561 
Red staining and cells in their immediate vicinity were counted. Plaque load was determined by 562 
analysing the cortical area covered by Congo Red and/or anti-Aβ staining using the area fraction 563 
fractionator technique46. The volume of neuronal damage and microglial activation after brain ischemia 564 
was determined using the Cavalieri estimator technique.  565 
For analysing microglial morphology, three images from three non-consecutive brain sections per 566 
animal were acquired from Iba-1 immunostained sections using identical camera acquisition settings, 567 
at 20X/0.5NA magnification. In order to perform the filament tracing in IMARIS (v.8.3.1), images were 568 
pre-processed in Fiji to optimise their contrast for reconstruction. The image background was 569 
subtracted using the in-built Fiji plugin to obtain an evenly distributed intensity and enhance contrast to 570 
the cells; subsequently the images were sharpened and their intensity was adjusted to the respective 571 
minimum and maximum histogram values. Filaments were then traced in IMARIS using the in-built 572 
Autopath algorithm. Reconstruction parameters were kept constant among all images; each cell was 573 
reconstructed as a 'filament' element in IMARIS, associated with a total length and volume. 574 
 575 
ELISA 576 
For quantification of Aβ by ELISA (Meso Scale Discovery) in brain homogenates or by SIMOA (Single 577 
Molecule Array, Quanterix) in isolated microglial cells, samples were pre-treated with formic acid 578 
(Sigma-Aldrich, final concentration: 70% vol/vol), sonicated for 35 seconds on ice, and centrifuged at 579 
25,000g for 1 hour at 4°C. Neutralization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05% NaN3 (wt/vol)) 580 
was then added at a 1:20 ratio. Aβ was measured by an observer blinded to the treatment groups 581 
using human (6E10) Aβ triplex assay (Meso Scale Discovery, MSD) in brain homogenates or Simoa 582 
Human Abeta 42 2.0 Kit (Quanterix) in isolated microglia according to the manufacturer’s instructions.  583 
Soluble APPβ containing the Swedish mutations (as present in the APP23 transgene) was measured 584 
using the sw soluble APPβkit (Mesoscale Discovery) following the manufacturer’s instructions after 585 
extraction with 1% Triton-X 100 and ultracentrifugation for 1h, 135,000g, 4 °C.  586 
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For cytokine measurements, brain homogenates were centrifuged at 25,000g for 30 minutes at 4°C. 587 
Supernatants were analysed using the mouse pro-inflammatory panel 1 V-plex plate (Mesoscale 588 
Discovery) according to the manufacturer’s instructions. To determine blood cytokines, serum was 589 
obtained by coagulation of whole blood in Vacuettes (Greiner Bio-One) for 10 min, RT, and 590 
centrifugation for 10 min, 2,000g. Serum samples were diluted 1:2 before measurements. The 591 
investigator was blinded to the treatment groups.  592 
Measurements were performed on a Mesoscale Sector Imager 6000 or a Simoa HD-1 Analyzer. For 593 
analyses of brain homogenates, protein levels were normalised against total protein amount as 594 
measured by BCA protein assay (Pierce).  595 
To determine levels of LPS in blood and brain homogenates, the Limulus Amebocyte Lysate assay 596 
was used according to the manufacturer’s instructions (Pierce LAL Chromogenic Endotoxin 597 
Quantitation Kit). Standards were prepared either in serum or brain homogenate from non-injected 598 
control animals. Serum samples were diluted 1:100 and brain homogenates 1:5 to eliminate matrix 599 
effects. 600 
 601 
Isolation of microglia and fluorescence-activated cell sorting (FACS) analysis 602 
Fluorescence-activated cell sorting of microglia was performed based on CD11bhigh and CD45low as 603 
previously described9 (see also Extended Data Fig.6). 604 
 605 
Assessment of microglial mitochondrial membrane potential and lactate release 606 
To assess the microglial mitochondrial membrane potential, 10k microglia were sorted into 70 μl PBS. 607 
Cells were incubated at 37°C with 3,3'-Dihexyloxacarbocyanine Iodide, DiOC6(3) (Thermo Fisher 608 
Scientific) at a final concentration of 0.2 nM for 20 minutes. At this concentration, mitochondrial dye 609 
accumulation is largely dependent on the mitochondrial membrane potential, with only minor 610 
contributions of the plasma membrane potential47. After incubation, the cell suspension was diluted 611 
with ice-cold PBS and DiOC6(3) fluorescence was immediately acquired with a Sony SH800 612 
instrument.  613 
For the assessment of microglial lactate release, 50k microglia from the same animals as used for 614 
DiOC6(3) staining were plated in 96-well plates with 125 µl of macrophage serum-free medium 615 
(Thermo Fisher Scientific) and incubated for 24h at 37°C, 5% CO2. Lactate concentration in the media 616 
was determined using a Lactate Assay Kit (BioVision) following the manufacturer’s instructions and 617 
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was correlated to DiOC6(3) fluorescence values from cells of the same animal using IBM SPSS 618 
Statistics 22 software. 619 
 620 
RNA-sequencing 621 
For RNA sequencing, 10k microglia were directly sorted into RNAse-free PCR strips containing 30 μl 622 
of H2O with 0.2% Triton-X and 0.8 U/μl RNAse inhibitor (Clontech) and samples were immediately 623 
frozen on dry ice. RNA was isolated using NucleoSpin RNA XS kit (Macherey-Nagel) according to the 624 
manufacturer’s instructions. 3 ng total RNA was used as input material for cDNA synthesis. cDNA 625 
synthesis and enrichment was performed following the Smart-seq2 v4 protocol as described by the 626 
manufacturer (Clontech). Sequencing Libraries were prepared with 1 ng of cDNA using the Nextera 627 
XT library preparation kit (Illumina) as described48. Multiplexing of samples was achieved using three 628 
different index-primers in each lane. For sequencing, samples from each group (APP and WT) were 629 
pooled to rule out amplification and sequencing biases. Libraries were quality-controlled and quantified 630 
using a Qubit 2.0 Fluorometer (Life Technologies) and Agilent 2100 Bioanalyzer (Agilent 631 
Technologies). Final library concentration of 2 nM was used for sequencing. Sequencing was 632 
performed using a 50 bp single read setup on the Illumina HiSeq 2000 platform.  633 
Base calling from raw images and file conversion to fastq files were achieved by Illumina standard 634 
pipeline scripts (bcl2fastq v.2.18.0). Quality control was then performed using FASTQC (v.2.18.0) 635 
program (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), eliminating one sample which 636 
had less than 20 million reads. Reads were trimmed off for sequencing adaptor and were mapped to 637 
mouse reference transcriptome (mm10) using STAR aligner 2.5.2b with non-default parameters. 638 
Unique read counts were obtained for each sample using HOMER v.4.8 software 639 
(http://homer.salk.edu/homer/) and ‘maketagdirectory -tbp 1’ command, followed by 640 
‘analyzeRepeats.pl rna mm10 -count exons -noadj -condenseGenes’. Raw read counts were imported 641 
into R (v.3.2) and normalized using the Bioconductor (v.3.2) DESeq2 package (v.1.10.1) using default 642 
parameter. After normalization, all transcripts having a maximum overall group mean lower than 10 643 
were removed. Unwanted or hidden sources of variation, such as batch and preparation date, were 644 
removed using the sva package49. The normalized rlog transformed expression values were adjusted 645 
according to the surrogate variables identified by sva using the function removeBatchEffect from the 646 
limma package50. To determine gene clusters associated with wildtype or APP23 animals following i.p. 647 
injections of 1x or 4xLPS at 3 months of age, we then used the 13,627 present genes and applied the 648 
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R implementation of the Weighted Gene Correlation Network Analysis (WGCNA). We then performed 649 
WGCNA clustering using the ‘1-TOMsimilarityFromExpr’ function with the network type "signed 650 
hybrid", a power parameter of 7 (as established by scale free topology network criteria), and a 651 
minimum module size of 50 dissecting the data into 10 modules. Finally, pathway enrichment analysis 652 
of genes within modules was performed using the ‘findmotifs.pl’ function of HOMER. Correction for 653 
multiple comparisons for KEGG pathway analyses was performed using the STATS package of R and 654 
applying Benjamini-Hochberg correction. To focus on the most important molecular pathways, only 655 
pathways with logP ≤ -3 and at least 5 genes were considered. 656 
 657 
Chromatin Immunoprecipitation, library preparation and analysis 658 
For microglia isolation for chromatin purification, 1 mM sodium butyrate, an inhibitor of histone 659 
deacetylases31, was added to the dissection medium and FACS buffers. After staining, microglia were 660 
fixed in 1% PFA for 10 minutes at room temperature, followed by addition of glycine (final 661 
concentration: 125 mM) for 5 minutes and washing in HBSS. Microglia were then sorted into 662 
homogenisation buffer (0.32 M sucrose, 5 mM CaCl2, 5 mM MgAc2, 50 mM HEPES, 0.1 mM EDTA, 1 663 
mM DTT, 0.1% vol/vol Triton-X-100) and centrifuged at 950 g for 5 minutes at 4 °C. The pellet was 664 
resuspended in 100 μl Nelson buffer (50 mM Tris, 150 mM NaCl, 20 mM EDTA, 1% vol/vol Triton-X-665 
100, 0.5% vol/vol NP-40) and frozen on dry ice. 666 
ChIP-sequencing was performed as previously described51, with slight modifications. In brief, two 667 
biological replicates were analysed for each condition and targeted histone modification. Cell lysates 668 
from 8-10 mice were pooled giving a total cell number of approximately 0.8-1 million cells per 669 
replicate. The cross-linked chromatin was sheared for 3x7 cycles (30 sec. On/Off) in a BioruptorPlus 670 
(Diagenode) to achieve an average fragment size of 350 bps. Proper shearing and chromatin 671 
concentration was validated by DNA isolation and quantification using a small amount of each sample 672 
individually. Samples were split in half and 1 µg of ChIP-grade antibody (H3K4me1: Abcam ab8895 or 673 
H3K27ac: Abcam ab4729) was added and incubated overnight at 4ºC. From each sample, 1% of the 674 
total volume was taken as input control prior to antibody binding. Immunoprecipitation was performed 675 
by incubating samples with 30 µl BSA-blocked protein A magnetic beads (Dynabeads, Invitrogen) for 676 
1h at 4ºC. After purifying the precipitated chromatin and isolating the DNA, DNA libraries were 677 
generated using the Next Ultra DNA Library Prep Kit for Illumina and the Q5 polymerase (New 678 
England Biolabs). Multiplexing of samples was done using 6 different index-primers from the Library 679 
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Prep Kit. For each replicate, samples from each condition (genotype and treatment) were pooled to 680 
rule out amplification and sequencing biases within the final data. Input samples were pooled and 681 
processed accordingly. The ideal number of amplification cycles was estimated via RealTime PCR to 682 
avoid over-amplification. Accordingly, samples were amplified for 13-15 cycles and the DNA was 683 
isolated afterwards. Individual libraries were pooled whereby each pool represented one whole batch 684 
of samples for each condition and targeted histone modification and was set to a final DNA 685 
concentration of 2 nM before sequencing (50 bp) on a HiSeq 2000 (Illumina) according to the 686 
manufacturer's instructions. 687 
Base calling from raw images and file conversion to fastq files was achieved by standard Illumina 688 
pipeline scripts. Sequencing reads were then mapped to mouse reference genome (mm10) using rna-689 
STAR aligner v2.3.0 with non-default parameters. Data were further processed using HOMER 690 
software (http://homer.salk.edu/homer/), following two recently published analyses on microglial 691 
epigenetic profiles31,32. Tag directories were created from bam files using ‘makeTagDirectory’ for 692 
individual samples and inputs, and peak calling was performed using ‘findpeaks -style histone’ with 4-693 
fold enrichment over background and input, a Poisson p-value of 0.0001, and a peak width of 500 bp 694 
for H3K4me1 and 250 bp for H3K27ac. Peaks common to both replicates were determined using 695 
‘mergepeaks’ (-prefix) function. To focus analysis on enhancers, peaks within ±2.5 kb of known TSS 696 
were filtered out. Union peak files for H3K4me1 and H3K27ac marks were then created for group-wise 697 
comparisons using ‘mergepeaks’ function. Active enhancers, i.e. genomic regions containing both 698 
H3K4me1 and H3K27ac peaks, were identified using the ‘window’ function of bedtools2 [52], requiring 699 
peaks of both marks to be located within a genomic region of 4 kb. Union peak files of active 700 
enhancers were then used for comparisons amongst groups for both H3K4me1 and H3K27ac marks 701 
using the ‘getDifferentialPeaks’ function (using a fold-change cut-off of 1.5 and a cumulative Poisson 702 
p-value of 0.0001). Finally, differential peaks were annotated using the ‘annotatepeaks.pl’ function, 703 
including gene ontology analysis. Correction for multiple comparisons for KEGG pathway analyses 704 
was performed using the STATS package of R and applying Benjamini-Hochberg correction. To focus 705 
on the most important molecular pathways, only pathways with logP ≤ -3 and at least three genes 706 
were considered. 707 
For the generation of UCSC browser files, the ‘makeUCSCfile’ function was used, including 708 
normalisation to respective input and library size, with a resolution of 10 bp. Files for heatmaps of 24 
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kb genomic regions and with a resolution of 250 bp were generated using the ‘annotatePeaks.pl’ 710 
function; clustering was then performed using Gene Cluster 3.0 and visualised using JavaTreeView.  711 
To identify transcription factors involved in the differential activation of enhancers, the 712 
‘findMotifsGenome.pl’ command was used to analyse a region of 500 bp around enhancer peaks (-713 
size 500), as this resulted in more robust identification of motifs for known microglial lineage-714 
determining transcription factors when determining motifs of all identified microglial enhancers 715 
(Extended Data Fig.8). For all active enhancers, motif analysis was performed using the union 716 
H3K27ac peak file and standard background (i.e. random genomic sequence created by HOMER). In 717 
the case of pairwise comparisons amongst conditions, the first condition’s specific H3K27ac peak file 718 
was used as input and the second condition’s peak file as background. Because motif enrichment was 719 
often relatively low, we focussed on the most relevant results by determining transcription factor 720 
(families), whose motifs occurred at least twice in ‘known’ and ‘de-novo’ motifs.  721 
 722 
Comparison between enhancer activation and gene expression 723 
From our 14 pairwise comparisons (Fig.4, Extended Data Fig.7 and Supplementary Table 2), we 724 
analysed 772 differentially activated enhancers and compared increased/decreased H3K27ac levels 725 
with the direction of change in the expression of the nearest gene (difference in z-scores between the 726 
groups used for pairwise comparisons). The 14 concordance values were then statistically compared 727 
to chance level (50%) using a two-tailed Wilcoxon signed rank test. 728 
 729 
Statistics and Reproducibility 730 
Statistical analyses were performed using IBM SPSS Statistics 22 or Prism 5 software. Data were 731 
assessed for normal distribution (Shapiro-Wilk test) and statistical outliers using the ‘explore’ function. 732 
If the normality criterion was met, data were analysed using a one-way ANOVA (for experiments on 733 
single genotypes), followed by pairwise comparison (if P<0.05) with post-hoc Tukey correction (for 734 
samples with non-significant homogeneity of variance Levene’s test) or Dunnett test (if homogeneity of 735 
variances not given). For comparisons across treatments and genotypes (e.g. cytokine analyses in 736 
Fig.2), a two-way ANOVA was performed, followed by posthoc testing with Tukey correction for 737 
significant main effects (P<0.05). As the cytokine data for acute LPS stimulation (Fig.1) showed 738 
inequality of variance as well as skewedness, a non-parametric independent-samples median test was 739 
performed followed by pairwise comparison with correction for multiple comparison.  740 
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All experiments were performed at least twice and in independent batches of animals for key 741 
findings (figures show the pooled data). Due to batch-related variation in some dependent variables, 742 
‘batch’ was added as a random variable to analyses where a significant batch effect was observed. 743 
For data sets with small sample size (e.g. Western Blotting analyses), the Kruskal-Wallis test was 744 
performed, followed by pairwise comparisons if P< 0.05. In the figure legends ‘n’ denotes the number 745 
of animals per treatment group. Minimum sample sizes were determined a priori using power analyses 746 
or as dictated by the methodology (e.g. ChIP-Seq).  747 
 748 
Raw and processed data are provided in the Gene Expression Omnibus (accession number 749 
GSE82170; subseries GSE82168 for ChIP-Seq and GSE104630 for RNA-Seq datasets). Other data 750 
that support the findings of this study are available from the corresponding author upon reasonable 751 
request. 752 
 753 
  754 
Publications 
 
 111 
 
 
 
 
 
 
 13
Figure 1: Peripheral immune stimulation evokes immune memory in microglia. 391 
a, Experimental approach. b, White bars: Peripheral cytokine levels in wildtype/APP23 animals 392 
following lipopolysaccharide (LPS) injections. Note that tolerance is induced with repeated injections. 393 
c, Brain cytokine levels: 2xLPS amplifies IL-1β/TNF-α release, demonstrating immune training; 394 
tolerance occurs with 3x/4xLPS. Cytokines return to baseline within 24h (1xLPS,1xPBS/4xLPS+1day). 395 
Grey bars: Microglia-specific knockout of Tak1 or Hdac1/2 selectively prevents immune training in the 396 
brain. In (b/c) n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 from left to right. */**/***P <0.05/ 0.01/0.001 for 397 
independent-samples median test with correction for multiple comparisons. Data are means±s.e.m. 398 
 399 
Figure 2: Cerebral β-amyloidosis is altered after peripheral immune stimulation.  400 
a, Experimental design. b, Analysis of cortical amyloid-β plaque load (n=22,10,10 animals) and protein 401 
levels (n=14,10,10 animals). c, Analysis of total cortical and plaque-associated microglia 402 
(n=7,7,7,14,10,10 animals) and d, cytokine levels of IL-10 and IL-1β in wildtype and APP23 mice 403 
(n=8,8,7 and n=14,10,10 animals). Scale bar: 50 µm. */**/***P <0.05/0.01/ 0.001 for one-way (b) and 404 
two-way ANOVA (c/d) with Tukey correction. Data are means ± s.e.m. 405 
 406 
Figure 3: Stroke pathology is altered after peripheral immune stimulation. 407 
Pathological features of brain ischemia induced one month after intraperitoneal injection with 1x or 408 
4xLPS. a, Neuronal damage (cresylviolet, n=6,6,7,6 animals), microglial numbers (Iba1-positive, 409 
n=6,6,6 animals) and b, cytokine profiles one day post-ischemia (n=5,7,5,5 animals). c, Overview of 410 
microglial activation in the infarct and d, quantification of neuronal damage and microglial activation 411 
seven days post-ischemia (n=3,13,8,9 animals). Scale bar: 500 µm. */**/*** P <0.05/0.01/ 0.001 for 412 
one-way ANOVA with Tukey correction. Data are means ± s.e.m. 413 
 414 
Figure 4: The microglial enhancer repertoire 6 months after immune stimulation.  415 
Pathway enrichment of enhancers (with Benjamini-Hochberg correction) with differentially regulated 416 
H3K4me1 (a) and H3K27ac (b) levels (based on nearest gene; cumulative Poisson P-value <0.0001). 417 
n=2 replicates (8-10 animals/replicate).  418 
 419 
Figure 5: Microglial gene expression and function 6 months after immune stimulation. 420 
a, Weighted gene correlation network analysis (top: correlation coefficient; bottom: P-value; 421 
n=9,9,6,6,5,4 animals). b, Selected KEGG pathways enriched in modules. c, Heatmaps of genes 422 
within modules, z-scores (boxplot whiskers: 5-95th percentile; n=1601,990,949,3543 genes in 423 
modules) and selected genes. d, Microglial mitochondrial membrane potential (left/middle; 424 
n=9,6,6,8,3,4 animals) and Pearson’s correlation with lactate release (right; n=11,10,10 animals). e, 425 
Staining for top: HIF-1α, microglia (CD11b) and amyloid plaques (Methoxy-X04) and bottom: HIF-1α 426 
and microglial nuclei (Pu.1; single confocal plane) in brain sections from 9-month-old animals. Scale 427 
bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) HIF-1α 428 
staining intensity. g, Microglial Aβ content (n=5,11,10,10 animals). */**/*** P<0.05/0.01/0.001 for one-429 
way ANOVA with Tukey correction. Data are means± s.e.m.  430 
 431 
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Figure 1: Peripheral immune stimulation evokes immune memory in microglia. 391 
a, Experim ntal approach. b, White bars: Peripheral cytokine levels in wildtype/APP23 animals 392 
following lipopolysaccharide (LPS) injections. Note that tolerance is induced with repeated injections. 393 
c, Brain cytokine levels: 2xLPS amplifies IL-1β/TNF-α release, demonstrating immune training; 394 
tolerance occurs with 3x/4xLPS. Cytokines return to baseline within 24h (1xLPS,1xPBS/4xLPS+1day). 395 
Grey bars: Microglia-specific knockout of Tak1 or Hdac1/2 selectively prevents immune training in the 396 
brain. In (b/c) n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 from left to right. */**/***P <0.05/ 0.01/0.001 for 397 
independent-samples median test with correction for multipl  comparisons. Data are means±s.e.m. 398 
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Figure 2: Cerebral β-amyloidosis is altered after peripheral immune stimulation.  400 
a, Experimental design. b, Analysis of cortical amyloid-β plaque load (n=22,10,10 animals) and protein 401 
levels (n=14,10,10 animals). c, Analysis of total cortical and plaque-associated microglia 402 
(n=7,7,7,14,10,10 animals) and d, cytokine levels of IL-10 and IL-1β in wildtype and APP23 mice 403 
(n=8,8,7 and n=14,10,10 animals). Scale bar: 50 µm. */**/***P <0.05/0.01/ 0.001 for one-way (b) and 404 
two-way ANOVA (c/d) with Tukey correction. Data are means ± s.e.m. 405 
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Figure 3: Stroke pathology is altered after peripheral immune stimulation. 407 
Pathological features of brain ischemia induced one month after intraperitoneal injection with 1x or 408 
4xLPS. a, Neuronal damage (cresylviolet, n=6,6,7,6 animals), microglial numbers (Iba1-positive, 409 
n=6,6,6 animals) and b, cytokine profiles one day post-ischemia (n=5,7,5,5 animals). c, Overview of 410 
microglial activation in the infarct and d, quantification of neuronal damage and microglial activation 411 
seven days post-ischemia (n=3,13,8,9 animals). Scale bar: 500 µm. */**/*** P <0.05/0.01/ 0.001 for 412 
one-way ANOVA with Tukey correction. Data are means ± s.e.m. 413 
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Figure 4: The microglial enhancer repertoire 6 months after immune stimulation.  415 
Pathway enrichment of enhancers (with Benjamini-Hochberg correction) with differentially regulated 416 
H3K4me1 (a) and H3K27ac (b) levels (based on nearest gene; cumulative Poisson P-value <0.0001). 417 
n=2 replicates (8-10 animals/replicate).  418 
 419 
Figure 5: Microglial gene expression and function 6 months after immune stimulation. 420 
a, Weighted gene correlation network analysis (top: correlation coefficient; bottom: P-value; 421 
n=9,9,6,6,5,4 animals). b, Selected KEGG pathways enriched in modules. c, Heatmaps of genes 422 
within modules, z-scores (boxplot whiskers: 5-95th percentile; n=1601,990,949,3543 genes in 423 
modules) and selected genes. d, Microglial mitochondrial membrane potential (left/middle; 424 
n=9,6,6,8,3,4 animals) and Pearson’s correlation with lactate release (right; n=11,10,10 animals). e, 425 
Staining for top: HIF-1α, microglia (CD11b) and amyloid plaques (Methoxy-X04) and bottom: HIF-1α 426 
and microglial nuclei (Pu.1; single confocal plane) in brain sections from 9-month-old animals. Scale 427 
bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) HIF-1α 428 
staining intensity. g, Microglial Aβ content (n=5,11,10,10 animals). */**/*** P<0.05/0.01/0.001 for one-429 
way ANOVA with Tukey correction. Data are means± s.e.m.  430 
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Figure 1: Peripheral immune stimulation evokes immune memory in microglia. 391 
a, Experimental approach. b, White bars: Peripheral cytokine levels in wildtype/APP23 animals 392 
following lipopolysaccharide (LPS) injections. Note that tolerance is induced with repeated injections. 393 
c, Brain cytokine levels: 2xLPS am lifies IL-1β/TNF-α release, demonstrating immune training; 394 
tolerance occurs with 3x/4xLPS. Cytokines return to baseline within 24h (1xLPS,1xPBS/4xLPS+1day). 395 
Grey bars: Microglia-specific knockout of Tak1 or Hdac1/2 selectively prevents immune training in the 396 
brain. In (b/c) n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 from left to right. */**/***P <0.05/ 0.01/0.001 for 397 
independent-samples median test with correction for multiple comparisons. Data are means±s.e.m. 398 
 399 
Figure 2: Cerebral β-amyloidosis is altered after peripheral immune stimulation.  400 
a, Experimental design. b, Analysis of cortical amyloid-β plaque load (n=22,10,10 animals) and protein 401 
levels (n=14,10,10 animals). c, Analysis of total cortical and plaque-associated microglia 402 
(n=7,7,7,14,10,10 animals) and d, cytokine levels of IL-10 and IL-1β in wildtype and APP23 mice 403 
(n=8,8,7 and n=14,10,10 animals). Scale bar: 50 µm. */**/***P <0.05/0.01/ 0.001 for one-way (b) and 404 
two-way ANOVA (c/d) with Tukey correction. Data are means ± s.e.m. 405 
 406 
Figure 3: Stroke pathology is altered after peripheral i mune stimulation. 407 
Pathological features of brain ischemia induced one month after intraperitoneal injection with 1x or 408 
4xLPS. a, Neuronal damage (cresylviolet, n=6,6,7,6 animals), microglial numbers (Iba1-positive, 409 
n=6,6,6 animals) and b, cytokine profiles one day post-ischemia (n=5,7,5,5 animals). c, Overview of 410 
microglial activation in the infarct and d, quantification of neuronal damage and microglial activation 411 
seven days post-ischemia (n=3,13,8,9 animals). Scale bar: 500 µm. */**/*** P <0.05/0.01/ 0.001 for 412 
one-way ANOVA with Tukey correction. Data are means ± s.e.m. 413 
 414 
Figure 4: The microglial enhancer repertoire 6 months after immune stimulation.  415 
Pathway enrichment of enhancers (with Benjamini-Hochberg correction) with differentially regulated 416 
H3K4me1 (a) and H3K27ac (b) levels (based on nearest gene; cumulative Poisson P-value <0.0001). 417 
n=2 replicates (8-10 animals/replicate).  418 
 419 
Figure 5: Microglial gene expression and function 6 months after immune stimulation. 420 
a, Weighted gene correlation network analysis (top: correlation coefficient; bottom: P-value; 421 
n=9,9,6,6,5,4 animals). b, Selected KEGG pathways enriched in modules. c, Heatmaps of genes 422 
within modules, z-scores (boxplot whiskers: 5-95th percentile; n=1601,990,949,3543 genes in 423 
modules) and selected genes. d, Microglial mitochondrial membrane potential (left/middle; 424 
n=9,6,6,8,3,4 animals) and Pearson’s correlation with lactate release (right; n=11,10,10 animals). e, 425 
Staining for top: HIF-1α, microglia (CD11b) and amyloid plaques (Methoxy-X04) and bottom: HIF-1α 426 
and microglial nuclei (Pu.1; single confocal plane) in brain sections from 9-month-old animals. Scale 427 
bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) HIF-1α 428 
staining intensity. g, Microglial Aβ content (n=5,11,10,10 animals). */**/*** P<0.05/0.01/0.001 for one-429 
way ANOVA with Tukey correction. Data are means± s.e.m.  430 
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Figure 1: Peripheral immune stimulation evokes immune memory in microglia. 391 
a, Experimental approach. b, White bars: Peripheral cytokine levels in wildtype/APP23 animals 392 
following lipopolysaccharide (LPS) injections. Note that tolerance is induced with repeated injections. 393 
c, Brain cytoki e levels: 2xLPS amplifies IL-1β/TNF-α release, demonstrating immune training; 394 
tolerance occurs with 3x/4xLPS. Cytokines return to baseline within 24h (1xLPS,1xPBS/4xLPS+1day). 395 
Gr y bars: icroglia-specific knockout of Tak1 or Hdac1/2 selectively revents immune training in the 396 
brain. In (b/c) n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 from left to right. */**/***P <0.05/ 0.01/0.001 for 397 
independent-samples median test with correction for multiple comparisons. Data are means±s.e.m. 398 
 399 
Figure 2: Cerebral β-amyloidos s is altered after peripheral immune stimulation.  400 
a, Experimental design. b, Analysi  of cortical amyloid-β plaque load (n=22,10,10 an mals) and protein 401 
levels (n=14,10,10 animals). c, Analysis of total cortical and plaque-associated microglia 402 
(n=7,7,7,14,10,10 animals) and d, cytokine levels of IL-10 and IL-1β in wildtype and APP23 mice 403 
(n=8,8,7 and n=14,10,10 imals). Scale bar: 50 µm. */**/***P <0.05/0.01/ 0.001 for one-way (b) and 404 
two-way ANOVA (c/d) with Tukey correction. Data are means ± s.e.m. 405 
 406 
Figure 3: Stroke pathology is altered after peripheral immune stimulation. 407 
Pathological features of brain ischemia induced one month aft r intraperitoneal injection with 1x or 408 
4xLPS. a, Neuronal damage (cresylvi let, n=6,6,7,6 animals), microglial numbers (Iba1-positive, 409 
n=6,6,6 animal ) and b, cytokine profiles one day post-ischemia (n=5,7,5,5 animals). c, Overview of 410 
microglial activation in the infarct and d, quantification of neuronal d mage and microglial activation 411 
seven days post-ischemia (n=3,13,8,9 animals). Scale bar: 500 µm. */**/*** P <0.05/0.01/ 0.001 for 412 
one-way ANOVA with Tukey correction. Data are means ± s.e.m. 413 
 414 
Figure 4: The microglial enhancer repertoire 6 months after immune stimulation.  415 
Pathway enrichment of enhancers (with Benjamini-Hochberg correction) with differentially regulated 416 
H3K4me1 (a) and H3K27ac (b) levels (based on nearest gene; cumulative Poisson P-value <0.0001). 417 
n=2 replicates (8-10 animals/replicate).  418 
 419 
Figure 5: Microglial gene expression and function 6 months after immune stimulation. 420 
a, Weighted gene correlation network analysis (top: correlation coefficient; bottom: P-value; 421 
n=9,9,6,6,5,4 animals). b, Selected KEGG pathways enriched in modules. c, Heatmaps of genes 422 
within modules, z-scores (boxplot whiskers: 5-95th percentile; n=1601,990,949,3543 genes in 423 
modules) and selected genes. d, Microglial mitochondrial membrane potential (left/middle; 424 
n=9,6,6,8,3,4 animals) and Pearson’s correlation with lactate release (right; n=11,10,10 animals). e, 425 
Staining for top: HIF-1α, microglia (CD11b) and amyloid plaques (Methoxy-X04) and bottom: HIF-1α 426 
and microglial nuclei (Pu.1; single confocal plane) in brain sections from 9-month-old animals. Scale 427 
bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) HIF-1α 428 
staining intensity. g, Microglial Aβ content (n=5,11,10,10 animals). */**/*** P<0.05/0.01/0.001 for one-429 
way ANOVA with Tukey correction. Data are means± s.e.m.  430 
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bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) HIF-1α 428 
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Extended Data Figure 1: Acute responses to LPS injections.  755 
a, Weight changes after injection of lipopolysaccharides (LPS) (wildtype animals: n=11,11,11,11,4 for 756 
PBS, n=9,9,9,8,7 for 1xLPS, n=10,10,10,10,7 for 4xLPS; APP animals: n=14,14,14,14,7 for PBS, 757 
n=8,8,8,5,5 for 1xLPS; n=10,10,10,10,10 for 4xLPS; Cre animals n=5,5,4). b/c, Morphological 758 
changes in microglia (n=6,6,6,6,6 animals). Scale bar: 50 µm. d, Numbers of microglia and activated 759 
(GFAP+) astrocytes (microglia n=6,7,8,6,6 animals, astrocytes n=6,8,9,7,5 animals). e, Blood and 760 
brain levels of LPS after daily injections with 500 µg/kg bodyweight (n=4,3,3,3,3 animals). f, 761 
Assessment of iron entry from the blood (detected by Prussian Blue staining) shows positive staining 762 
in an aged (>25 months) APP transgenic animal, but not after repeated intraperitoneal LPS injections 763 
(n=3 mice analysed). g, In mice expressing red fluorescent protein (RFP) under the 'type 2 CC 764 
chemokine receptor’ (Ccr2) promoter, no entry of CCR2-expressing blood monocytes is detected after 765 
repeated LPS injection (staining for RFP; insert shows RFP-positive monocytes in the choroid plexus; 766 
n=3 mice analysed). Scale bar: 100 µm. Data are means±s.e.m. */**/*** P <0.05/0.01/ 0.001 for one-767 
way ANOVA with Tukey correction.  768 
 769 
Extended Data Figure 2: Cytokine response after acute LPS injections. 770 
a, Additional cytokines (cp. Fig.1) analysed in the serum (top) and brain (bottom) 3h after each daily 771 
intraperitoneal lipopolysaccharide (LPS) injection on four consecutive days in 3-month-old mice 772 
(control animals received PBS injections; n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 mice for groups from left 773 
to right). b/c, Cytokine response in the blood only in wildtype (b, n=6,7,8,5,5,3,3 animals) or APP23 (c, 774 
n=10,3,3,3,4,3,3 animals) mice. d/e, Cytokine response in the brain only in wildtype (d, n=6,7,8,5,5,3,3 775 
animals) or APP23 (e, n=10,4,4,4,4,4,4 animals) mice. Data are means± s.e.m. */**/*** 776 
P <0.05/0.01/ 0.001 for independent-samples median test with correction for multiple comparisons. 777 
 778 
Extended Data Figure 3: APP levels and processing, neuritic dystrophy and astrocyte 779 
activation in 9-month-old APP23 animals. 780 
 781 
a/b, Micrograph of fluorescent staining for amyloid plaque (Methoxy-X04; green) and amyloid 782 
precursor protein (APP; red) shows neuritic dystrophy surrounding the amyloid deposit, which is 783 
unchanged by LPS treatments (b; n=5,5,5 animals). c, Overall Pearson’s correlation of plaque size 784 
with neuritic dystrophy (‘APP area’; n=49,39,42 plaques for PBS/1xLPS/4xLPS groups). d, Western 785 
Blotting analysis (for gel source data, see Supplementary Figure 1) of brain homogenates for amyloid 786 
precursor protein (APP) and C-terminal fragment-β (CTFβ; n=7,4,7 animals), and soluble APPβ ELISA 787 
(n=6,6,6 animals). e, Micrograph of activated astrocytes (glial fibrillar acidic protein: GFAP) 788 
surrounding an amyloid plaque (Congo Red) and quantification of the number of plaque-associated 789 
GFAP-positive astrocytes (n=6,6,5 animals). Scale bar: 10 µm in (a), 20 µm in (e). Data are 790 
means±s.e.m. * P <0.05 for one-way ANOVA with Tukey correction. 791 
 792 
Extended Data Figure 4: Cytokine levels in 9-month-old animals  793 
a, Cytokine measurements in brain homogenates of 9-month-old wildtype (n=8,8,7 animals) and 794 
APP23 (n=14,10,10 animals) mice treated i.p. with 1x or 4xLPS at 3 months of age. b, Cytokine 795 
measurements in the serum of 9-month-old wildtype (WT; n=14,9,13 animals) and APP23 (APP; 796 
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Extended Data Figure 1: Acute responses to LPS injections.  755 
a, Weight changes after injection of lipopolysaccharides (LPS) (wildtype animals: n=11,11,11,11,4 for 756 
PBS, n=9,9,9,8,7 for 1xLPS, n=10,10,10,10,7 for 4xLPS; APP animals: n=14,14,14,14,7 for PBS, 757 
n=8,8,8,5,5 for 1xLPS; n=10,10,10,10,10 for 4xLPS; Cre animals n=5,5,4). b/c, Morphological 758 
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(GFAP+) astrocytes (microglia n=6,7,8,6,6 animals, astrocytes n=6,8,9,7,5 animals). e, Blood and 760 
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a/b, Micrograph of fluorescent staining for amyloid plaque (Methoxy-X04; green) and amyloid 782 
precursor protein (APP; red) shows neuritic dystrophy surrounding the amyloid deposit, which is 783 
unchanged by LPS treatments (b; n=5,5,5 animals). c, Overall Pearson’s correlation of plaque size 784 
with neuritic dystrophy (‘APP area’; n=49,39,42 plaques for PBS/1xLPS/4xLPS groups). d, Western 785 
Blotting analysis (for gel source data, see Supplementary Figure 1) of brain homogenates for amyloid 786 
precursor protein (APP) and C-terminal fragment-β (CTFβ; n=7,4,7 animals), and soluble APPβ ELISA 787 
(n=6,6,6 animals). e, Micrograph of activated astrocytes (glial fibrillar acidic protein: GFAP) 788 
surrounding an amyloid plaque (Congo Red) and quantification of the number of plaque-associated 789 
GFAP-positive astrocytes (n=6,6,5 animals). Scale bar: 10 µm in (a), 20 µm in (e). Data are 790 
means±s.e.m. * P <0.05 for one-way ANOVA with Tukey correction. 791 
 792 
Extended Data Figure 4: Cytokine levels in 9-month-old animals  793 
a, Cytokine measurements in brain homogenates of 9-month-old wildtype (n=8,8,7 animals) and 794 
APP23 (n=14,10,10 animals) mice treated i.p. with 1x or 4xLPS at 3 months of age. b, Cytokine 795 
measurements in the serum of 9-month-old wildtype (WT; n=14,9,13 animals) and APP23 (APP; 796 
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Extended Data Figure 1: Acute responses to LPS injections.  755 
a, Weight changes after injection of lipopolysaccharides (LPS) (wildtype animals: n=11,11,11,11,4 for 756 
PBS, n=9,9,9,8,7 for 1xLPS, n=10,10,10,10,7 for 4xLPS; APP animals: n=14,14,14,14,7 for PBS, 757 
n=8,8,8,5,5 for 1xLPS; n=10,10,10,10,10 for 4xLPS; Cre animals n=5,5,4). b/c, Morphological 758 
changes in microglia (n=6,6,6,6,6 animals). Scale bar: 50 µm. d, Numbers of microglia and activated 759 
(GFAP+) astrocytes (microglia n=6,7,8,6,6 animals, astrocytes n=6,8,9,7,5 animals). e, Blood and 760 
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n=3 mice analysed). Scale bar: 100 µm. Data are means±s.e.m. */**/*** P <0.05/0.01/ 0.001 for one-767 
way ANOVA with Tukey correction.  768 
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animals) or APP23 (e, n=10,4,4,4,4,4,4 animals) mice. Data are means± s.e.m. */**/*** 776 
P <0.05/0.01/ 0.001 for independent-samples median test with correction for multiple comparisons. 777 
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n=18,12,14 animals) mice after i.p. stimulation with 1x or 4xLPS at 3 months of age. c, Cytokine 797 
measurements in the serum of wildtype animals stimulated i.p. with 1x or 4xLPS at 3 months of age 798 
and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age (n=10,7,10 animals). 799 
Data are means±s.e.m. */** P <0.05/0.01 for two-way ANOVA with Tukey correction. In (b) a 800 
significant main effect for genotype is indicated by bars spanning all conditions of the same genotype.  801 
 802 
Extended Data Figure 5: Cytokine levels after brain ischemia and in blood of 4-month-old 803 
animals. 804 
Three-month-old animals were i.p. injected with 1x or 4xLPS and incubated for 4 weeks before 805 
receiving a stroke. a, Cytokine measurements in brain homogenates 24h after stroke (n=5,7,5,5 806 
animals). b, Cytokine measurements in the serum (n=6,6,6 animals). Data are means±s.e.m. *** 807 
P<0.001 for one-way ANOVA with Tukey correction. 808 
 809 
Extended Data Figure 6: Microglial sorting strategy.  810 
Microglia were sorted as CD11bhigh and CD45low cells (population P4) from 9-month-old APP23 811 
animals or wildtype littermates following i.p. injections of 1x or 4xLPS at 3 months of age.  812 
 813 
Extended Data Figure 7: Analysis of microglial enhancers.  814 
Microglial enhancers were analysed in 9-month-old wildtype and APP23 (APP) mice treated 815 
intraperitoneally with 1x or 4xLPS at 3 months of age. a, Exemplary UCSC browser images of 816 
genomic region around the Hif1a gene (normalised to input and library dimension). b, Numbers of 817 
regions with differentially regulated H3K4me1 levels. c, Heatmaps of H3K4me1 regions (centred on 818 
H3K27ac peaks). d, Pairwise correlations between the two replicates of H3K4me1 read densities in 819 
differentially regulated regions. e-g, Analyses of H3K27ac levels analogous to (b-d) for H3K4me1. n=2 820 
replicates (8-10 animals/replicate); differential enhancers showed a cumulative Poisson P-value 821 
<0.0001; Benjamini-Hochberg correction was applied for pathway enrichment. 822 
 823 
Extended Data Figure 8: Transcription factor motif analysis of active enhancer regions.  824 
Motif analysis was performed for selected conditions to identify transcription factors involved in the 825 
differential activation of enhancers (using putative enhancer regions present in both replicates within 826 
500 bp around enhancer peaks). a, For all active enhancers, motif analysis was performed using the 827 
union H3K27ac peak file and standard background (random genomic sequence). b, Pairwise 828 
comparisons between conditions, using the first condition’s H3K27ac peak file as input and the second 829 
condition’s peak file as background. As motif enrichment was often relatively low, the analysis was 830 
focussed on transcription factor (families), whose motifs occurred at least twice in ‘known’ (black) and 831 
‘de-novo’ motifs (blue). Motifs are identified by HOMER software using hypergeometric testing (no 832 
adjustment for multiple comparisons was made).  833 
 834 
Extended Data Figure 9: Peripherally applied cytokines induce immune memory in the brain. 835 
a, Experimental design. b, Cytokine responses in the brain, four weeks after peripheral cytokine 836 
application (n=17,5,5,21,8,8,15 animals). Note that TNF-α dose-dependently enhances (low dose) or 837 
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n=18,12,14 animals) mice after i.p. stimulation with 1x or 4xLPS at 3 months of age. c, Cytokine 797 
measurements in the serum of wildtype animals stimulated i.p. with 1x or 4xLPS at 3 months of age 798 
and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age (n=10,7,10 animals). 799 
Data are means±s.e.m. */** P <0.05/0.01 for two-way ANOVA with Tukey correction. In (b) a 800 
significant main effect for genotype is indicated by bars spanning all conditions of the same genotype.  801 
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and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age (n=10,7,10 animals). 799 
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n=18,12,14 animals) mice after i.p. stimulation with 1x or 4xLPS at 3 months of age. c, Cytokine 797 
measurements in the serum of wildtype animals stimulated i.p. with 1x or 4xLPS at 3 months of age 798 
and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age (n=10,7,10 animals). 799 
Data are means±s.e.m. */** P <0.05/0.01 for two-way ANOVA with Tukey correction. In (b) a 800 
significant main effect for genotype is indicated by bars spanning all conditions of the same genotype.  801 
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measurements in the serum of wildtype animals stimulated i.p. with 1x or 4xLPS at 3 months of age 798 
and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age (n=10,7,10 animals). 799 
Data are means±s.e.m. */** P <0.05/0.01 for two-way ANOVA with Tukey correction. In (b) a 800 
significant main effect for genotype is indicated by bars spanning all conditions of the same genotype.  801 
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a, Experimental design. b, Cytokine responses in the brain, four weeks after peripheral cytokine 836 
application (n=17,5,5,21,8,8,15 animals). Note that TNF-α dose-dependently enhances (low dose) or 837 
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decreases (high dose) certain cytokines. Similar to high dose TNF-α, certain cytokines are also 838 
reduced by peripheral application of IL-10 four weeks earlier. c, Cytokine responses in the periphery 839 
are unaffected (n=8,21,9,5,10 animals). Data are means±s.e.m. */**/*** P<0.05/0.01/0.001 for one-way 840 
ANOVA with Tukey correction. 841 
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Abstract  
The phagocytic removal of amyloid-β (Aβ) in Alzheimer’s disease (AD) may be able to combat 
disease progression and is therefore of therapeutic interest. Previously, it was suggested that 
the protein milk fat globule-EGF factor 8 (MFG-E8) may play a role in the removal of Aβ via 
microglia-mediated phagocytosis. Moreover, altered MFG-E8 levels in the brain of AD patients 
suggest a function of MFG-E8 in the pathology of AD. Here, we report that genetic deletion of 
MFG-E8 in APP transgenic (tg) mice results in significantly reduced Aβ levels and plaque load 
at early stages of cerebral β-amyloidosis, but does not induce alterations in the microglial 
phagocytosis of Aβ nor in inflammatory cytokine production. However, immunostaining for 
MFG-E8 in the brain of APP tg mice showed very strong co-localization with Aβ plaques and 
MFG-E8 levels increased both with age and the extent of cerebral β-amyloidosis. Furthermore, 
electron microscopy confirmed localization of MFG-E8-immunoreactivity to Aβ fibrils. These 
data argue against a beneficial effect of MFG-E8 on Aβ pathology through facilitating the 
removal of Aβ, but suggest a microglia-independent interaction between MFG-E8 and Aβ that 
accelerates Aβ plaque formation. Preventing this detrimental interaction between MFG-E8 and 
Aβ may therefore provide a novel opportunity for therapeutic interference with Aβ deposition. 
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Introduction 
The aggregation and deposition of the amyloid-β (Aβ) peptide in the brain can be a result of 
increased production and/or impaired clearance. For the rare forms of familial Alzheimer’s 
disease (FAD), it is well known that genetic alterations in the APP or PSEN1/2 genes result in 
an overproduction of Aβ1-5. In contrast, for sporadic late-onset AD (LOAD), which accounts 
for >99 percent of all AD cases5, a variety of risk factors such as obesity or type 2 diabetes have 
been reported6,7. In addition, recent genome-wide association studies (GWAS) have revealed 
several new susceptibility genes that are associated with innate immunity and inflammation 
suggesting an immune system dysfunction in LOAD8-10. In the brain, microglia are the main 
immune effector cells; however, for many of the identified risk loci, the exact role in the 
microglia-mediated immune response is still a matter of debate. Therefore, studies that aim to 
understand the overall contribution of the innate immune response to the pathogenesis of AD 
are of great importance to therapeutically target such risk factors.  
Our study focused on milk-fat globule-EGF factor 8 (MFG-E8, also known as 
lactadherin), a bivalent-binding, secretory glycoprotein known for its role in promoting the 
phagocytic removal of apoptotic neurons in the injured brain11. Moreover, MFG-E8 was 
previously reported to directly bind Aβ and initiate its phagocytosis by microglia12. In 
particular, genetic deletion of MFG-E8 was shown to decrease phagocytosis of Aβ by peritoneal 
macrophages12. Furthermore, in human post-mortem AD brains, MFG-E8 staining was found 
to be reduced in areas enriched in Aβ plaques, suggesting that Aβ favors accumulation in areas 
with reduced MFG-E8 production or that MFG-E8 is removed after binding to Aβ. However, 
the exact mechanism how MFG-E8 modifies the pathogenesis of AD remains to be elucidated. 
To study the in vivo contribution of MFG-E8 to Aβ pathology, we generated two 
transgenic mouse models of cerebral β-amyloidosis, APPPS1 and APP23, which were deficient 
for MFG-E8, and analyzed pathological hallmarks. Here we demonstrate that lack of MFG-E8 
has no significant effects on the microglia-mediated immune response to cerebral β-
amyloidosis, including the phagocytosis of Aβ. However, contrary to the hypothesis that MFG-
E8 may be beneficial for AD pathology, the deficiency of MFG-E8 in mouse models of AD 
pathology significantly reduced cortical Aβ plaque burden at early stages of Aβ deposition. 
Thus, our results indicate a critical role for MFG-E8 in the initial process of Aβ aggregation 
and suggest MFG-E8 as a potential candidate for therapeutic intervention of Aβ aggregation.  
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Material and Methods 
Mice 
APPPS1 (C57BL/6J- Tg(Thy1-APPK670N/M671L and Thy1-PS1L166P) and APP23 mice 
(C57BL/6J-Tg(Thy1-APPK670N;M671L) that have been backcrossed with C57BL/6J mice for >20 
generations were bred in-house (APP tg mice)13,14. Mfge8-/- mice (B6.129P2 
Mfge8Gt(KST227)Byg) were obtained from Clotilde Théry, PhD (INSERM U932, Institut 
Curie, France)15. Hemizygous APP tg mice were crossed with Mfge8-/- mice. The resulting APP 
tg x Mfge8+/- males were crossed with Mfge8+/- females to obtain APP tg and non-tg Mfge8+/+ 
and Mfge8-/- animals.  
The mice were maintained under specific pathogen-free conditions. All experiments were 
performed in accordance with the veterinary office regulations of Baden-Württemberg 
(Germany) and were approved by the Ethical Commission for animal experimentation of 
Tübingen, Germany. 
 
Tissue collection 
For brain preparation, mice were deeply anesthetized using sedaxylan/ketamine (64 mg/kg//472 
mg/kg) and killed by transcardial perfusion with phosphate-buffered saline (PBS). Brains were 
removed and hemispheres were separated. One half was freshly frozen on dry ice for 
biochemical analyses, whereas the other half was stored for 24 h in 4 % paraformaldehyde 
(PFA) in PBS and was then transferred to 30 % sucrose for another 48 h. PFA-fixed 
hemispheres were frozen in 2-methyl-butane and coronal sections of 25 µm thickness were cut 
with a freezing sliding microtome (Leica). Cut sections were stored at -20°C in cryoprotectant 
medium. 
 
Microglia isolation 
APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice were deeply anesthetized and perfused as 
described. The cerebellum and brain stem were removed from the brain and discarded. The rest 
of the brain was finely minced in ice-cold Hanks Buffered Salt Solution (HBSS) containing 15 
mM HEPES, 0.54 % D-Glucose and 0.1 % DNase weight/volume (w/v). Minced tissue was 
sequentially homogenized in Dounce and Potter homogenizers to achieve a homogeneous 
solution. Homogenates were filtered through a 70 µm cell strainer and centrifuged at 300 g for 
10 min at 4°C. The resulting pellet was resuspended in 70 % isotonic Percoll solution, overlaid 
with 37 % and 30 % isotonic Percoll layers and centrifuged for 30 min, 800 g, 4°C. Cells were 
recovered from the 70/37 % interphase and washed in fluorescence-activated cell sorting 
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(FACS) buffer (PBS, 2 % fetal calf serum, 10 mM EDTA). Washed cells were resuspended and 
blocked with Fc block (BD Bioscience) for 10 minutes on ice, followed by staining for 15 min 
at 4°C with CD11b-APC (1:200, BioLegend) and CD45-Alexa700 (1:200, Sony). 
CD11bhigh/CD45low microglia were sorted on a Sony SH800 flow cytometer and collected in 
FACS buffer containing 25 mM HEPES. Cells were pelleted at 800 g for 7 min and, supernatant 
was discarded and cells were resuspended in lysis buffer (50 mM Tris pH8, 150 mM NaCl, 5 
mM EDTA, phosphatase and protease inhibitors and 1 % Triton X-100) and snap frozen on dry 
ice. 
 
In vivo phagocytosis assay  
Prior to microglia isolation (24 h), 2-and 4-month-old APPPS1 x Mfge8+/+ and APPPS1 x 
Mfge8-/- mice received an intraperitoneal injection of the amyloid dye Methoxy-X04 (stock: 4 
% vol of 10 mg/ml Methoxy-X04 in DMSO, 7.7 % vol CremophoreEL in 88.3 % vol PBS; 17.5 
µl/g bodyweight). Microglia were isolated as described above and the proportion of Methoxy-
X04-positive microglia was determined by flow cytometry with a MACSQuant® Analyzer 
(Miltenyi Biotec). Microglia from 2-month-old mice were additionally stained with Methoxy-
X04 for 15 min (1:250). Background signals of Methoxy-X04 were eliminated after signal 
subtraction of the analyzed microglia fraction from APPPS1 non-tg mice. Signals of APPPS1 
x Mfge8-/- were normalized to the APPPS1 x Mfge8+/+ group of each experiment. The Methoxy-
X04-positive fraction of APPPS1 x Mfge8+/+ was normalized to the mean of the entire 
experimental group. 
 
Immunostaining 
Immunostainings were performed on free-floating sections either using Vectastain Elite ABC 
kits (Vector laboratories) or fluorescent secondary antibodies. For immunohistochemical (IHC) 
detection, sections were quenched 30 min with H2O2 (0.3 %) prior blocking with the respective 
antiserum for 1 h. The following primary antibodies were applied over night at 4°C: rabbit anti-
Iba1 (WAKO; 1:1,000), rabbit anti-PU.1 (Cell Signaling, 1:1,000 for IHC, 1:250 for 
immunofluorescence staining (IF)), rat-anti CD68 (AbD Serotec, 1:1,000), goat anti-MFG-E8 
(R&D; 1:1,000) and rabbit anti-Aβ (in-house CN6; 1:1,000). Congo-red staining was conducted 
in accordance to standard protocols. Images were acquired on an Axioplan 2 microscope with 
Axioplan MRm and AxioVision 4.7 software (Carl Zeiss).  
For immunofluorescent staining, sections were incubated with the respective fluorophore-
conjugated IgG secondary antibodies (Invitrogen, 1:250). For plaque labeling, Methoxy-X04 
Publications 
 
 129 
staining was applied for 15 min (1:10) on brain sections. For staining of the arteries, sections 
were incubated 1-2 min with Alexa Fluor 633 hydrazide (1:1,000)  as previously described16. 
Fluorescent images were acquired using a LSM 510 META (Axiovert 200M) confocal 
microscope with an oil immersion 63X/1.4NA objective and LSM software 4.2 (Carl Zeiss), 
using sequential excitation of fluorophores. 
For CD68 quantification, z-stacks of three plaques per section (3 sections/animal) stained in 
parallel were acquired. Methoxy-X04-positive plaques were randomly and blinded chosen. 
PU.1 staining was used to confirm that CD68 was expressed by microglia. Analysis of signal 
intensity of CD68 around plaques was performed using ImageJ. Quantification of co-
localization of CD68 and Methoxy-X04, as well as reconstruction of 3D images were done with 
Imaris 8.3.1.  
 
Western Blotting 
Fresh frozen hemispheres were homogenized using a Precellys® lysing kit at 10 % (w/v) in 
Tris-HCl buffer (50 mM Tris pH 8, 150 mM NaCl, 5 mM EDTA) containing phosphatase and 
protease inhibitors (Pierce) and sonicated 3x5 seconds (LabSonic, B. Braun Biotech 
International GmbH, 0.5 mm diameter sonotrode, cycle 1, amplitude 80).   
Total protein of the brain homogenates was quantified with a microplate bicinchoninic acid 
(BCA) assay (Pierce Biotechnology) and adjusted to 10-15 µg for Western Blot analysis. 
For APP, CTF-β and Aβ analysis, samples were diluted in NuPAGE® LDS sample buffer 
(Thermo fisher Scientific Inc.) containing 5 % β-mercaptoethanol, heated at 70°C and run on 
NuPage Bis-Tris mini gels (Invitrogen). For MFG-E8 levels, samples were treated with urea 
(final concentration 6 M), diluted in sample buffer (10 % glycerol, 2 % SDS, 2 % β-
mercaptoethanol, 0.1 M Tris-HCl pH 8.6) and loaded on a Tris-Tricine 10-20 % gradient gel 
(Invitrogen). After electrophoresis, gels were transferred to a nitrocellulose membrane in a 
semi-dry blotting system. Transfer was confirmed by Ponceau-S staining and the membrane 
was boiled for 5 min in PBS. Blocking was performed with 5 % milk (APP, CTF-β, Aβ) or 5 
% donkey serum (MFG-E8) in PBS-T for 1 h. Subsequently, membranes were incubated over 
night at 4°C with either mouse anti-Aβ (6E10, 1:1,000, Covance Research Products), anti-CTF-
β (1:2,000, Sigma-Aldrich) or goat anti-MFG-E8 (R&D, 1:1,000) diluted in PBS-T. 
Membranes were then probed with the respective secondary horseradish peroxidase (HRP)-
labelled antibodies (1:20,000, Jackson ImmunoLaboratories). Protein bands were detected 
using a chemiluminescent peroxidase substrate (ECL prime, GE Healthcare). Images of the 
blots were recorded using an ECL imager (Stella 3200, Raytest). Densitometric values of the 
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protein band intensities were analyzed with the software package Aida (or ImageJ for MFG-
E8) and normalized to GAPDH. 
 
ELISA 
For quantification of Aβ by ELISA (Meso Scale Disccovery) in brain homogenates or by 
SIMOA (single Molecule Array, Quanterix) in isolated microglial cells (50 000 cells/sample), 
samples were pre-treated with formic acid (Sigma-Aldrich, final concentration: 70 % vol/vol), 
sonicated for 30 seconds on ice, and centrifuged at 25,000 g for 1 hour at 4°C. Supernatants 
were equilibrated in neutralization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05 % NaN3 (w/v)). 
Aβ was measured by a commercial human (6E10) Aβ triplex assay (Meso Scale Discovery, 
MSD) in brain homogenates or with the SIMOA Human Aβ42 2.0 Kit (Quanterix) in isolated 
microglia according to the manufacturer’s instructions. Samples and calibrators were measured 
as duplicates. Brain Aβ levels were normalized against total protein amount as measured by 
BCA protein assay.  
For microglial cytokine measurements, cells were diluted in 50 µl Tris-HCl buffer 
containing 1 % Triton X-100 and phosphatase inhibitor (50 mM Tris pH8, 150 mM NaCl, 5 
mM EDTA). Cytokines were recorded in single measurements using the mouse pro-
inflammatory panel 1 V-plex plate (MSD). 
 
Electron microscopy 
Two-month-old APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice were deeply anesthetized 
using sedaxylan/ketamine (64 mg/kg//472 mg/kg) and killed by transcardial perfusion with a 
fixative containing 4 % PFA, 0.1 % glutardialdehyde in sodium cacodylate buffer (0.2 M, pH 
7.4). The brain was removed and post-fixed in 4 % PFA in PBS. Brains were cut with a 
vibratome (50 µm) and washed in PBS. Sections were stained according to standard 3,3' 
diaminobenzidine (DAB) staining protocols. Sections were osmicated (0.5 % OsO4 in PBS), 
dehydrated (70 % ethanol containing 1% uranyl acetate) and embedded between liquid release-
coated slides. Selected sections were re-embedded in blocks and ultrathin sections were 
collected and examined using a Zeiss electron microscope (Zeiss EM 900). 
 
Stereology and plaque number analysis 
Stereological analysis was performed by a blinded observer on sets of every 36th systematically 
sampled 25 µm thick brain section throughout the neocortex using a microscope (Axioskop, 
Zeiss, Germany) equipped with a motorized x-y-z-stage coupled to a video-microscopy system 
(Microfire, Optronics, California, USA). Analysis was conducted using the Stereologer 
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software (Stereo Investigator 6; MBF Bioscience). For the determination of the number of 
microglia per brain, Iba1-positive cells were determined with the optical fractionator technique 
with three dimensional dissectors as previously described17. For the assessment of plaque 
associated PU.1-positive cells the diameter of the Congo red-positive plaques was determined 
and only microglia in the two-fold vicinity of the size of the plaque diameter were counted. 
Plaque load was determined based on Congo red and anti-Aβ staining using the area fraction 
fractionator technique18. 
For the analysis of the plaque number, mosaics of the same brain sections as sampled 
for plaque load were acquired on an Axioplan 2 microscope with Axioplan MRm and 
AxioVision 4.7 software (Carl Zeiss). Plaque number was determined with Fiji software. On 
each brain section, the cortical region was selected and a manually set intensity threshold was 
applied to identify plaques. In the APPPS1 mice, plaques were grouped as < 25 µm2 (very 
small), 25-100 µm2 (small), 100-300 µm2 (medium), 300-600 µm2 (large) and > 600 µm2 (very 
large). In APP23 mice, size groups were the following 10-25 µm2 (very small), 25-100 µm2 
(small), 100-1000 µm2 (medium) and > 1000 µm2 (large).  
 
Statistics 
All values reported are mean ± s.e.m. and a p-value < 0.05 was considered as significant. Test 
for Gaussian distribution of the data was performed with D’Agostino-Pearson normality test. If 
the normality criterion was met, statistical significance of pairwise comparisons of 
experimental groups was tested with Student’s t-test. Data that did not meet normality criterion 
were analyzed using non-parametric Mann-Whitney-U test. For analysis of more than two 
groups Kruskal-Wallis test was performed, if p < 0.05 Dunn’s post hoc test was conducted. For 
comparisons of different plaque sizes multiple t-tests corrected for multiple comparisons, 
(Holm-Sidak) were performed. All analyses were done with Prism 6.0 software. 
 
 
Results 
MFG-E8 is produced by glial cells and can be found in the cerebral vasculature 
Macrophages in a variety of tissues have been shown to express and secrete MFG-E819-21. In 
the brain, RNA sequencing of different central nervous system (CNS)-derived cells 
demonstrated that MFG-E8 is expressed by the resident glia cells, especially by astrocytes, but 
to a lesser degree also by microglia22. Accordingly, immuno-staining after stroke demonstrated 
that MFG-E8 co-localizes with astrocytes and microglia23. By co-staining of MFG-E8 and glial 
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fibrillary acidic protein (GFAP; a marker for astrocytes) in brain sections from wildtype mice, 
we could confirm high protein levels of MFG-E8 in astrocytes (Fig. 1A). Moreover, cerebral 
arteries visualized with an artery-specific dye, Alexa Fluor 633 hydrazide16, which binds to 
elastin fibers, were positive for MFG-E8 (Fig. 1B) indicating its occurrence in vascular cells 
and around vascular structures as previously described24. To confirm staining specificity, we 
used genetically modified mice, in which the genetic insertion of a transmembrane domain 
fused to the β-galactosidase reporter protein (TM-β-geo) into the C2 domain of the Mfge8 gene 
results in the retention of the resulting MFG-E8-β-galactosidase fusion protein within the cell 
(Fig. 1C)24. Retention within the cell leads to a rapid degradation and, therefore, to a loss of 
MFG-E8 function. Accordingly, in mice homozygous for the inserted TM-β-geo construct 
(hereafter referred to as Mfge8-/-), only intracellular, punctate MFG-E8 staining was observed 
confirming the specificity of the MFG-E8 signal (Fig. 1B).  
To evaluate the role of MFG-E8 in the pathology of AD in vivo, we bred two mouse 
models of cerebral β-amyloidosis with Mfge8-/- mice, namely the APPPS1 mouse line that co-
expresses mutated human APP and PSEN1 genes leading to rapid onset of β-cerebral 
amyloidosis at six to eight weeks13 and the APP23 mouse line that overexpresses mutant human 
APP leading to a disease onset of around six to seven months of age14. Western Blotting of 
primary microglia isolated from APPPS1 x Mfge8-/- and APPPS1 x Mfge8+/+ mice, showed the 
presence of the two described different isoforms of the MFG-E8 protein only in APPPS1 x 
Mfge8+/+ microglia, which validates the specificity of MFG-E8 deficiency in the crossed 
APPPS1 mice and further confirms MFG-E8 expression in microglia (Fig. 1D)25.  
 
MFG-E8 levels increase with Aβ pathology 
To determine whether the levels of MFG-E8 change with ageing and/or cerebral β-amyloidosis, 
we analyzed the protein levels of MFG-E8 across different ages and at different stages of 
cerebral β-amyloidosis. In particular, we compared MFG-E8 levels of the shorter but more 
abundant isoform in brain homogenates of young (3-4 months) and aged (20 months) wildtype, 
APPPS1 and APP23 mice by Western Blotting (Fig. 2A). In accordance with published 
findings11, MFG-E8 expression in the brain increased more than threefold in wildtype mice 
with age (Fig. 2A/B). However, in contrast to previous studies indicating that MFG-E8 levels 
decrease in a mouse model of AD pathology and in human AD brain tissue11,12, we found that 
cerebral β-amyloidosis induced a significant increase in MFG-E8 levels both in APPPS1 and 
APP23 lines (Fig. 2A/B). Strikingly, a strong increase in MFG-E8 levels coincided with the 
onset of Aβ deposition. Thus, APPPS1 mice with an onset of plaque deposition at six to eight 
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weeks had 2.5-fold higher MFG-E8 levels at young age compared to wildtype mice. In contrast, 
APP23 mice, which only start to deposit plaques around six to seven months of age, showed no 
consistent increase in MFG-E8 levels in the young age group (Fig. 2A). However, at 20 months 
of age, when Aβ levels in APP23 mice are the highest, MFG-E8 was also drastically elevated 
and even exceeded MFG-E8 levels in APPPS1 mice (Fig. 2A/B).  
The effects of ageing and AD disease progression on MFG-E8 levels were further 
studied in additional age groups of APP23 mice. Similarly, the results showed a steady increase 
in MFG-E8 concentration that mirrored the rise in Aβ (Fig. 2C/D). In particular, the robust 
increase of MFG-E8 between 12 and 20 months of age is also reflected by Aβ levels in the brain 
of APP23 mice (Fig. 2C). 
 
MFG-E8 co-localizes with Aβ deposits in APP transgenic mice 
To determine the origin of the sudden increase in MFG-E8 protein levels in parallel with the 
onset of Aβ plaque pathology in APP transgenic (tg) mice, we stained brain sections of APPPS1 
and APP23 mice with an antibody directed against MFG-E8. In both mouse models, MFG-E8 
was not only present in astrocytes but also co-localized strongly with Congo red-positive 
amyloid plaques. Of note, the absence of MFG-E8 immunoreactivity on plaques, but the 
presence of the intracellular punctate MFG-E8 signal in APPPS1 x Mfge8-/- mice confirmed the 
specificity of the detected signal (Fig. 3A). Since no cellular marker, such as Iba1 or GFAP to 
visualize microglia or astrocytes respectively, showed co-localization with the plaque-
associated MFG-E8 signal (data not shown), the secreted, soluble form of MFG-E8 seems to 
strongly associate with amyloid plaques.  
Immunofluorescent co-staining of MFG-E8 with Aβ and subsequent 3D-reconstruction 
revealed that MFG-E8 was found throughout the entire amyloid plaque and partially co-
localized with Aβ (Fig. 3B). In addition, immuno-electron microscopy of amyloid plaques from 
APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice stained for MFG-E8 confirmed the 
association of secreted MFG-E8 with Aβ fibrils (Fig. 3C). Notably, electron microscopy 
analysis also suggested the presence of less fibrillar material in amyloid plaques of APPPS1 x 
Mfge8-/- mice, indicating that the lack of MFG-E8 influences amyloid aggregation.  
 
The microglial immune response is unaffected in APPPS1 x Mfge8-/- mice 
MFG-E8 may have an immuno-protective function in AD as it has been reported to play a role 
in macrophage-mediated phagocytosis of Aβ12. Thus, we investigated whether the absence of 
the MFG-E8 protein in APPPS1 tg mice would lead to alterations in the microglial immune 
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response during the pathogenesis of cerebral β-amyloidosis. Therefore, we analyzed microglia 
in two- and four-month-old mice reflecting either an early disease state or a robust amyloid 
pathology in the brain. To determine if lack of MFG-E8 affects cortical microglia number, we 
immuno-stained brain sections for the myeloid transcription factor PU.1 and stereologically 
quantified the number of PU.1-positive cells in the cortex of APPPS1 x Mfge8+/+ mice 
compared to APPPS1 x Mfge8-/- mice. Although we observed the expected increase in microglia 
with cerebral Aβ deposition from two to four months of age, no differences in the microglial 
cell number between the age-matched APPPS1 x Mfge8-/- and APPPS1 x Mfge8+/+ animals were 
noticeable (Fig. 4A). Also, the number of plaque-associated microglia was indistinguishable in 
APPPS1 x Mfge8-/- mice compared to APPPS1 x Mfge8+/+ mice (Fig. 4B,C), suggesting that 
MFG-E8 is not required for the induction of microgliosis found around Aβ depositions.  
We next examined whether microglial cytokine production in APPPS1 mice is affected 
by the lack of MFG-E8. For that purpose, we used fluorescence-activated cell sorting (FACS) 
to isolate microglia from APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice, which were 
identified as the CD11bhigh, CD45low cell population. We then determined microglial cytokine 
levels by enzyme linked immunosorbent assay (ELISA). At two months of age the microglial 
production of pro- and anti-inflammatory cytokines was comparable between the genotypes 
(Fig. 4D). However, at four months of age we noticed a general trend towards reduced cytokine 
levels in APPPS1 x Mfge8-/- microglia, with the release of the pro-inflammatory cytokine TNF-
α being significantly reduced by 51 ± 19 percent in APPPS1 x Mfge8-/- mice (P < 0.05; Fig. 4E).  
Suppression of inflammation has been shown to increase phagocytosis of Aβ26, 
therefore we analyzed the phagocytic capacity of microglia in vivo using intraperitoneal 
administration of the amyloid-staining dye Methoxy-X04 in APPPS1 x Mfge8+/+ and APPS1 x 
Mfge8-/- animals. Microglial cells were isolated, identified by flow cytometry and analyzed for 
their Methoxy-X04 signal intensity (Fig. 5A). In accordance with the cytokine levels, the uptake 
of Methoxy-X04-labeled Aβ, was unaffected at two months of age, but unexpectedly also at 
four months of age (Fig. 5B). Interestingly, the direct determination of Aβ42 levels from isolated 
microglia by ELISA showed a trend towards less Aβ42 in APPPS1 x Mfge8-/- at two and also 
four months of age, but did not reach statistical significance (Fig. 5C).  
Since Aβ visualization with Methoxy-X04 and also ELISA measurements cannot 
necessarily distinguish between bound, already engulfed or degraded Aβ, we determined 
whether lack of MFG-E8 influences the intracellular degradation process of Aβ. To this end, 
we additionally analyzed phagocytic activity of plaque-associated microglia by performing 
triple-staining for CD68 (a marker for phagolysosomes), PU.1 and Methoxy-X04 in brain 
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sections of APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice (Supplementary fig. 1A). We then 
quantified immunofluorescence intensity of CD68 levels in plaque-associated microglia in 
three-dimensional reconstructed z-stack images taken by confocal microscopy. However, 
intensity analysis of plaque-associated CD68-immunoreactivity in microglia revealed similar 
levels between genotypes (Supplementary fig. 1B).  
 
Lack of MFG-E8 reduces pathology of cerebral β-amyloidosis in mice  
Given the strong co-localization of MFG-E8 with amyloid plaques and the lack of immune 
modulation in the absence of MFG-E8, we next investigated whether the generation or 
deposition of Aβ may be directly affected in APP transgenic mice. Strikingly, Aβ40+42 levels 
declined by 38 ± 12 percent (P < 0.01) in two-month-old APPPS1 x Mfge8-/- mice in formic 
acid-extracted (Fig. 6A) and by 43 ± 14 percent (P < 0.01) in SDS-soluble fractions of brain 
homogenates (Fig. 6B, E). Of note, these reductions in Aβ levels occurred while amyloid 
precursor protein (APP) and its processing product C-terminal fragment-β (CTF-β) levels were 
unaffected (Fig. 6C, D), indicating that changes in Aβ were not a result of altered APP 
production or cleavage.   
To determine whether the decrease in Aβ levels results in reduced plaque deposition, 
we immuno-stained brain sections of APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice for Aβ 
and Congo red. In line with the reduction in Aβ levels measured by ELISA, stereological 
quantification of the area covered by Ab plaques in the cortical region of APPPS1 x Mfge8-/- 
mice revealed a 39 ± 9 percent reduced plaque load compared to APPPS1 x Mfge8+/+ mice (P 
< 0.001; Fig. 6F/G).  
We confirmed these results by crossing Mfge8-/- mice to the APP23 mouse line, which 
has a slower disease onset with initial plaques occurring at six to seven months of age14. Aβ 
levels in the resulting APP23 x Mfge8-/- mouse line were analyzed at nine months of age, a time 
point reflecting approximately the same time span between the first appearance of cortical Aβ 
plaques and analysis as performed in the APPPS1 mouse line. In accordance with the results 
from the APPPS1 x Mfge8-/- mouse line, APP23 x Mfge8-/- mice had reduced Aβ levels as well 
as less Aβ plaque deposition compared to aged-matched APP23 x Mfge8+/+ mice 
(Supplementary fig. 2A-D). Again, APP processing was unaffected (Supplementary fig. 2C/D).  
Interestingly, when we analyzed plaque deposition in mice at a more advanced disease 
state of four months (APPPS1 x Mfge8-/-) or 12 months of age (APP23 x Mfge8-/-), differences 
in plaque load and Aβ levels were no longer apparent (Supplementary Fig. 2A, B), arguing for 
an early role of MFG-E8 in promoting amyloid plaque deposition. 
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We next quantified the number cortical plaques and grouped them into different size 
categories to determine whether MFG-E8 had an influence on the generation of new plaques or 
plaque growth. We observed a significant increase in small plaques in two- and four-month-old 
APPPS1 x Mfge8+/+ mice (Fig. 6H, Supplementary fig. 3C). However, when we did the same 
analysis in male 12-month-old APP23 mice, the absolute plaque number in the different size 
groups was indistinguishable between Mfge8+/+ and Mfge8-/- genotypes (Supplementary Fig. 
3D). These observations suggest that the initial reduction in Aβ plaque load resulting from the 
lack of MFG-E8 may have been caused by a delay in the early formation of insoluble Aβ 
aggregates. 
 
 
Discussion 
Two studies have previously investigated the possible contribution of MFG-E8 to AD 
pathology and concluded that MFG-E8 can directly interact with Aβ and facilitate its 
phagocytosis by macrophages11,12. This suggested that increasing the levels of MFG-E8 may 
be a valuable tool for the clearance of Aβ. However, our findings provide evidence for a 
detrimental role of MFG-E8 in the pathology of cerebral β-amyloidosis, as we show that the 
absence of MFG-E8 in mouse models of AD pathology reduces Aβ plaque load.  
MFG-E8 was initially identified as a secreted bridging protein that mediates 
phosphatidylserine-dependent phagocytosis in many different tissues by binding to both 
apoptotic cells and macrophages. In brain tissue, several transcriptome-based studies on cells 
of the CNS identified astrocytes as the main source of MFG-E822,27. We confirmed those 
findings by immunofluorescent staining of mouse brain sections with MFG-E8 and GFAP that 
showed strong co-localization throughout most of the cell (Fig. 1A). Interestingly, microglia, 
which are the key players for phagocytosis in the brain, were reported to express only minor 
amounts of MFG-E822. Nevertheless, we detected the two existing isoforms for MFG-E8 in 
primary isolated microglia by Western Blotting and a recent proteomics analysis in a different 
mouse model of AD pathology also found that microglial MFG-E8 levels increased with 
progressing pathology28.  
Apart from MFG-E8-mediated engulfment of apoptotic neurons, it has been reported 
that released MFG-E8 can bind to Aβ and facilitate its removal by peripheral macrophages12, 
which raises the question about its contribution to the pathogenesis of AD. To address this issue, 
we analyzed both the inflammatory immune response and Aβ pathology in two mouse models 
for cerebral β-amyloidosis, APPPS1 and APP23, which were deficient for functional MFG-E8. 
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To our surprise, we found that the lack of MFG-E8 reduced Aβ plaque burden in brains of the 
APPPS1 and APP23 mice at early disease stages with only minor alterations in the immune 
response, including negligible changes in Aβ phagocytosis by microglia. These findings deviate 
from the previously held assumption that MFG-E8 enhances phagocytic removal of Aβ and 
thereby alleviates neuropathology12. In fact, at the time point when plaque load was reduced in 
APPPS1 x Mfge8-/- mice, no alterations in the immune response as determined by microglial 
number, cytokine levels or Aβ phagocytosis, were observed. 
In particular, the unaltered phagocytic uptake of Aβ by microglia in APPPS1 x  
Mfge8-/- mice was not expected but, to our knowledge, this is the first in vivo study that analyzed 
the capability of microglia to phagocytose Aβ in APP transgenic mice deficient for MFG-E8. 
Therefore, it cannot be ruled out that the relatively slow but inexorable Aβ accumulation in vivo 
affects the microglial phagocytic function differently than the rapid addition of high 
concentrations of fibrillar Aβ to cultured microglia used for the reported in vitro studies12. 
Additionally, MFG-E8 may have a different affinity to in vivo formed Aβ fibrils compared to 
recombinant Aβ preparations that were applied to cultivated microglia.  
Since our results point towards a role of MFG-E8 in the Aβ aggregation process rather 
than Aβ clearance, we examined whether MFG-E8 affects the production of Aβ. Although we 
observed the same trend of reduction in SDS-soluble Aβ levels in APPPS1 x Mfge8-/- and 
APP23 x Mfge8-/- mice, both APP production and processing were unaltered by lack of MFG-
E8. These findings, together with the observation that secreted MFG-E8 accumulates and co-
localizes with Aβ depositions, indicate that MFG-E8 is involved in Aβ fibril formation and 
subsequent plaque deposition.  
Similar to our findings of MFG-E8 co-localizing with Aβ plaques, a close association 
with Aβ has also been described for components of the classical complement activation 
pathway, such as C1q or C3b and C429. Moreover, in vitro data on Aβ aggregation analyzed by 
Thioflavin T emission showed enhanced Aβ fibrillation in the presence of nanomolar 
concentration of C1q30. However contrary to the observed reduction in Aβ levels and plaque 
burden in APPPS1 x Mfge8-/- and APP23 x Mfge8-/- mice, lack of C1q did not affect Aβ levels31 
and C3 deficiency accelerated Aβ deposition32,33. Furthermore, absence of these complement 
components was reported to alter the microglial activation state31-33, which was not detectable 
at time points of reduced plaque deposition in APPPS1 x Mfge8-/- mice.  
In contrast to complement factors, the depletion of receptors that are known to bind to 
Aβ such as CD14 or TLR2 induced a reduction in plaque load in APP tg mice, as reported in 
our study34,35. But for both receptors, reduction in Aβ plaque load was accompanied by changes 
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in the microglial immune response as cytokine production or microglia number were altered as 
well. Thus, the underlying mechanisms that lead to the reduction of Aβ in APP tg x Mfge8-/- 
mice appears to differ from those described for other immune-related molecules.  
Interestingly, in wildtype mice, we found that brain levels of MFG-E8 increased with 
ageing. However, in APP23 and APPPS1 mice, an even more robust increase of MFG-E8 levels 
was observed that occurred simultaneously with increased levels of Aβ and the majority of 
MFG-E8 appeared to accumulate around Congo red-positive deposits. Electron microscopy of 
such plaques indicated that the grade of fibrillation was more pronounced in the presence of 
MFG-E8. These findings makes it tempting to speculate that MFG-E8 possesses characteristics 
that particularly promote Aβ aggregation. In line with this hypothesis, we counted a reduced 
number of small-sized cortical Aβ plaques in two- and four-month-old APPPS1 x Mfge8-/- mice, 
but detected no difference in the number of large or medium-sized plaques suggesting that the 
initial plaque formation is impaired by lack of MFG-E8 but not the subsequent plaque growth.  
Interestingly, in humans, MFG-E8 contains a small amyloidogenic fragment named 
medin that is localized within the C2 domain of the full-length protein. Several publications 
describe the presence of medin-amyloid in the arterial vasculature including cranial blood 
vessels36-38. In mice, where the Mfge8 gene shows 64 percent sequence similarity with the 
human gene, medin has not yet been described. However, we found MFG-E8-positive cerebral 
arteries in our mice, which may indicate the presence of medin also in mice. Interestingly, a 
recent study showed that blood-derived Aβ can enter the brain and induce Aβ plaque pathology 
in wildtype mice after parabiosis with APP tg mice39. Since the Mfge8-/- mice used in our study 
lack the entire C2 domain that harbors the amyloidogenic medin fragment, and as the knockout 
of Mfge8 in the examined APPPPS1 and APP23 mice led to reduced Aβ levels, one could 
speculate about a possible cross-seeding effect of blood vessel-derived medin and Aβ.  
During amyloid formation, the nucleation process is the rate limiting step in which 
medin seeds might accelerate the formation of a nucleus which in turn decreases lag time and 
promotes polymerization of amyloid fibrils. Accordingly, absence of medin would not only 
delay the nucleation process but also the initial Aβ deposition as reflected in a decreased plaque 
load in two-month-old APPPS1 x Mfge8-/- and nine-month-old APP23 x Mfge8-/- mice, both 
representing a time point of early plaque deposition. In the further course of the disease, after 
the first plaques are formed, the growth of fibrillar amyloid material increases exponentially 
and possibly overwhelms the changes in plaque load at early disease stages as we did not detect 
changes in Aβ depositions at later disease stages in four-month-old APPPS1 x Mfge8-/- or 12-
month-old APP23 x Mfge8-/- mice. 
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Taken together, the data presented here extend the role of MFG-E8 in AD pathology 
and suggest that MFG-E8 or single fragments of the protein, such as medin, accelerate the 
aggregation and subsequent deposition of Aβ. However, further studies are necessary to 
precisely determine the overall contribution of MFG-E8 to Aβ pathology but also to identify 
and characterize possible fragments of MFG-E8 which might have amyloidogenic 
characteristics and therefore promote cerebral β-amyloidosis. 
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Figures 
 
Figure 1: MFG-E8 is expressed in glia cells and cerebral blood vessels. A, Fluorescent staining for the astrocyte 
marker glial fibrillar acidic protein (GFAP) and MFG-E8 shows co-localization in cortical astrocytes of wildtype 
mice. B, MFG-E8 is present in cerebral arteries, which are visualized with the neocortical artery-specific dye Alexa 
Fluor 633 hydrazide. In Mfge8-/- mice, MFG-E8 staining is intracellular due to the insertion of a transmembrane 
domain. C, Top, Schematic structure of the Mfge8 wildtype gene. Bottom, structure of the knock-in form of 
truncated Mfge8. D, Western Blotting detection of the two isoforms of MFG-E8 in primary microglia isolated 
from APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice.  
 
 
Figure 2: MFG-E8 levels increase with age and cerebral β-amyloidosis. A, Western Blotting analysis of MFG-
E8 and Aβ protein levels in brain homogenates from young (3-4 months of age) and aged (20 months of age) 
wildtype (Wt), APPPS1, and APP23 mice. B, Semi-quantitative analysis of MFG-E8 levels normalized to GAPDH 
levels (n=3 for each group). C, Aβ pathology-dependent increase of MFG-E8 levels in APP23 mice. D, Semi-
quantitative analysis of MFG-E8 levels normalized to GAPDH (n=3,3,3,3). * p<0.05, as determined by Dunn’s 
multiple comparison test.  
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Figure 3: Co-localization of MFG-E8 with 
amyloid plaques in the brain of APPPS1 mice. 
A, Immunohistochemical staining for MFG-E8 
in APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- 
mice. Secreted MFG-E8 is closely associated 
with Congo red-positive amyloid plaques. B, 
3D-reconstruction of an amyloid plaque co-
stained for Aβ and MFG-E8, demonstrating their 
co-localization (bottom right). C, Electron 
micrographs of amyloid plaques stained for 
MFG-E8; arrows indicate MFG-E8 localization 
within the plaque structure (encircled). Please 
note a possible change in the plaque structure, 
with less pronounced fibrils in APPPS1 x Mfge8-
/- animals. Scale bar: low magnification: 1000 
nm, high magnification: 500 nm. 
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Figure 4: Microglia number and cytokine production is unaffected in APPPS1 x Mfge8-/- mice. 
A, Stereological quantification of PU.1-positive cortical cells at 2 and 4 months of age in APPPS1 x Mfge8+/+ and 
APPPS1 x Mfge8-/- mice (2 months: n=9,9; 4 months: n=6,8). B, Micrograph of nuclear PU.1 staining in plaque-
associated microglia. Scale bar: 20 µm. C, Number of plaque-associated PU.1-positive cells in relation to Congo 
red-positive plaque area (2 months: n=9,9; 4 months: n=6,6). D, E, Cytokine measurements in primary microglia 
FACS isolated from APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice at 2 months (D; n=5,5) and 4 months of 
age (E; n=7,5) of age. * p < 0.05, as determined by non-parametric Mann-Whitney test. 
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Figure 5: Microglial phagocytosis of Aβ is unchanged by the lack of MFG-E8. A, Gating strategy. Microglia 
were gated as CD11bhigh and CD45low and analyzed for the fraction of amyloid-containing, Methoxy-X04-positive 
cells (gating was established based on cells from a non-transgenic animal). B, Fraction of Methoxy-X04-positive 
microglia normalized to APPPS1 x Mfge8+/+ Methoxy-X04-positive cells at 2 (n=12,8) and 4 (n=18,15) months 
of age. C, Analysis of microglial Aβ42 content (n2months=5,4) and (n4months=4,3). 
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Figure 6: Genetic deletion of MFG-E8 in 2-month-old APPPS1 mice reduces Aβ levels and plaque load 
without affecting APP processing. A, Formic-acid extracted Aβ levels in brain homogenates measured by 
ELISA. B, Representative Western Blot from brain homogenates for detection of amyloid precursor protein (APP), 
its processing product C-terminal fragment-β (CTF-β) and Aβ. C-E, Densitometric analysis of (C) APP, (D) CTF-
β and (E) Aβ levels normalized to GAPDH protein (n=12,12). F, Micrographs of cortical Ab plaques. Scale bar: 
50 µm. G, Stereological quantification of cortical Aβ plaque load (n=15,15). H, Number of plaques grouped by 
size. Presented as median and 5-95 percentile (n=30,40 values per size group). Wt: APPPS1 x Mfge8+/+, hom: 
APPPS1 x Mfge8-/-. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by Student’s t-test (A,E,G) or multiple t-
tests corrected for multiple comparisons (Holm-Sidak correction) (H). Ctx: cortex. 
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Supplementary figure 1: A, Representative staining for the lysosomal marker CD68 in plaque-associated 
microglia (identified with PU.1 and Methoxy-X04) in brain sections of APPPS1 x Mfge8+/+ (WT), APPPS1 x 
Mfge8-/- (HOM) mice. CD68 staining was minimal in non-plaque associated microglia. B, Intensity quantification 
of the CD68 signal at 4 months of age (n=6,6). 
 
 
Supplementary figure 2: MFG-E8 deficiency in male APP23 mice reduces Aβ plaque deposition. 
A, Stereological quantification of cortical Aβ plaque load at 9 months of age (n=7,7). B, Formic acid-extracted Aβ 
levels measured by ELISA. C, Western Blot from brain homogenates for detection of APP, CTF-β and Aβ. D, 
Densitometric analysis of APP, CTF-β and Aβ levels normalized to GAPDH expression (n=7,7). *p < 0.05, as 
determined by non-parametric Mann-Whitney test. Ctx: cortex. 
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Supplementary figure 3: MFG-E8 does not influence Aβ deposition and size distribution at progressing 
disease states. A, B, Stereological quantification of cerebral Aβ plaque load in (A) APPPS1 x Mfge8+/+ and 
APPPS1 x Mfge8-/- mice at 4 months of age (n=15,19) and (B) in male APP23 x Mfge8+/+ and APP23 x Mfge8-/- 
mice at 12 months of age (n=10,8). C, D, Number of plaques grouped by size. Presented as median and 5-95 
percentile in (C) 4-month-old APPPS1 x Mfge8+/+ and APPPS1 x Mfge8-/- mice (n=30,40 values per size group) 
and (D) 12-month-old APP23 x Mfge8+/+ and APP23 x Mfge8-/- male mice (n=50,40 values per size group). *p < 
0.05, as determined by multiple t-tests corrected for multiple comparisons (Holm-Sidak correction). Ctx: cortex. 
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5. Appendix 
5.1 Abbreviations 
 
 
AA Serum amyloid-A 
ABCA7 ATP binding cassette subfamiliy A member 7 
AD Alzheimer's disease 
ADAM10 A disintegrin and metalloproteinase domain-conatining protein 10 
AP-1 Activator protein 1 
APOE Apolipoprotein E 
APP Amyloid precursor protein 
Aβ Amyloid-beta 
ATP Adenosine trisphosphate 
BACE Beta-secretase 1 
BBB Blood-brain barrier 
BCG Bacillus Calmette-Guérin 
BCSFB Blood-cerebrospinal fluid barrier 
BIN1 Bridging integrator 1 
BM Bone marrow 
CAA Cerebral amyloid angiopathy 
C-terminal Carboxy-terminal 
C3 Complement 3 
cAMP Cyclic adenosine monophosphate 
CASS4 Cas scaffolding protein family member 4 
CCL2 C-C motif chemokine ligand 2 
CCR2 C-C motif chemokine receptor 2 
CD11b Integrin alpha M 
CD2AP CD associated protein 
CD33 Siglec-3 
cDNA complementary deoxyribonucleic acid 
CELF1 CUGBP Elav-like family member 1 
CLU Clusterin 
CNS Central nervous system 
CR1 Complement C3b/C4b receptor 1 
CSF1R Colony stimulating factor 1 receptor 
CTF-β C-terminal fragment beta 
CX3CR1 Fractalkine receptor 
DAMP Damage-associated molecur pattern 
DAP TYRO protein tyrosine kinase binding protein 
DSG2 Desmoglein 2 
EAE Experimental autoimmune encephalomyelitis 
EPHA1 EPH receptor A1 
FAD Familal Alzheimer's disease 
FERMT2 Fermitin family member 2 
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GCV Ganciclovir 
GFP Green fluorescent protein 
GWAS Genome-wide association studies 
Hdac Histone deacetylase 
HDLS Hereditary diffuse leukoencephalopathy with speroids 
Hexb Hexosaminidase subunit beta 
HIF-1α Hypoxia inducible fator 1 alpha 
HSV Herpes simplex virus 
IDE  Insulin-degrading enzyme 
IFN Interferone 
IL-1β Interleukine 1 beta 
iNOS inducible nitric oxide synthase 
INPP5D Inositol polyphosphate-5-phosphatase D 
kDa Kilodalton 
LOAD Late-onset Alzheimer's disease 
LPS Lipopolysaccharide 
LRP1 Low deonsity lipoprotein receptor-related protein 1 
Ly6C Lymphocyte antigen 6 complex 
MAPT Microtubule-associated protein tau 
MCP-1 Monocyte chemoattractant protein 1 (alias CCL2) 
MEF2C  Myocyte enhancer factor 2C 
MFG-E8 Milk-fat globule-EGF factor 8 protein 
MMP Matrix metallopeptidase 
MS4A Membrane spanning 4-domains A 
mTOR Mechanistic traget of Rapamycin 
NAD+ Nicotinamide adenine dunucleotide 
NF-κB Nucler factor kappa B 
NME8 NME/NM23 family member 8 
P2ry12 Purinergic receptor P2Y12 
PAMP Pathogen-associated molecular pattern 
PICALM Phosphatidylinositol binding clathrin assembly protein 
PLD3 Phospholipase D family member 3 
PRR Pattern recognition receptor 
PSEN Presenilin  
PTK2B Protein tyrosine kinase 2 beta 
Rap1 Ras-related protein 1 
RET Reverse electron transport 
RFP Red fluorescent protein 
RGD Arginyl-glycyl-aspartic acid 
RIN3 Ras and rab interactor 3 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Sall1 Spalt like transcription factor 1 
SAR Systemic acquired resistance 
Appendix 
 
 151 
 
  
 
	
SLC4A4 Solute carrier family member 4 
SORL1 Sortilin related receptor 1 
STAT Signal transducer and activator of transcription 
TAK1 Transforming growth factor-beta-activated kinase 1 
TF Transcription factor 
Tg Transgenic 
TK Thymidinkinase 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor alpha 
TREM2 Triggering receptor expressed on myeloid cells like 2 
TYROBP TYRO protein tyrosine kinase binding protein (alias DAP) 
UNC5C Unc-5 netrin receptor 
VLDLR Very-low-density-lipoprotein receptor 
WT Wildtype 
ZCWPW1 Zinc finger CW-type and PWWP domain containing 1 
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